

POMES, SMITH, LANDRE & ROSE
2029 Century Park East, 38th Floor
Los Angeles, CA 90067-3024
(714) 263-8250

"Express Mail" mailing label number
Date of Deposit:

Tb658542995 US
1/21/97

I hereby certify that this paper, together with any other papers described as attached or enclosed, or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Box Patent Application, Washington, D.C. 20231.

(Typed or printed name of person mailing paper or fee)

Angela Wendel

(Signature of person mailing paper or fee)

THE COMMISSIONER OF PATENTS AND TRADEMARKS

DOCKET NO. 120-243

BOX PATENT APPLICATION

WASHINGTON, D.C. 20231

Sir:

Transmitted herewith for filing is the patent application of inventor:

For: Abundant Extracellular Products and Methods for their Production & Use

Enclosed are:

215 pages of Specification, 28 Claims (8 pages), and 1 page of Abstract, totaling 224 pages.
25 sheets of drawing(s).

An assignment of the invention to _____ application.

A Declaration, ~~Power of Attorney~~ and Petition.

Verified statement(s) to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27.

The filing fee has been calculated as shown below:

(COL. 1)		(COL. 2)	SMALL ENTITY		or	OTHER THAN A SMALL ENTITY	
For:	No. Filed	No. Extra	Rate	Fee		Rate	Fee
Basic Fee				\$ 385	or		\$ 770
Total Claims	* 28 - 20 =	8	8 x \$ 11 =	\$ 88	or	x \$ 22 =	\$
Independent Claims	* 7 - 03 =	4	4 x \$ 40 =	\$ 160	or	x \$ 80 =	\$
<input type="checkbox"/> Multiple Dependent Claims Presented			+ \$ 130 =	\$	or	+ \$ 260 =	\$
*IF THE DIFFERENCE IN COL. 1 IS LESS THAN ZERO, ENTER "0" IN COL. 2.			Total	\$ 633	or	Total	\$

☐ Please charge my Deposit Account No. 16-2230 the amount of \$____. A duplicate copy of this sheet is enclosed.

☒ A check in the amount of \$633.00 to cover the filing fee is enclosed.

☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication to Deposit Account No. 16-2230. Please refund any overpayment by check. A duplicate copy of this sheet is enclosed.

☒ Any additional filing fees required under 37 CFR 1.16.

☒ Any patent application processing fees under 37 CFR 1.17.

☐ The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application to Deposit Account No. 16-2230 or to refund any overpayment by check. A duplicate copy of this sheet is enclosed.

☐ Any patent application processing fees under 37 CFR 1.17.

☐ The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).

☐ Any filing fees under 37 CFR 1.16 for presentation of extra claims.

Respectfully submitted,

Michael A. Kondzella

Michael A. Kondzella

Reg. No. 18,013

Attorney for Applicant(s)

25 informal

633.60 - 101 - A

001186500

1

ABUNDANT EXTRACELLULAR PRODUCTS AND
METHODS FOR THEIR PRODUCTION AND USE



Cross-Reference to Related Applications

This application is a continuation-in-part of copending U.S. patent application Serial No. 08/652,842, filed on May 23, 1996, which is a continuation-in-part of copending U.S. patent application Serial No. 08/568,357 filed on December 6, 1995, which is a continuation-in-part of copending U.S. patent application Serial No. 08/551,149 filed on October 31, 1995, which is a continuation-in-part of copending U.S. patent application Serial No. 08/447,398 filed on May 23, 1995, which is a continuation-in-part of copending U.S. patent application Serial No. 08/289,667 filed on August 12, 1994, which is a continuation-in-part of copending U.S. patent application Serial No. 08/156,358 filed on November 23, 1993, all incorporated herein by reference.

This application is also a continuation-in-part of copending U.S. patent application Serial No. 08/545,926, filed on October 20, 1995, which is a continuation-in-part of copending U.S. patent application Serial No. 08/447,398 filed on May 23, 1995, which is a continuation-in-part of copending U.S. patent application Serial No. 08/289,667 filed on August 12, 1994, which is a continuation-in-part of copending U.S. patent application Serial No. 08/156,358 filed on November 23, 1993, all incorporated herein by reference.

Reference to Government

This invention was made with Government support under Grant No. AI-31338 awarded by the Department of Health and Human Services. The Government has certain rights in this invention.

Field of the Invention

The present invention generally relates to immunotherapeutic agents and vaccines against pathogenic organisms such as bacteria, protozoa, viruses and fungus. More specifically, unlike prior art vaccines and immunotherapeutic agents based upon pathogenic subunits or products which exhibit the greatest or most specific molecular immunogenicity, the present invention uses the most prevalent or majorly abundant immunogenic determinants released by a selected pathogen such as *Mycobacterium tuberculosis* to stimulate an effective immune response in mammalian hosts. Accordingly, the acquired immunity and immunotherapeutic activity produced through the present invention is directed to those antigenic markers which are displayed most often on infected host cells during the course of a pathogenic infection without particular regard to the relative or absolute immunogenicity of the administered compound.

Background of the Invention

It has long been recognized that parasitic microorganisms possess the ability to infect animals thereby causing disease and often the death of the host. Pathogenic agents have been a leading cause of death throughout history and continue to inflict immense suffering. Though the last hundred years have seen dramatic advances in the prevention and treatment of many infectious diseases, complicated host-parasite interactions still limit the universal effectiveness of therapeutic measures. Difficulties in countering the sophisticated invasive mechanisms displayed by many pathogenic vectors is evidenced by the resurgence of various diseases such as tuberculosis, as well as the appearance of numerous drug resistant strains of bacteria and viruses.

Among those pathogenic agents of major epidemiological concern, intracellular bacteria have proven to be par-

particularly intractable in the face of therapeutic or prophylactic measures. Intracellular bacteria, including the genus *Mycobacterium* and the genus *Legionella*, complete all or part of their life cycle within the cells of the infected host organism rather than extracellularly. Around the world, intracellular bacteria are responsible for millions of deaths each year and untold suffering. Tuberculosis, caused by *Mycobacterium tuberculosis*, is the leading cause of death from infectious disease worldwide, with 10 million new cases and 2.9 million deaths every year. In addition, intracellular bacteria are responsible for millions of cases of leprosy. Other debilitating diseases transmitted by intracellular agents include cutaneous and visceral leishmaniasis, American trypanosomiasis (Chagas disease), listeriosis, toxoplasmosis, histoplasmosis, trachoma, psittacosis, Q-fever, and Legionellosis including Legionnaires' disease. At this time, relatively little can be done to prevent debilitating infections in susceptible individuals exposed to these organisms.

Due to this inability to effectively protect populations from tuberculosis and the inherent human morbidity and mortality caused by tuberculosis, this is one of the most important diseases confronting mankind. More specifically, human pulmonary tuberculosis primarily caused by *M. tuberculosis* is a major cause of death in developing countries. Capable of surviving inside macrophages and monocytes, *M. tuberculosis* may produce a chronic intracellular infection. By concealing itself within the cells primarily responsible for the detection of foreign elements and subsequent activation of the immune system, *M. tuberculosis* is relatively successful in evading the normal defenses of the host organism. These same pathogenic characteristics have heretofore prevented the development of an effective immunotherapeutic agent or vaccine against tubercular infections. At the same time tubercle bacilli are relatively easy to culture and observe under

laboratory conditions. Accordingly, *M. tuberculosis* is particularly well suited for demonstrating the principles and advantages of the present invention.

Those skilled in the art will appreciate that the following exemplary discussion of *M. tuberculosis* is in no way intended to limit the scope of the present invention to the treatment of *M. tuberculosis*. Similarly, the teachings herein are not limited in any way to the treatment of tubercular infections. On the contrary, this invention may be used to advantageously provide safe and effective vaccines and immunotherapeutic agents against the immunogenic determinants of any pathogenic agent expressing extracellular products and thereby inhibit the infectious transmission of those organisms.

Currently it is believed that approximately half of the world's population is infected by *M. tuberculosis* resulting in millions of cases of pulmonary tuberculosis annually. While this disease is a particularly acute health problem in the developing countries of Latin America, Africa, and Asia, it is also becoming more prevalent in the first world. In the United States specific populations are at increased risk, especially urban poor, immunocompromised individuals and immigrants from areas of high disease prevalence. Largely due to the AIDS epidemic the incidence of tuberculosis is presently increasing in developed countries, often in the form of multi-drug resistant *M. tuberculosis*.

Recently, tuberculosis resistance to one or more drugs was reported in 36 of the 50 United States. In New York City, one-third of all cases tested in 1991 were resistant to one or more major drugs. Though nonresistant tuberculosis can be cured with a long course of antibiotics, the outlook regarding drug resistant strains is bleak. Patients infected with strains resistant to two or more major antibiotics have a fatality rate of around 50%.

Accordingly, a safe and effective vaccine against such varieties of *M. tuberculosis* is sorely needed.

Initial infections of *M. tuberculosis* almost always occur through the inhalation of aerosolized particles as the pathogen can remain viable for weeks or months in moist or dry sputum. Although the primary site of the infection is in the lungs, the organism can also cause infection of the bones, spleen, meninges and skin. Depending on the virulence of the particular strain and the resistance of the host, the infection and corresponding damage to the tissue may be minor or extensive. In the case of humans, the initial infection is controlled in the majority of individuals exposed to virulent strains of the bacteria. The development of acquired immunity following the initial challenge reduces bacterial proliferation thereby allowing lesions to heal and leaving the subject largely asymptomatic but possibly contagious.

When *M. tuberculosis* is not controlled by the infected subject, it often results in the extensive degradation of lung tissue. In susceptible individuals lesions are usually formed in the lung as the tubercle bacilli reproduce within alveolar or pulmonary macrophages. As the organisms multiply, they may spread through the lymphatic system to distal lymph nodes and through the blood stream to the lung apices, bone marrow, kidney and meninges surrounding the brain. Primarily as the result of cell-mediated hypersensitivity responses, characteristic granulomatous lesions or tubercles are produced in proportion to the severity of the infection. These lesions consist of epithelioid cells bordered by monocytes, lymphocytes and fibroblasts. In most instances a lesion or tubercle eventually becomes necrotic and undergoes caseation.

While *M. tuberculosis* is a significant pathogen, other species of the genus *Mycobacterium* also cause disease in animals including man and are clearly within

the scope of the present invention. For example, *M. bovis* is closely related to *M. tuberculosis* and is responsible for tubercular infections in domestic animals such as cattle, pigs, sheep, horses, dogs and cats. Further, *M. bovis* may infect humans via the intestinal tract, typically from the ingestion of raw milk. The localized intestinal infection eventually spreads to the respiratory tract and is followed shortly by the classic symptoms of tuberculosis. Another important pathogenic vector of the genus *Mycobacterium* is *M. leprae* which causes millions of cases of the ancient disease leprosy. Other species of this genus which cause disease in animals and man include *M. kansasii*, *M. avium intracellulare*, *M. fortuitum*, *M. marinum*, *M. chelonae*, *M. africanum*, *M. ulcerans*, *M. microti* and *M. scrofulaceum*. The pathogenic mycobacterial species frequently exhibit a high degree of homology in their respective DNA and corresponding protein sequences and some species, such as *M. tuberculosis* and *M. bovis* are highly related.

For obvious practical and moral reasons, initial work in humans to determine the efficacy of experimental compositions with regard to such afflictions is infeasible. Accordingly, in the early development of any drug or vaccine it is standard procedure to employ appropriate animal models for reasons of safety and expense. The success of implementing laboratory animal models is predicated on the understanding that immunodominant epitopes are frequently active in different host species. Thus, an immunogenic determinant in one species, for example a rodent or guinea pig, will generally be immunoreactive in a different species such as in humans. Only after the appropriate animal models are sufficiently developed will clinical trials in humans be carried out to further demonstrate the safety and efficacy of a vaccine in man.

With regard to alveolar or pulmonary infections by *M. tuberculosis*, the guinea pig model closely resembles

the human pathology of the disease in many respects. Accordingly, it is well understood by those skilled in the art that it is appropriate to extrapolate the guinea pig model of this disease to humans and other mammals. As
5 with humans, guinea pigs are susceptible to tubercular infection with low doses of the aerosolized human pathogen *M. tuberculosis*. Unlike humans where the initial infection is usually controlled, guinea pigs consistently develop disseminated disease upon exposure to the aerosolized pathogen, facilitating subsequent analysis. Further,
10 both guinea pigs and humans display cutaneous delayed-type hypersensitivity reactions characterized by the development of a dense mononuclear cell induration or rigid area at the skin test site. Finally, the characteristic tubercular lesions of humans and guinea pigs exhibit
15 similar morphology including the presence of Langhans giant cells. As guinea pigs are more susceptible to initial infection and progression of the disease than humans, any protection conferred in experiments using this animal model provides a strong indication that the same
20 protective immunity may be generated in man or other less susceptible mammals. Accordingly, for purposes of explanation only and not for purposes of limitation, the present invention will be primarily demonstrated in the exemplary context of guinea pigs as the mammalian host. Those
25 skilled in the art will appreciate that the present invention may be practiced with other mammalian hosts including humans and domesticated animals.

Any animal or human infected with a pathogenic vector
30 and, in particular, an intracellular organism presents a difficult challenge to the host immune system. While many infectious agents may be effectively controlled by the humoral response and corresponding production of protective antibodies, these mechanisms are primarily effective
35 only against those pathogens located in the body's extracellular fluid. In particular, opsonizing antibodies bind

to extracellular foreign agents thereby rendering them susceptible to phagocytosis and subsequent intracellular killing. Yet this is not the case for other pathogens. For example, previous studies have indicated that the humoral immune response does not appear to play a significant protective role against infections by intracellular bacteria such as *M. tuberculosis*. However, the present invention may generate a beneficial humoral response to the target pathogen and, as such, its effectiveness is not limited to any specific component of the stimulated immune response.

More specifically, antibody mediated defenses seemingly do not prevent the initial infection of intracellular pathogens and are ineffectual once the bacteria are sequestered within the cells of the host. As water soluble proteins, antibodies can permeate the extracellular fluid and blood, but have difficulty migrating across the lipid membranes of cells. Further, the production of opsonizing antibodies against bacterial surface structures may actually assist intracellular pathogens in entering the host cell. Accordingly, any effective prophylactic measure against intracellular agents, such as *Mycobacterium*, should incorporate an aggressive cell-mediated immune response component leading to the rapid proliferation of antigen specific lymphocytes which activate the compromised phagocytes or cytotoxically eliminate them. However, as will be discussed in detail below, inducing a cell-mediated immune response does not equal the induction of protective immunity. Though cell-mediated immunity may be a prerequisite to protective immunity, the production of vaccines in accordance with the teachings of the present invention requires animal based challenge studies.

This cell-mediated immune response generally involves two steps. The initial step, signaling that the cell is infected, is accomplished by special molecules (major histocompatibility or MHC molecules) which deliver pieces

of the pathogen to the surface of the cell. These MHC molecules bind to small fragments of bacterial proteins which have been degraded within the infected cell and present them at the surface of the cell. Their presentation to T-cells stimulates the immune system of the host to eliminate the infected host cell or induces the host cell to eradicate any bacteria residing within.

Unlike most infectious bacteria *Mycobacterium*, including *M. tuberculosis*, tend to proliferate in vacuoles which are substantially sealed off from the rest of the cell by a membrane. Phagocytes naturally form these protective vacuoles making them particularly susceptible to infection by this class of pathogen. In such vacuoles the bacteria are effectively protected from degradation, making it difficult for the immune system to present integral bacterial components on the surface of infected cells. However, the infected cell's MHC molecules will move to the vacuole and collect any free (released) bacterial products or move to other sites in the host cell to which the foreign extracellular bacterial products have been transported for normal presentation of the products at the cell surface. As previously indicated, the presentation of the foreign bacterial products will provoke the proper response by the host immune system.

The problems intracellular pathogens pose for the immune system also constitute a special challenge to vaccine development. Thus far, the production of an effective vaccine against *Mycobacterium* infections and, in particular, against *M. tuberculosis* has eluded most researchers. At the present time the only widely available vaccine against intracellular pathogens is the live attenuated vaccine BCG, an avirulent strain of *M. bovis*, which is used as a prophylactic measure against the tubercle bacillus. Yet in 1988, extensive World Health Organization studies from India determined that the efficacy of the best BCG vaccines was so slight as to be

unmeasurable. Despite this questionable efficacy, BCG vaccine has been extensively employed in high incidence areas of tuberculosis throughout the world. Complicating the matter even further individuals who have been vaccinated with BCG will often develop sensitivity to tuberculin which negates the usefulness of the most common skin test for tuberculosis screening and control.

Another serious problem involving the use of a live, attenuated vaccine such as BCG is the possibility of initiating a life-threatening disease in immunocompromised patients. These vaccines pose a particular risk for persons with depressed cell-mediated immunity because of their diminished capacity to fight a rapidly proliferating induced infection. Such individuals include those weakened by malnourishment and inferior living conditions, organ transplant recipients, and persons infected with HIV. In the case of BCG vaccine, high risk individuals also include those suffering from lung disorders such as emphysema, chronic bronchitis, pneumoconiosis, silicosis or previous tuberculosis. Accordingly, the use of attenuated vaccines is limited in the very population where they have the greatest potential benefit.

The use of live attenuated vaccines may also produce other undesirable side effects. Because live vaccines reproduce in the recipient, they provoke a broader range of antibodies and a less directed cell-mediated immune response than noninfectious vaccines. Often this shotgun approach tends to occlude the immune response directed at the molecular structures most involved in cellular prophylaxis. Moreover, the use of live vaccines with an intact membrane may induce opsonizing antibodies which prepare a foreign body for effective phagocytosis. Thus, upon host exposure to virulent strains of the target organism, the presence of such antibodies could actually enhance the uptake of nonattenuated pathogens into host cells where they can survive and multiply. Further, an

attenuated vaccine contains thousands of different molecular species and consequently is more likely to contain a molecular species that is toxic or able to provoke an adverse immune response in the patient. Other problems
5 with live vaccines include virulence reversion, natural spread to contacts, contaminating viruses and viral interference, and difficulty with standardization.

Similarly, noninfectious vaccines, such as killed organisms or conventional second generation subunit
10 vaccines directed at strongly antigenic membrane bound structures, are limited with respect to the inhibition of intracellular bacteria. Like attenuated vaccines, killed bacteria provoke an indiscriminate response which may inhibit the most effective prophylactic determinants.
15 Further, killed vaccines still present large numbers of potentially antigenic structures to the immune system thereby increasing the likelihood of toxic reactions or opsonization by the immune system. Traditional subunit vaccines incorporating membrane bound structures, whether
20 synthesized or purified, can also induce a strong opsonic effect facilitating the entry of the intracellular pathogen into phagocytes in which they multiply. By increasing the rate of bacterial inclusion, killed vaccines directed to intracellular surface antigens may increase the rela-
25 tive virulence of the pathogenic agent. Thus, conventional attenuated or killed vaccines directed against strongly antigenic bacterial surface components may be contraindicated in the case of intracellular pathogens.

In order to circumvent the problems associated with
30 the use of traditional vaccines, developments have been made using extracellular proteins or their immunogenic analogs to stimulate protective immunity against specific intracellular pathogens. For example, this inventor's U.S. Patent No. 5,108,745, issued April 28, 1992 discloses
35 vaccines and methods of producing protective immunity against *Legionella pneumophila* and *M. tuberculosis* as well

as other intracellular pathogens. These prior art vaccines are broadly based on extracellular products originally derived from proteinaceous compounds released extracellularly by the pathogenic bacteria into broth culture
5 *in vitro* and released extracellularly by bacteria within infected host cells *in vivo*. As disclosed therein, these vaccines are selectively based on the identification of extracellular products or their analogs which stimulate a strong immune response against the target pathogen in a
10 mammalian host.

More specifically, these prior art candidate extracellular proteins were screened by determining their ability to provoke either a strong lymphocyte proliferative response or a cutaneous delayed-type hypersensitivity
15 response in mammals which were immune to the pathogen of interest. Though this disclosed method and associated vaccines avoid many of the drawbacks inherent in the use of traditional vaccines, conflicting immunoresponsive results due to cross-reactivity and host variation may
20 complicate the selection of effective immunizing agents. Thus, while molecular immunogenicity is one indication of an effective vaccine, other factors may complicate its use in eliciting an effective immune response *in vivo*.

More importantly, it surprisingly was discovered
25 that, particularly with respect to *M. tuberculosis*, conventional prior art methods for identifying effective protective immunity inducing vaccines were cumbersome and potentially ineffective. For example, SDS-PAGE analysis of bulk *M. tuberculosis* extracellular protein followed by
30 conventional Western blot techniques aimed at identifying the most immunogenic of these extracellular components produced inconsistent results. Repeated testing failed to identify which extracellular product would produce the strongest immunogenic response and, consistent with prior
35 art thinking, thereby function as the most effective vaccine. Many of the extracellular products of *M. tuber-*

culosis are well known in the art, having been identified and, in some cases, sequenced. Further, like any foreign protein, it can be shown that these known compounds induce an immune response. However, nothing in the art directly
5 indicates that any of these known compounds will induce protective immunity as traditionally identified.

Accordingly, it is a principal object of the present invention to provide vaccines or immunotherapeutic agents and methods for their production and use in mounting an
10 effective immune response against infectious bacterial pathogens which do not rely upon traditional vaccine considerations and selection techniques based upon highly specific, strongly immunogenic operability.

It is another object of the present invention to provide vaccines or immunotherapeutic agents and methods for
15 their use to impart acquired immunity in a mammalian host against intracellular pathogens including *M. tuberculosis*, *M. bovis*, *M. kansasii*, *M. avium-intracellulare*, *M. fortuitum*, *M. chelonae*, *M. marinum*, *M. scrofulaceum*, *M. leprae*,
20 *M. africanum*, *M. ulcerans* and *M. microti*.

It is an additional object of the present invention to provide easily produced vaccines and immunotherapeutic agents exhibiting reduced toxicity relative to killed or attenuated vaccines.

25 Summary of the Invention

The present invention accomplishes the above-described and other objects by providing compounds for use as vaccines and/or immunotherapeutic agents and methods for their production and use to generate protective or
30 therapeutic immune responses in mammalian hosts against infection by pathogens. In a broad aspect, the invention provides the means to induce a protective or therapeutic immune response against infectious vectors producing extracellular compounds. While the compounds of the
35 present invention are particularly effective against

For purposes of the present invention, the term "majorly abundant" should be understood as a relative term identifying those extracellular products released in the greatest quantity by the pathogen of interest. For example, with respect to *M. tuberculosis* grown under various conditions of culture to an optical density of approximately 0.5, one skilled in the art should expect to obtain on the order of 10 $\mu\text{g/L}$ or more of a majorly abundant extracellular product. Thus, out of the total exemplary 4 mg/L total output of extracellular product for *M. tuberculosis* grown under normal or heat shock conditions, approximately fifteen to twenty (alone or in combination) of the one hundred or so known extracellular products will constitute approximately ninety percent of the total quantity. These are the majorly abundant extracellular products contemplated as being within the scope of the present invention and are readily identifiable as the broad bands appearing in SDS/PAGE gels. In addition, the extracellular products of interest may further be characterized and differentiated by amino acid sequencing. The remaining extracellular products are minor. Those skilled in the art will also appreciate that the relative quantitative abundance of specific major extracellular products may vary depending upon conditions of culture. However, in most cases, the identification of an individual majorly abundant extracellular product will not change.

UCLA-ID-VACCINE\120243.APP\MAK/fv/12/1/96 11:08am

products, the vaccines and methods of the present invention are particularly effective in generating protective immunity against intracellular pathogens, including various species and serogroups of the genus *Mycobacterium*.

- 5 The vaccines of the present invention are also effective as immunotherapeutic agents for the treatment of existing disease conditions.

Surprisingly, it has been found by this inventor that immunization with the most or majorly abundant products
10 released extracellularly by bacterial pathogens or their immunogenic analogs can provoke an effective immune response irrespective of the absolute immunogenicity of the administered compound. Due to their release from the organism and hence their availability to host molecules
15 involved in antigen processing and presentation and due to their naturally high concentration in tissue during infection, the majorly abundant extracellular products of a pathogenic agent are processed and presented to the host immune system more often than other bacterial components.
20 In the case of intracellular pathogens, the majorly abundant extracellular products are the principal immunogenic determinants presented on the surface of the infected host cells and therefore exhibit a greater presence in the surrounding environment. Accordingly, acquired immunity
25 against the majorly abundant extracellular products of a pathogenic organism allows the host defense system to swiftly detect pathogens sequestered inside host cells and effectively inhibit them.

More particularly, the principal or majorly abundant
30 products released by pathogenic bacteria appear to be processed by phagocytes and other host immune system mechanisms at a greater rate than less prevalent or membrane bound pathogenic components regardless of their respective immunogenic activity or specificity. This immunoprocess-
35 ing disparity is particularly significant when the pathogenic agent is an intracellular bacteria sequestered from

normal immune activity. By virtue of their profuse and continual presentation to the infected host's immune system, the most prevalent bacterial extracellular products or their immunogenic analogs provoke a vigorous
5 immune response largely irrespective of their individual molecular immunogenic characteristics.

Majorly abundant extracellular products are the principal constituents of proteins and other molecular entities which are released by the target pathogen into
10 the surrounding environment. Current research indicates that in some instances a single majorly abundant extracellular product may comprise up to 40% by weight of the products released by a microorganism. More often, individual majorly abundant extracellular products account for
15 between from about 0.5% to about 25% of the total products released by the infectious pathogen. Moreover, the top five or six majorly abundant extracellular products may be found to comprise between 60% to 70% of the total mass released by a microorganism. Of course those skilled in
20 the art will appreciate that the relative levels of extracellular products may fluctuate over time as can the absolute or relative quantity of products released. For example, pH, oxidants, osmolality, heat and other conditions of stress on the organism, stage of life cycle, reproduction status and the composition of the surrounding environment may alter the composition and quantity of products
25 released. Further, the absolute and relative levels of extracellular products may differ greatly from species to species and even between strains within a species.

30 In the case of intracellular pathogens extracellular products appear to expand the population of specifically immune lymphocytes capable of detecting and exerting an antimicrobial effect against macrophages containing live bacteria. Further, by virtue of their repeated display on
35 the surface of infected cells, the majorly abundant or principal extracellular products function as effective

antigenic markers. Accordingly, pursuant to the teachings of the present invention, vaccination and the inducement of protective immunity directed to the majorly abundant extracellular products of a pathogenic bacteria or their immunogenically equivalent determinants, prompts the host immune system to mount a rapid and efficient immune response with a strong cell-mediated component when subsequently infected by the target pathogen.

In direct contrast to prior art immunization activities which have primarily been focused on the production of vaccines and the stimulation of immune responses based upon the highly specific molecular antigenicity of individual screened pathogen components, the present invention advantageously exploits the relative abundance of bacterial extracellular products or their immunogenic analogs (rather than their immunogenic specificities) to establish or induce protective immunity with compounds which may actually exhibit lower immunogenic specificity than less prevalent extracellular products. For the purposes of this disclosure an immunogenic analog is any molecule or compound sufficiently analogous to at least one majorly abundant extracellular product expressed by the target pathogen, or any fraction thereof, to have the capacity to stimulate a protective immune response in a vaccinated mammalian host upon subsequent infection by the target pathogen. In short, the vaccines of the present invention are identified or produced by selecting the majorly abundant product or products released extracellularly by a specific pathogen (or molecular analogs capable of stimulating a substantially equivalent immune response) and isolating them in a relatively pure form or subsequently sequencing the DNA or RNA responsible for their production to enable their synthetic or endogenous production. The desired prophylactic immune response to the target pathogen may then be elicited by formulating one or more of the isolated immunoreactive products or the

03786533-01249

encoding genetic material using techniques well known in the art and immunizing a mammalian host prior to infection by the target pathogen.

It is anticipated that the present invention will
5 consist of at least one, two or, possibly even several well defined immunogenic determinants. As a result, the present invention produces consistent, standardized vaccines which may be developed, tested and administered with relative ease and speed. Further, the use of a few
10 well defined molecules corresponding to the majorly abundant secretory or extracellular products greatly reduces the risk of adverse side effects associated with conventional vaccines and eliminates the possible occlusion of effective immunogenic markers. Similarly, because the
15 present invention is not an attenuated or a killed vaccine the risk of infection during production, purification or upon administration is effectively eliminated. As such, the vaccines of the present invention may be administered safely to immunocompromised individuals, including asymp-
20 tomatic tuberculosis patients and those infected with HIV. Moreover, as the humoral immune response is directed exclusively to products released by the target pathogen, there is little chance of generating a detrimental opsonic immune component. Accordingly, the present invention
25 allows the stimulated humoral response to assist in the elimination of the target pathogen from antibody susceptible areas.

Another beneficial aspect of the present invention is the ease by which the vaccines may be harvested or pro-
30 duced and subsequently purified and sequenced. For example, the predominantly abundant extracellular products may be obtained from cultures of the target pathogen, including *M. tuberculosis* or *M. bovis*, with little effort. As the desired compounds are released into the media
35 during growth, they can readily be separated from the intrabacterial and membrane-bound components of the target

pathogen utilizing conventional techniques. More preferably, the desired immunoreactive constituents of the vaccines of the present invention may be produced and purified from genetically engineered organisms into which the genes expressing the specific extracellular products of *M. tuberculosis*, *M. bovis*, *M. leprae* or any other pathogen of interest have been cloned. As known in the art, such engineered organisms can be modified to produce higher levels of the selected extracellular products or modified immunogenic analogs. Alternatively, the immunoprotective products, portions thereof or analogs thereof, can be chemically synthesized using techniques well known in the art or directly expressed in host cells injected with naked genes encoding therefor. Whatever production source is employed, the immunogenic components of the predominant or majorly abundant extracellular products may be separated and subsequently formulated into deliverable vaccines using common biochemical procedures such as fractionation, chromatography or other purification methodology and conventional formulation techniques or directly expressed in host cells containing directly introduced genetic constructs encoding therefor.

For example, in an exemplary embodiment of the present invention the target pathogen is *M. tuberculosis* and the majorly abundant products released extracellularly by *M. tuberculosis* into broth culture are separated from other bacterial components and used to elicit an immune response in mammalian hosts. Individual proteins or groups of proteins are then utilized in animal based challenge experiments to identify those which induce protective immunity making them suitable for use as vaccines in accordance with the teachings of the present invention. More specifically, following the growth and harvesting of the bacteria, by virtue of their physical abundance the principal extracellular products are separated from intrabacterial and other components through

centrifugation and filtration. If desired, the resultant bulk filtrate is then subjected to fractionation using ammonium sulfate precipitation with subsequent dialysis to give a mixture of extracellular products, commonly termed
5 EP. Solubilized extracellular products in the dialyzed fractions are then purified to substantial homogeneity using suitable chromatographic techniques as known in the art and as described more fully below.

These exemplary procedures result in the production
10 of fourteen individual proteinaceous major extracellular products of *M. tuberculosis* having molecular weights ranging from 110 kilo Daltons (KD) to 12 KD. Following purification each individual majorly abundant extracellular product exhibits one band corresponding to its respec-
15 tive molecular weight when subjected to polyacrylamide gel electrophoresis thereby allowing individual products or groups of products corresponding to the majorly abundant extracellular products to be identified and prepared for use as vaccines in accordance with the teachings of the
20 present invention. The purified majorly abundant extracellular products may further be characterized and distinguished by determining all or part of their respective amino acid sequences using techniques common in the art. Sequencing may also provide information regarding possible
25 structural relationships between the majorly abundant extracellular products.

Subsequently, immunization and the stimulation of acquired immunity in a mammalian host system may be accomplished through the teachings of the present inven-
30 tion utilizing a series of subcutaneous or intradermal injections of these purified extracellular products over a course of time. For example, injection with a purified majorly abundant bacterial extracellular product or products in incomplete Freund's adjuvant followed by a
35 second injection in the same adjuvant approximately three weeks later can be used to elicit a protective response

upon subsequent challenge with the virulent pathogen. Other exemplary immunization protocols within the scope and teachings of the present invention may include a series of three or four injections of purified extracellular product or products or their analogs in Syntex Adjuvant Formulation (SAF) over a period of time. While a series of injections may generally prove more efficacious, the single administration of a selected majorly abundant extracellular product or its immunogenic subunits or analogs can impart the desired immune response and is contemplated as being within the scope of the present invention as well.

Such exemplary protocols can be demonstrated using art accepted laboratory models such as guinea pigs. For example, as will be discussed in detail, immunization of several guinea pigs with a combination of five majorly abundant extracellular products (purified from *M. tuberculosis* as previously discussed) was accomplished with an immunization series of three injections of the bacterial products in SAF adjuvant with corresponding sham-immunization of control animals. Exemplary dosages of each protein ranged from 100 μ g to 2 μ g. Following the last vaccination all of the animals were simultaneously exposed to an infectious and potentially lethal dose of aerosolized *M. tuberculosis* and monitored for an extended period of time. The control animals showed a significant loss in weight when compared with the animals immunized with the combination of the majorly abundant extracellular products of *M. tuberculosis*. Moreover, half of the control animals died during the observation period while none of the immunized animals succumbed to tuberculosis. Autopsies conducted after this experiment revealed that the non-immunized control animals had significantly more colony forming units (CFU) and corresponding damage in their lungs and spleens than the protected animals. Seventeen additional combinations of purified majorly abundant

extracellular products provided immunoprophylaxis when tested, thereby demonstrating the scope of the present invention and broad range of vaccines which may be formulated in accordance with the teachings thereof.

5 However, it should be emphasized that the present invention is not restricted to combinations of secretory or extracellular products. For example, several alternative experimental protocols demonstrate the capacity of a single abundant extracellular product to induce mammalian
10 protective immunity in accordance with the teachings of the present invention. In each experiment guinea pigs were immunized with a single majorly abundant extracellular product purified from *M. tuberculosis* EP using the chromatography protocols detailed herein. In one example
15 the animals were vaccinated in multiple experiments with an adjuvant composition containing a purified abundant secretory product having a molecular weight corresponding to 30 KD. In another example of the present invention, different guinea pigs were vaccinated with an adjuvant
20 composition containing an abundant extracellular product isolated from *M. tuberculosis* having a molecular weight corresponding to 71 KD. Following their respective immunizations both sets of animals and the appropriate controls were exposed to lethal doses of aerosolized
25 *M. tuberculosis* to determine vaccine effectiveness.

More particularly, in one experiment six guinea pigs were immunized with 100 μ g of 30 KD protein in SAF on three occasions spread over a period of six weeks. Control animals were simultaneously vaccinated with
30 corresponding amounts of a bulk preparation of extracellular proteins (EP) or buffer. Three weeks after the final vaccination, the animals were challenged with an aerosolized lethal dose of *M. tuberculosis* and monitored for a period of 14 weeks. The 30 KD immunized guinea pigs and
35 those immunized with the bulk extracellular preparation had survival rates of 67% and 50% respectively (illustrat-

ing the unexpectedly superior performance of the majorly abundant extracellular product versus EP), while the sham-immunized animals had a survival rate of only 17%. Upon termination of the experiment the animals were sacrificed
5 and examined for viable tubercle bacilli. Not surprisingly, the nonimmunized animal showed markedly higher concentrations of *M. tuberculosis* in the lungs and spleen.

Similar experiments were performed on those animals vaccinated with 71 KD protein. In one experiment six
10 guinea pigs were vaccinated with an SAF adjuvant composition containing 100 μ g purified 71 KD protein two times over a period of three weeks. Other animals were similarly immunized with a bulk preparation of unpurified extracellular proteins or EP for use as a positive control
15 and with buffer for use as a negative control. Following exposure to lethal doses of aerosolized tubercle bacilli the weight of the guinea pigs was monitored for a period of 6 months. Once again the animals immunized with the purified form of the abundant extracellular product devel-
20 oped protective immunity with respect to the virulent *M. tuberculosis*. By the end of that period the buffer immunized animals showed a significant loss in weight when compared with the immunized animals. Further, while the positive controls and 71 KD immunized animals had survival
25 rates of 63% and 50% respectively, the nonimmunized animals all died before the end of the observation period.

It is important to note that the formulation of the vaccine is not critical to the present invention and may be optimized to facilitate administration. Solutions of
30 the purified immunogenic determinants derived from the majorly abundant pathogenic extracellular products may be administered alone or in combination in any manner designed to generate a protective immune response. The purified protein solutions may be delivered alone, or formu-
35 lated with an adjuvant before being administered.

Alternatively, genetic material encoding the genes for one or more of the immunogenic determinants derived from the majorly abundant pathogenic extracellular products may be coupled with eucaryotic promoter and/or
 5 secretion sequences and injected directly into a mammalian host to induce endogenous expression of the immunogenic determinants and subsequent protective immunity.

Other objects, features and advantages of the present invention will be apparent to those skilled in the art
 10 from a consideration of the following detailed description of preferred exemplary embodiments thereof taken in conjunction with the figures which will first be described briefly.

Brief Description of the Drawings

15 Fig. 1 is a representation of 4 coomassie blue stained gels, labeled 1a to 1d, illustrating the purification of exemplary majorly abundant extracellular products of *M. tuberculosis* as identified by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).

20 Fig. 2 is a tabular representation identifying the five N-terminal amino acids of fourteen exemplary majorly abundant extracellular products of *M. tuberculosis* (Sequence ID Nos. 1-14) and the apparent molecular weight for such products.

25 Fig. 3 is a tabular representation of the extended N-terminal amino acid sequence of three exemplary majorly abundant secretory products of *M. tuberculosis* (Sequence ID Nos. 15-17) which were not distinguished by the five N-terminal amino acids shown in Fig. 2.

30 Fig. 4 is a graphical comparison of the survival rate of guinea pigs immunized with exemplary purified majorly abundant 30 KD secretory product of *M. tuberculosis* versus positive controls immunized with a prior art bulk preparation of extracellular proteins and nonimmunized negative

controls following exposure to an aerosolized lethal dose of *M. tuberculosis*.

Fig. 5 is a graphical comparison of mean guinea pig body weight of animals immunized with purified majorly abundant 71 KD extracellular product versus positive controls immunized with a prior art bulk preparation of extracellular proteins from *M. tuberculosis* and non-immunized negative controls following exposure to an aerosolized lethal dose of *M. tuberculosis*.

Fig. 6 is a graphical comparison of the survival rate of guinea pigs immunized in Fig. 5 with exemplary majorly abundant purified 71 KD extracellular product of *M. tuberculosis* versus positive controls immunized with a prior art bulk preparation of extracellular proteins from *M. tuberculosis* and nonimmunized negative controls following exposure to an aerosolized lethal dose of *M. tuberculosis*.

Fig. 7 is a graphical comparison of mean guinea pig body weight of animals immunized with exemplary purified majorly abundant 71 KD extracellular product and non-immunized negative controls following exposure to an aerosolized lethal dose of *M. tuberculosis* in a second, separate experiment.

Figs. 8a and b are graphical comparisons of lymphocyte proliferative responses to exemplary purified majorly abundant 71 KD extracellular product in PPD+ (indicative of infection with *M. tuberculosis*) and PPD- human subjects. Fig. 8a is a graph of the values measured at 2 days after incubation of lymphocytes with this antigen while Fig. 8b is a graph of the values measured at 4 days after incubation.

Fig. 9 is a graphical comparison of mean guinea pig body weight of animals immunized with vaccine comprising a combination of extracellular products produced according to the teachings of the present invention and nonimmunized

controls following exposure to an aerosolized lethal dose of *M. tuberculosis*.

Fig. 10 is a graphical comparison of mean guinea pig body weight of animals immunized with three different dosages of a vaccine comprising a combination of extracellular products produced according to the teachings of the present invention and nonimmunized controls following exposure to an aerosolized lethal dose of *M. tuberculosis*.

Fig. 11 is a graphical comparison of mean guinea pig body weight of animals immunized with vaccines comprising six different combinations of extracellular products produced according to the teachings of the present invention and nonimmunized controls following exposure to an aerosolized lethal dose of *M. tuberculosis*.

Figs. 12a and b are graphical illustrations of the mapping of the immunodominant epitopes of the 30 KD protein of *M. tuberculosis*. Fig. 12a illustrates the percentage of 24 guinea pigs immunized with the 30 KD protein responding to overlapping peptides (15-mer) covering the entire 30 KD protein sequence. Fig. 12b illustrates a corresponding set of data for a group of 19 sham immunized guinea pigs. The response of each group of animals to native 30 KD protein, purified protein derivative (PPD) and concanavalin A (con A) appears at the right of each graph.

Fig. 13 is a graphical illustration of the mapping of the immunodominant epitopes of the 32A KD protein of *M. tuberculosis*.

Fig. 14 provides a diagrammatic representation of the constructs used for the expression of recombinant 30 KD protein. the diagram depicts the pET22b vectors used for the expression of recombinant 30 KD protein. The vectors express the mature 30 KD protein fused to its own leader (30W-pET22b) or the plasmid encoded pel B leader (30M-pET22b). Abbreviations used: Ori, ColE1 type origin of replication; F1 ori, phage F1 origin of replication;

Amp, ampicillin resistance gene; 30W/M, full length (30W) or mature (30M) 30 KD protein; lacI, lac repressor gene; P_{T7}, phage T7 RNA polymerase specific promoter; NdeI and NcoI, restriction enzyme sites at vector/insert junctions.

5 Fig. 15 shows electrophoresis test results and a Western blot analysis which confirm the expression of full-length and mature 30 KD protein in *E. coli* BL21(DE3)pLySS.

Fig. 16 is a diagrammatic representation of an
10 alternate construct system used to express the 30 KD
protein.

Fig. 17 shows electrophoresis test results which confirm the expression of the *M. tuberculosis* 30 KD protein in *M. smegmatis*.

15 Fig. 18 depicts the results of a Western blot
analysis, confirming the expression of the *M. tuberculosis*
30 KD protein in *M. smegmatis*.

Fig. 19 provides a diagrammatic representation of the constructs used for the expression of recombinant 32A KD protein. The diagram depicts the pSMT3 vector used for the expression of recombinant 32A KD protein. In (A) the DNA fragment carrying the gene for the 32A KD protein is arranged in the opposite direction from the hsp 60 promoter. In (B) the DNA fragment carrying the gene for the 32A KD protein is arranged in the same direction as the hsp 60 promoter.

Fig. 20 shows electrophoresis test results comparing secretion of recombinant mature *M. tuberculosis* 32A KD major extracellular protein at 28°C (Lane 3) and 37°C (Lane 2).

Fig. 21 is a graphical comparison of the growth of guinea pig lymphoblasts in the presence of various concentrations of recombinant human and murine IL-12.

Fig. 22 is a graphical comparison of the growth of 35 guinea pig lymphoblasts in the presence of various

concentrations of recombinant human and murine IL-12 from a guinea pig different from that of Fig. 21.

Fig. 23 is a graphical comparison of mean guinea pig body weight gain or loss of animals immunized with a vaccine comprising a combination of purified 32A KD, 30 KD, and 16 KD extracellular proteins, MF 59 adjuvant, and IL-12 versus nonimmunized controls following exposure to an aerosolized lethal dose of *M. tuberculosis*.

Fig. 24 is a graphical comparison of mean guinea pig body weight gain or loss of animals immunized with a vaccine comprising a combination of purified 32A KD, 30 KD, and 16 KD extracellular proteins with MF 59 adjuvant, with IL-12, and with a mixture of MF 59 and IL-12 versus nonimmunized controls following exposure to an aerosolized lethal dose of *M. tuberculosis*.

Detailed Description

The present invention is directed to compounds and methods for their production and use against pathogenic organisms as vaccines and immunotherapeutic agents. More specifically, the present invention is directed to the production and use of majorly abundant extracellular products released by pathogenic organisms, their immunogenic analogs or the associated genetic material encoding therefor as vaccines or immunotherapeutic agents and to associated methods for generating protective immunity in mammalian hosts against infection. These compounds will be referred to as vaccines throughout this application for purposes of simplicity.

In exemplary embodiments, illustrative of the teachings of the present invention, the majorly abundant extracellular products of *M. tuberculosis* were distinguished and subsequently purified. Guinea pigs were immunized with purified forms of these majorly prevalent extracellular products with no determination of the individual product's specific molecular immunogenicity. Further, the

007363-0149

exemplary immunizations were carried out using the purified extracellular products alone or in combination and with various dosages and routes of administration. Those skilled in the art will recognize that the foregoing
5 strategy can be utilized with any pathogenic organism or bacteria to practice the method of the present invention and, accordingly, the present invention is not specifically limited to vaccines and methods directed against *M. tuberculosis*.

10 In these exemplary embodiments, the majorly abundant extracellular products of *M. tuberculosis* were separated and purified using column chromatography. Determination of the relative abundance and purification of the extracellular products was accomplished using polyacrylamide
15 gel electrophoresis. Following purification of the vaccine components, guinea pigs were vaccinated with the majorly abundant extracellular products alone or in combination and subsequently challenged with *M. tuberculosis*. As will be discussed in detail, in addition to developing
20 the expected measurable responses to these extracellular products following immunization, the vaccines of the present invention unexpectedly conferred an effective immunity in these laboratory animals against subsequent lethal doses of aerosolized *M. tuberculosis*.

25 While these exemplary embodiments used purified forms of the extracellular products, those skilled in the art will appreciate that the present invention may easily be practiced using immunogenic analogs which are produced through recombinant means or other forms of chemical synthesis using techniques well known in the art. Further,
30 immunogenic analogs, homologs or selected segments of the majorly abundant extracellular products may be employed in lieu of the naturally occurring products within the scope and teaching of the present invention.

35 A further understanding of the present invention will be provided to those skilled in the art from the following

447273-663363

nonlimiting examples which illustrate exemplary protocols for the identification, isolation, production and use of majorly abundant extracellular products (alone and in combination) as vaccines.

5

Example 1

Isolation and Production of Bulk Extracellular Proteins (EP) from *Mycobacterium tuberculosis*

M. tuberculosis Erdman strain (ATCC 35801) was obtained from the American Tissue Culture Collection (Rockville, Md.). The lyophilized bacteria were reconstituted in Middlebrook 7H9 culture medium (Difco Laboratories, Detroit, Mich.) and maintained on Middlebrook 7H11 agar. 7H11 agar was prepared using Bacto Middlebrook 7H10 agar (Difco), OADC Enrichment Medium (Difco), 0.1% casein enzymatic hydrolysate (Sigma), and glycerol as previously described by Cohn (Cohn, M.1., *Am. Rev. Respir. Dis.* 98:295-296) and incorporated herein by reference. Following sterilization by autoclaving, the agar was dispensed into bacteriologic petri dishes (100 by 15 mm) and allowed to cool.

M. tuberculosis was then plated using sterile techniques and grown at 37°C in 5% CO₂-95% air, 100% humidity. After culture on 7H11 for 7 days, the colonies were scraped from the plates, suspended in 7H9 broth to 10⁸ CFU/ml and aliquoted into 1.8-ml Nunc cryotubes (Roskilde, Denmark). Each liter of the broth was prepared by rehydrating 4.7 g of Bacto Middlebrook 7H9 powder with 998 ml of distilled water, and 2 ml of glycerol (Sigma Chemical Co., St. Louis, Mo.) before adjusting the mixture to a pH value of 6.75 and autoclaving the broth for 15 min at 121°C. The aliquoted cells were then slowly frozen and stored at -70°C. Cells stored under these conditions remained viable indefinitely and were used as needed.

Bulk extracellular protein (EP) preparations were obtained from cultures of *M. tuberculosis* grown in the

Middlebrook 7H9 broth made as above. Following reconstitution, 150 ml aliquots of the broth were autoclaved for 15 min at 121°C and dispensed into vented Co-star 225 cm² tissue culture flasks. *M. tuberculosis* cells stored at
5 -70°C as described in the previous paragraph were thawed and used to inoculate 7H11 agar plates. After culture for 7 days, the colonies were scraped from the plates, suspended in a few ml of 7H9 broth, and sonicated in a water bath to form a single cell suspension. The *M. tubercu-*
10 *losis* cells were suspended in the sterile 150 ml aliquots at an initial optical density of 0.05, as determined by a Perkin-Elmer Junior model 35 spectrophotometer (Norwalk, Conn). The cells were then incubated at 37°C in 5% CO₂-95% air for 3 weeks until the suspension showed an optical
15 density of 0.4 to 0.5. These cultures were used as stock bottles for subsequent cultures also in 7H9 broth. The stock bottles were sonicated in a water bath to form a single cell suspension. The *M. tuberculosis* cells were then diluted in 7H9 broth to an initial optical density of
20 0.05 and incubated at 37°C in 5% CO₂-95% air for 2½ to 3 weeks until the suspension showed an optical density of 0.4 to 0.5. Culture supernatant was then decanted and filter sterilized sequentially through 0.8 µm and 0.2 µm low-protein-binding filters (Gelman Sciences Inc., Ann
25 Arbor, Mich.). The filtrate was then concentrated approximately 35 fold in a Filtron Minisette with an Omega membrane having a 10 KD cutoff and stored at 4°C. Analysis of the bulk extracellular protein preparation by sodium deodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
30 PAGE) revealed a protein composition with multiple bands. Bulk extracellular protein mixture (EP) was prepared by obtaining a 40-95% ammonium sulfate cut of the culture filtrate.

Purification of Principal Majorly Abundant Extracellular Products of *Mycobacterium tuberculosis*

20 Following centrifugation, the precipitated proteins were resolubilized in the appropriate cold buffer and dialyzed extensively in a Spectrapor dialysis membrane (Spectrum Medical Industries, Los Angeles, California) with a 6,000 to 8,000 molecular weight cut-off to remove
25 the salt. Extracellular protein concentration was determined by a bicinchoninic acid protein assay (Pierce Chemical Co., Rockford, Illinois) and fraction components were determined using SDS-PAGE. The fractions were then applied to chromatography columns for further purification.

UCLA\ID-VACCINE\120243.APP\MAK/r/12/196 11:08am

A. 110 KD Extracellular Product

1. A 50-100% ammonium sulfate precipitate was obtained as discussed above.
2. The resolubilized precipitate was dialyzed and applied to a DEAE Sepharose CL-6B or QAE Sepharose ion exchange column in column buffer consisting of 10% sorbitol, 10 mM potassium phosphate, pH 7, 5 mM 2-mercaptoethanol, and 0.2 mM EDTA and eluted with a sodium chloride gradient. Fractions containing 110 KD protein elute at approximately 550 mM salt and were collected.
3. Collected fractions were applied to S200 Sepharose size fractionation column in PBS (phosphate buffered saline) buffer. The protein eluted as a homogeneous 110 KD protein.

B. 80 KD Extracellular Product

1. The 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded and the 25-60% ammonium sulfate cut (overnight at 0°C) was retained as discussed above.
2. A DEAE CL-6B column (Pharmacia) was charged with 25mM Tris, pH 8.7 containing 1M NaCl and equilibrated with 25mM Tris, pH 8.7, 10mM NaCl and the protein sample was dialyzed against 25mM Tris, pH 8.7, 10mM NaCl and applied to the column. The column was washed overnight with the same buffer. A first salt gradient of 10mM to 200 mM NaCl in 25mM Tris, pH 8.7 was run through the column to elute other proteins. A second salt gradient (200 to 300 mM NaCl) was run through the column and the 80 KD protein eluted at approximately 275 mM NaCl.
3. A Q-Sepharose HP column was charged with 25mM Tris, pH 8.7, 1M NaCl and re-equilibrated to 25mM Tris, pH 8.7, 10mM NaCl. The protein

sample was dialyzed against 25mM Tris, pH 8.7, 10mM NaCl and applied to the column. The column was washed in the same buffer and then eluted with 200-300 mM NaCl in 25mM Tris, pH 8.7.

- 5 4. Fractions containing the 80 KD protein were collected and dialyzed against 25mM Tris, pH 8.7, 10mM NaCl, and then concentrated in a Speed-Vac concentrator to 1-2 ml. The protein sample was applied to a Superdex 75 column and
- 10 eluted with 25 mM Tris, pH 8.7, 150 mM NaCl. The 80 KD protein eluted as a homogenous protein.

C. 71 KD Extracellular Product

- 15 1. A 40-95% ammonium sulfate precipitate was obtained as discussed above with the exception that the 71 KD product was cultured in 7H9 broth at pH 7.4 and at 0% CO₂ and heat-shocked at 42°C for 3h once per week. The precipitate was dialyzed against Initial Buffer (20 mM Hepes,
- 20 2 mM MgAc, 25 mM KCl, 10 mM (NH₄)₂SO₄, 0.8 mM DL-Dithiothreitol, pH 7.0).
- 25 2. The resolubilized precipitate was applied to an ATP Agarose column equilibrated with Initial Buffer. Effluent was collected and reapplied to the ATP Agarose column. The 71 KD protein bound to the column.
- 30 3. Subsequently the ATP Agarose column was washed, first with Initial Buffer, then 1 M KCl, then Initial Buffer.
4. Homogeneous 71 KD protein was eluted from the column with 10 mM ATP and dialyzed against phosphate buffer.

D. 58 KD Extracellular Product

1. A 25-50% ammonium sulfate precipitate was obtained as discussed above.
2. The resolubilized precipitate was dialyzed and applied to a DEAE-Sepharose CL-6B or QAE-Sepharose column and eluted with NaCl. Collected fractions containing the 58 KD Protein eluted at approximately 400 mM NaCl.
3. Collected fractions were then applied to a Sepharose CL-6B size fractionation column. The protein eluted at approximately 670-700,000 Daltons.
4. The eluted protein was applied to a thiopropyl-sepharose column. The homogeneous 58 KD protein eluted at approximately 250-350 mM 2-mercaptoethanol. The eluted protein was monitored using SDS-PAGE and exhibited the single band shown in Fig. 1A, col. 2.

E. 45 KD Extracellular Product

1. a. A 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded.
- b. The 25-60% ammonium sulfate cut (overnight at 0°C) was retained.
2. a. A DEAE CL-6B column (Pharmacia) was charged with 2.5 mM Tris, pH 8.7 containing 1 M NaCl and equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7.
- b. The protein sample was dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7 and applied to column. The column was then washed overnight with the same buffer.
- c. The column was eluted with a salt gradient (10 mM to 200 mM) in 25 mM Tris, pH 8.7 buffer. The 45 KD protein eluted at approximately 40 mM NaCl.

3. a. A Q-Sepharose HP (Pharmacia) column was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl and re-equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7.
- 5 b. The protein sample was dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7 and applied to column with subsequent washing using the same buffer.
- 10 c. The column was eluted with 10-150 mM NaCl in 25 mM Tris, pH 8.7.
4. a. Fractions containing the 45 KD product were collected, pooled and dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7, before concentration to 1 ml in a Speed Vac concentrator.
- 15 b. Concentrate was Applied to Superdex 75 column equilibrated with 25 mM Tris 150 mM NaCl, pH 8.7. The product eluted as a homogeneous protein. The eluted protein was monitored using SDS-PAGE and resulted in the single band shown in Fig. 1B, col. 2.
- 20

F. 32 KD Extracellular Product (A)

- 25 1. a. A 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded.
- b. The 25-60% ammonium sulfate cut (overnight at 0°C) was retained.
- 30 2. a. A DEAE CL-6B column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl and then equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7.
- b. The protein sample was dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing overnight with same buffer.
- 35

- 5 c. The column was eluted with a salt gradient (10 mM to 200 mM) in 25 mM Tris, pH 8.7 buffer. The 32 KD protein eluted at approximately 70 mM NaCl.
- 10 3. a. Fractions containing the 32 KD product were collected, pooled and dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7, before concentrating the protein sample to 1 ml in a Speed-Vac Concentrator.
- b. The concentrate was then Applied to a Superdex 75 column equilibrated with 25 mM Tris, 150 mM NaCl, pH 8.7 and eluted with this buffer. The 32 KD product eluted as homogeneous protein.
- 15 4. a. A Q-Sepharose HP column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl, and re-equilibrated with 25 mM Tris, 10mM NaCl, pH 8.7.
- 20 b. The protein sample was dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing in the same buffer.
- 25 c. The column was eluted with a 100-300 mM NaCl gradient. Labeled 32A, the homogeneous protein elutes at approximately 120 mM NaCl and is shown as a single band in Fig. 1B, col. 4.

G. 32 KD Extracellular Product (B)

- 30 1. a. A 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded.
- b. The 25-60% ammonium sulfate cut (overnight at 0°C) was retained.
2. a. A DEAE CL-6B column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl

and then equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7.

- 5 b. The protein sample was dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing overnight with same buffer.
- 10 c. A preliminary salt gradient of 10 mM to 200 mM NaCl in 25 mM Tris, pH 8.7 was run, eluting various proteins. Following column equilibration, a second salt gradient (200 to 300 mM NaCl) was run. The 32 KD protein eluted at approximately 225 mM NaCl.
- 15 3. a. A Q-Sepharose HP column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl, and re-equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7.
- 20 b. The protein sample was dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing in the same buffer.
- 25 c. The column was eluted with a 200-300 mM NaCl gradient in the same buffer.
- 30 4. a. Fractions containing the 32 KD product were collected, pooled and dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7, before concentrating the protein sample to 1 ml in a Speed-Vac Concentrator.
- 35 b. The concentrate was then applied to a Superdex 75 column equilibrated with 25 mM Tris, 150 mM NaCl, pH 8.7 and eluted with the same buffer. The 32 KD product, labeled 32B to distinguish it from the protein of 32 KD separated using protocol H, eluted as homogeneous protein and is shown as a single band on Fig. 1B, col. 3.

H. 30 KD Extracellular Product

1. a. A 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded.
- 5 b. The 25-60% ammonium sulfate cut (overnight at 0°C) was retained.
2. a. A DEAE CL-6B column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl and then equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7.
- 10 b. The protein sample was dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing overnight with same buffer.
- 15 c. The column was eluted with a salt gradient (10 mM to 200 mM) in 25 mM Tris, pH 8.7 buffer. The 30 KD protein eluted at approximately 140 mM NaCl.
- 20 3. a. Fractions containing the 30 KD product were collected, pooled and dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7, before concentrating the protein sample to 1 ml in a Speed-Vac Concentrator.
- 25 b. The concentrate was then Applied to a Superdex 75 column equilibrated with 25 mM Tris, 150 mM NaCl, pH 8.7 and eluted with this buffer. The 30 KD product eluted as homogeneous protein and is shown as a single band on Fig. 1B, col. 5.

I. 24 KD Extracellular Product

- 30 1. a. A 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded.
- b. The 25-60% ammonium sulfate cut (overnight at 0°C) was retained.
2. a. A DEAE CL-6B column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl
- 35

and then equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7.

- 5 b. The protein sample was dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing overnight with same buffer.
 - 10 c. A preliminary salt gradient of 10 mM to 200 mM NaCl in 25 mM Tris, pH 8.7 was run, eluting various proteins. Following column equilibration a second salt gradient (200 to 300 mM NaCl) was run. The 24 KD elutes at approximately 250 mM NaCl.
 - 15 3. a. A Q-Sepharose HP column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl, and re-equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7.
 - 20 b. The protein sample was dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing in the same buffer.
 - 25 c. The column was eluted with a 200-300 mM NaCl gradient in the same buffer.
 - 25 4. a. Fractions containing the 24 KD product were collected, pooled and dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7, before concentrating the protein sample to 1 ml in a Speed-Vac Concentrator.
 - 30 b. The concentrate was then applied to a Superdex 75 column equilibrated with 25 mM Tris, 150 mM NaCl, pH 8.7 and eluted with the same buffer. The 24 KD product eluted as homogeneous protein and is shown as a single band on Fig. 1B, col 7.

J. 23.5 KD Extracellular Product

1. a. A 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded.
- 5 b. The 25-60% ammonium sulfate cut (overnight at 0°C) was retained.
2. a. A DEAE CL-6B column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl and then equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7.
- 10 b. The protein sample was dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7 and applied to the column prior to subsequent washing overnight with same buffer.
- 15 c. The column was eluted with a salt gradient (10 mM to 200 mM) in 25 mM Tris, pH 8.7 buffer. The 23.5 KD protein eluted at approximately 80 mM NaCl.
- 20 3. a. A Q-Sepharose HP column was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl, and re-equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7.
- 25 b. The protein sample was dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing in the same buffer.
- 30 c. The column was eluted with 100-300 mM NaCl in 25 mM Tris, pH 8.7.
- 35 d. Steps 3a to 3c were repeated.
4. a. Fractions containing 23.5 KD product were collected, pooled and dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7, before concentrating the protein sample to 1 ml in a Speed-Vac Concentrator.
- b. The concentrate was then applied to a Superdex 75 column equilibrated with 25 mM Tris, 150 mM NaCl, pH 8.7 and eluted with

0878533-0149

the same buffer. The 23.5 KD product eluted as homogeneous protein. The eluted protein was monitored using SDS-PAGE and resulted in the single band shown in Fig. 1B, col 6.

5

K. 23 KD Extracellular Product

1. a. Ammonium sulfate cuts of 0-25% (1h at 0°C) and 25-60% (overnight at 0°C) were discarded.
- 10 b. A 60-95% ammonium sulfate cut was retained.
2. a. A DEAE CL-6B column (Pharmacia) was charged with 50 mM Bis-Tris pH 7.0 containing 1 M NaCl and equilibrated with 50 mM Bis-Tris, 100 mM NaCl, pH 7.0.
- 15 b. The protein sample was dialyzed against 50 mM Bis-Tris, pH 7.0, 100 mM NaCl buffer and applied to the column before washing the column overnight with the same buffer.
- 20 c. The column was eluted with a 100 to 300 mM NaCl linear gradient in 50 mM Bis-Tris pH 7.0.
- 25 d. Fractions were collected containing the 23 KD protein which eluted at approximately 100-150 mM NaCl.
3. a. The protein fractions were dialyzed against 25 mM Tris, pH 8.7, 10 mM NaCl and concentrated to 1-2 ml on a Savant Speed Vac Concentrator.
- 30 b. The concentrate was applied to a Superdex 75 column equilibrated with 25 mM Tris, 150 mM NaCl, pH 8.7. The product elutes as a homogeneous protein as is shown in Fig. 1B col. 8.

1. 16 KD Extracellular Product

1. a. A 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded.
- 5 b. The 25-60% ammonium sulfate cut (overnight at 0°C) was retained.
2. a. A DEAE CL-6B column (Pharmacia) was charged with 2.5 mM Tris, pH 8.7 containing 1 M NaCl and then equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7.
- 10 b. The protein sample was dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing overnight in the same buffer.
- 15 c. The column was eluted with a salt gradient (10 mM to 200 mM) in 25 mM Tris, pH 8.7 buffer. The 16 KD protein eluted at approximately 50 mM NaCl.
- 20 3. a. Fractions containing 16 KD product were collected, pooled and dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7, before concentrating the protein sample to 1 ml in a Speed-Vac Concentrator.
- 25 b. The concentrate was then applied to a Superdex 75 column equilibrated with 25 mM Tris, 150 mM NaCl, pH 8.7 and eluted with the same buffer. A 16 KD product eluted as homogeneous protein. The eluted protein was monitored using SDS-PAGE and resulted in the single band shown in Fig. 1B, col. 9.
- 30

M. 14 KD Extracellular Product

1. a. A 0-25% ammonium sulfate cut (1 hour at 0°C) was discarded.
- 35 b. The 25-60% ammonium sulfate cut (overnight at 0°C) was retained.

2. a. A DEAE CL-6B column (Pharmacia) was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl and then equilibrated with 25 mM Tris, 10 mM NaCl, pH 8.7.
- 5 b. The protein sample was dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing overnight in the same buffer.
- 10 c. The column was eluted with a salt gradient (10 mM to 200 mM) in 25 mM Tris, pH 8.7 buffer. The 14 KD protein eluted at approximately 60 mM NaCl.
- 15 3. a. A Q-Sepharose HP column was charged with 25 mM Tris, pH 8.7 containing 1 M NaCl, and re-equilibrated with 25 mM NaCl, pH 8.7.
- 20 b. The protein sample was dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7 and applied to the column with subsequent washing in the same buffer.
- c. The column was eluted with 10-150 mM NaCl in 25 mM Tris, pH 8.7.
- d. Steps 3a through 3c were repeated.
- 25 4. a. Fractions containing 14 KD product were collected, pooled and dialyzed against 25 mM Tris, 10 mM NaCl, pH 8.7, before concentrating the protein sample to 1 ml in a Speed-Vac Concentrator.
- 30 b. The concentrate was then applied to a Superdex 75 column equilibrated with 25 mM Tris, 150 mM NaCl, pH 8.7 and eluted with this buffer. The 14 KD product eluted as homogeneous protein. The eluted protein was monitored using SDS-PAGE and resulted in the single band shown in Fig. 1C, col 2.

N. 12 KD Extracellular Products

1. A 0-10% ammonium sulfate precipitate was obtained (overnight at 4°C).
2. The resolubilized precipitate was applied to a S200 Sephacryl size fractionation column eluting the protein as a 12 KD molecule.
3. The protein fractions were applied to a DEAE-Sepharose CL-6B or QAE-Sepharose ion exchange column and eluted with an NaCl gradient as previously described. Fractions containing two homogeneous proteins having molecular weights of approximately 12 KD eluted at approximately 300-350 mM NaCl and were collected. The proteins were labeled 12A and 12B and purified as a doublet shown in Fig. 1D, col. 2.

As illustrated in the SDS-PAGE profile of Fig. 1, the principal or majorly abundant extracellular proteins of *M. tuberculosis* were purified to homogeneity through the use of the protocols detailed in Examples 2A - 2N above. More particularly, Fig. 1 illustrates four exemplary 12.5% acrylamide gels developed using SDS-PAGE and labeled 1A, 1B, 1C, and 1D. The standard in lane 1 of gels 1A-1C has proteins with molecular weights of 66, 45, 36, 29, 24, 20, and 14 KD. In gel 1D the standard in lane 1 contains proteins with molecular weights of 68, 45, 31, 29, 20, and 14 KD. The lanes containing the respective purified extracellular products show essentially one band at the reported molecular weight of the individual protein. It should be noted that in gel 1 D the 12 KD protein runs as a doublet visible in lane 2. Sequence analysis shows that the lower 12 KD (or 12B KD band) is equivalent to the upper 12 KD (or 12A KD) band except that it lacks the first 3 N-terminal amino acids.

Further analysis of these individual exemplary majorly abundant extracellular products is provided in

Fig. 2. More particularly Fig. 2 is a tabular compilation of N-terminal sequence data obtained from these purified extracellular products showing that the majority of the isolated products are indeed distinct (Sequence ID Nos. 1-14). Proteins 32A, 32B and 30 all had the same 5 N-terminal amino acids therefore further sequencing was necessary to fully characterize and differentiate them. Fig. 3 shows the extended N-terminal amino acid sequences for these three purified secretory products (Sequence ID Nos. 15-17). Different amino acids at positions 16 (Sequence ID No. 17), 31 (Sequence ID No. 16) and 36 (Sequence ID No. 16) demonstrate that these isolated proteins are distinct from one another despite their similarity in molecular weight.

In addition to proteins 30, 32A and 32B, extended N-terminal amino acid sequences of other majorly abundant extracellular products were determined to provide primary structural data and to uncover possible relationships between the proteins. Sequencing was performed on the extracellular products purified according to Example 2 using techniques well known in the art. Varying lengths of the N-terminal amino acid sequence, determined for each individual extracellular product, are shown below identified by the apparent molecular weight of the intact protein, and represented using standard one letter abbreviations for the naturally occurring amino acids. In keeping with established rules of notation, the N-terminal sequences are written left to right in the direction of the amino terminus to the carboxy terminus. Those positions where the identity of the determined amino acid is less than certain are underlined. Where the amino acid at a particular position is unknown or ambiguous, the position in the sequence is represented by a dash. Finally, where two amino acids are separated by a slash, the correct constituent has not been explicitly identified and either one may occupy the position in that sequence.

08786533-01249

PROTEINN-TERMINAL AMINO ACID SEQUENCE

12 KD 5 10 15 20 25 30 35
FDTRL MRLED EMKEG RYEVN AELPG VDPDK DVDIM

5 40 45
VRDGQ LTIKA ERT

(Sequence ID No. 18)

14 KD 5 10 15 20 25 30
ADPRL QFTAT TLPGA PFDGA S/NLQK PAVLW

(Sequence ID Nos. 19 and 20)

16 KD 5 10 15 20 25 30
AYPIT GKLGS ELTMT DTVGQ VVLGW KVSDL

15 35 40 45
F/YKSTA VIPGY TV-EQ QI

(Sequence ID Nos. 21 and 22)

23 KD 5 10 15 20
AETYL PDLGW DYGA EPHIS GQ

(Sequence ID No. 23)

23.5 KD 5 10
APKTY -EELK GTD

(Sequence ID No. 24)

24 KD 5 10 15 20 25 30 35
APYEN LMVPS PSMGR DIPVA FLAGG PHAVY LLDAF

40 45 50 55 60
NAGPD VSNWV TAGNA MMTLA -KGIC/S

(Sequence ID Nos. 25 and 26)

UCLAID-VACCINE\20243.APP\MAK\R\121196 11:08am

5 10 15 20 25 30 35
30 KD FSRPG LPVEY LQVPS PSMGR DIKVQ FQSGG NNSPA
 40
 VYLLD

5 (Sequence ID No. 27)

5 10 15 20 25 30 35
32A KD FSRPG LPVEY LQVPS PSMGR DIKVQ FQSGG ANSP-
 40
 10 LYLLD

(Sequence ID No. 28)

5 10 15 20
32B KD FSRPG LPVEY LQVPS A-MGR DI

15 (Sequence ID No. 29)

5 10 15 20 25 30
45 KD DPEPA PPVPD DAASP PDDAA APPAP ADPP-

(Sequence ID No. 30)

5 10 15 20
58 KD TEKTP DDVFK LAKDE KVLYL

(Sequence ID No. 31)

25 5
71 KD ARAVG I

(Sequence ID No. 32)

30 80 KD 5
 TDRVS VGN

(Sequence ID No. 33)

467270-EE99280

(Sequence ID No. 34)

30 KD DNA SEQUENCE

UCLA\ID-VACCINE\120243.APP\MAK/f/121196 11:08am

481/161
 AGG GCC GTG AAG CCC ACC GGC AGC GCT GCA ATC GGC TTG TCG
 arg ala val lys pro thr gly ser ala ala ile gly leu ser
 511/171
 5 ATG GCC GGC TCG TCG GCA ATG ATC TTG GCC GCC TAC CAC CCC
 met ala gly ser ser ala met ile leu ala ala tyr his pro
 541/181 571/191
 CAG CAG TTC ATC TAC GCC GGC TCG CTG TCG GCC CTG CTG GAC
 gln gln phe ile tyr ala gly ser leu ser ala leu leu asp
 601/201
 10 CCC TCT CAG GGG ATG GGG CCT AGC CTG ATC GGC CTC GCG ATG
 pro ser gln gly met gly pro ser leu ile gly leu ala met
 631/211 661/221
 GGT GAC GCC GGC GGT TAC AAG GCC GCA GAC ATG TGG GGT CCC
 15 gly asp ala gly gly tyr lys ala ala asp met trp gly pro
 691/231
 TCG AGT GAC CCG GCA TGG GAG CGC AAC GAC CCT ACG CAG CAG
 ser ser asp pro ala trp glu arg asn asp pro thr gln gln
 721/241
 20 ATC CCC AAG CTG GTC GCA AAC AAC ACC CGG CTA TGG GTT TAT
 ile pro lys leu val ala asn asn thr arg leu trp val tyr
 751/251 781/261
 TGC GGG AAC GGC ACC CCG AAC GAG TTG GGC GGT GCC AAC ATA
 cys gly asn gly thr pro asn glu leu gly gly ala asn ile
 811/271
 25 CCC GCC GAG TTC TTG GAG AAC TTC GTT CGT AGC AGC AAC CTG
 pro ala glu phe leu glu asn phe val arg ser ser asn leu
 841/281 871/291
 AAG TTC CAG GAT GCG TGC AAC GCC GCG GGC GGG CAC AAC GCC
 30 lys phe gln asp ala tyr asn ala ala gly gly his asn ala
 901/301
 GTG TTC AAC TTC CCG CCC AAC GGC ACG CAC AGC TGG GAG TAC
 val phe asn phe pro pro asn gly thr his ser trp glu tyr
 931/311
 35 TGG GGC GCT CAG CTC AAC GCC ATG AAG GGT GAC CTG CAG AGT
 trp gly ala gin leu asn ala met lys gly asp leu gln ser
 961/321
 TCG TTA GGC GCC GGC TGA
 ser leu gly ala gly OPA (Sequence ID No. 35)

40 32 KD DNA SEQUENCE

1/1 31/11
 ATG CAG CTT GTT GAC AGG GTT CGT GGC GCC GTC ACG GGT ATG
 met gln leu val asp arg val arg gly ala val thr gly met
 61/21
 45 TCG CGT CGA CTC GTG GTC GGG CCC CTC CCC CCG GCC CTA CTG
 ser arg arg leu val val gly ala val gly ala ala leu val
 91/31 121/41
 TCC GGT CTG GTC GGC GCC GTC GGT GGC ACG GCG ACC GCG GGG
 ser gly leu val gly ala val gly gly thr ala thr ala gly

UCLA\ID-VACCINE\120243_APP\MAK/R/121196 11:08am

901/301

GGC GTG TTC GAC TTC CCG GAC AGC GGT ACG CAC AGC TGG GAG
gly val phe asp phe pro asp ser gly thr his ser trp glu
931/311 961/321

5 TAC TGG GGC GCG CAG CTC AAC GCT ATG AAG CCC GAC CTG CAA
tyr trp gly ala gln leu asn ala met lys pro asp leu gln
991/331

CGG GCA CTG GGT GCC ACG CCC AAC ACC GGG CCC GCG CCC CAG
arg ala leu gly ala thr pro asn thr gly pro ala pro gln

10 GGC GCC TAG
gly ala AMB

(Sequence ID No. 36)

16 KD DNA SEQUENCE

1/1 31/11
atg AAG CTC ACC ACA ATG ATC AAG ACG GCA GTA GCG GTC GTG GCC atg GCG GCC ATC GCG
Met lys leu thr thr met ile lys thr ala val ala val val ala met ala ala ile ala
61/21 91/31

5 ACC TTT GCG GCA CCG GTC GCG TTG GCT GCC TAT CCC ATC ACC GGA AAA CTT GGC AGT GAG
thr phe ala ala pro val ala leu ala ala tyr pro ile thr gly lys leu gly ser glu
121/41 151/51

10 CTA ACG ATG ACC GAC ACC GTT GGC CAA GTC GTG CTC GGC TGG AAG GTC AGT GAT CTC AAA
leu thr met thr asp thr val gly gln val val leu gly trp lys val ser asp leu lys
181/61 211/71

TCC AGC ACG GCA GTC ATC CCC GGC TAT CCG GTG GCC GGC CAG GTC TGG GAG GCC ACT GCC
ser ser thr ala val ile pro gly tyr pro val ala gly gln val trp glu ala thr ala
241/81 271/91

15 ACG GTC AAT GCG ATT CGC GGC AGC GTC ACG CCC GCG GTC TCG CAG TTC AAT GCC CGC ACC
thr val asn ala ile arg gly ser val thr pro ala val ser gln phe asn ala arg thr
301/101 331/111

GCC GAC GGC ATC AAC TAC CCG GTG CTG TGG CAA GCC GCG GGC CCC GAC ACC ATT AGC GGA
ala asp gly ile asn tyr arg val leu trp gln ala ala gly pro asp thr ile ser gly
361/121 391/131

20 GCC ACT ATC CCC CAA GGC GAA CAA TCG ACC GGC AAA ATC TAC TTC GAT GTC ACC GGC CCA
ala thr ile pro gln gly glu gln ser thr gly lys ile tyr phe asp val thr gly pro
421/141 451/151

TCG CCA ACC ATC GTC GCG ATG AAC AAC GGC ATG GAG GAT CTG CTG ATT TGG GAG CCG TAG
ser pro thr ile val ala met asn asn gly met glu asp leu leu ile trp glu pro AMB

25

(Sequence ID No. 92)

58 KD DNA SEQUENCE

1/1 31/11
gtg ACG GAA AAG ACG CCC GAC GAC GTC TTC AAA CTT GCC AAG GAC GAG AAG GTC GAA TAT
val thr glu lys thr pro asp asp val phe lys leu ala lys asp glu lys val glu tyr
61/21 91/31

30 GTC GAC GTC CGG TTC TGT GAC CTG CCT GGC ATC ATG CAG CAC TTC ACG ATT CCG GCT TCG
val asp val arg phe cys asp leu pro gly ile met gln his phe thr ile pro ala ser
121/41 151/51

35 GCC TTT GAC AAG AGC GTG TTT GAC GAC GGC TTG GCC TTT GAC GGC TCG TCG ATT CGC GGC
ala phe asp lys ser val phe asp asp gly leu ala phe asp gly ser ser ile arg gly
181/61 211/71

TTC CAG TCG ATC CAC GAA TCC GAC ATG TTG CTT CTT CCC GAT CCC GAG ACG GCG CGC ATC
phe gln ser ile his glu ser asp met leu leu leu pro asp pro glu thr ala arg ile
241/81 271/91

40 GAC CCG TTC CGC GCG GCC AAG ACG CTG AAT ATC AAC TTC TTT GTG CAC GAC CCG TTC ACC
asp pro phe arg ala ala lys thr leu asn ile asn phe phe val his asp pro phe thr
301/101 331/111

CTG GAG CCG TAC TCC CGC GAC CCG CGC AAC ATC GCC CGC AAG GCC GAG AAC TAC CTG ATC
leu glu pro tyr ser arg asp pro arg asn ile ala arg lys ala glu asn tyr leu ile

361/121 391/131
 AGC ACT GGC ATC GCC GAC ACC GCA TAC TTC GGC GCC GAG GCC GAG TTC TAC ATT TTC GAT
 ser thr gly ile ala asp thr ala tyr phe gly ala glu ala glu phe tyr ile phe asp
 421/141 451/151
 5 TCG GTG AGC TTC GAC TCG CGC GCC AAC GGC TCC TTC TAC GAG GTG GAC GCC ATC TCG GGG
 ser val ser phe asp ser arg ala asn gly ser phe tyr glu val asp ala ile ser gly
 481/161 511/171
 10 TGG TGG AAC ACC GGC GCG GCG ACC GAG GCC GAC GGC AGT CCC AAC CGG GGC TAC AAG GTC
 trp trp asn thr gly ala ala thr glu ala asp gly ser pro asn arg gly tyr lys val
 541/181 571/191
 CGC CAC AAG GGC GGG TAT TTC CCA GTG GCC CCC AAC GAC CAA TAC GTC GAC CTG CGC GAC
 arg his lys gly gly tyr phe pro val ala pro asn asp gln tyr val asp leu arg asp
 601/201 631/211
 15 AAG ATG CTG ACC AAC CTG ATC AAC TCC GGC TTC ATC CTG GAG AAG GGC CAC CAC GAG GTG
 lys met leu thr asn leu ile asn ser gly phe ile leu glu lys gly his his glu val
 661/221 691/231
 GGC AGC GGC GGA CAG GCC GAG ATC AAC TAC CAG TTC AAT TCG CTG CTG CAC GCC GCC GAC
 gly ser gly gly gln ala glu ile asn tyr gln phe asn ser leu leu his ala ala asp
 721/241 751/251
 20 GAC ATG CAG TTG TAC AAG TAC ATC ATC AAG AAC ACC GCC TGG CAG AAC GGC AAA ACG GTC
 asp met gln leu tyr lys tyr ile ile lys asn thr ala trp gln asn gly lys thr val
 781/261 811/271
 ACG TTC ATG CCC AAG CCG CTG TTC GGC GAC AAC GGG TCC GGC ATG CAC TGT CAT CAG TCG
 thr phe met pro lys pro leu phe gly asp asn gly ser gly met his cys his gln ser
 841/281 871/291
 25 CTG TGG AAG GAC GGG GCC CCG CTG ATG TAC GAC GAG ACG GGT TAT GCC GGT CTG TCG GAC
 leu trp lys asp gly ala pro leu met tyr asp glu thr gly tyr ala gly leu ser asp
 901/301 931/311
 30 ACG GCC CGT CAT TAC ATC GGC GGC CTG TTA CAC CAC GCG CCG TCG CTG CTG GCC TTC ACC
 thr ala arg his tyr ile gly gly leu leu his his ala pro ser leu leu ala phe thr
 961/321 991/331
 AAC CCG ACG GTG AAC TCC TAC AAG CGG CTG GTT CCC GGT TAC GAG GCC CCG ATC AAC CTG
 asn pro thr val asn ser tyr lys arg leu val pro gly tyr glu ala pro ile asn leu
 1021/341 1051/351
 35 GTC TAT AGC CAG CGC AAC CCG TCG GCA TGC GTG CGC ATC CCG ATC ACC GGC AGC AAC CCG
 val tyr ser gln arg asn arg ser ala cys val arg ile pro ile thr gly ser asn pro
 1081/361 1111/371
 AAG GCC AAG CGG CTG GAG TTC CGA AGC CCC GAC TCG TCG GGC AAC CCG TAT CTG GCG TTC
 lys ala lys arg leu glu phe arg ser pro asp ser ser gly asn pro tyr leu ala phe
 1141/381 1171/391
 40 TCG GCC ATG CTG ATG GCA GGC CTG GAC GGT ATC AAC AAC AAG ATC GAG CCG CAG GCG CCC
 ser ala met leu met ala gly leu asp gly ile lys asn lys ile glu pro gln ala pro
 1201/401 1231/411
 45 GTC GAC AAG GAT CTC TAC GAG CTG CCG CCG GAA GAG GCC GCG AGT ATC CCG CAG ACT CCG
 val asp lys asp leu tyr glu leu pro pro glu glu ala ala ser ile pro gln thr pro
 1261/421 1291/431
 ACC CAG CTG TCA GAT GTG ATC GAC CGT CTC GAG GCC GAC CAC GAA TAC CTC ACC GAA GGA
 thr gln leu ser asp val ile asp arg leu glu ala asp his glu tyr leu thr glu gly
 1321/441 1351/451
 50 GGG GTG TTC ACA AAC GAC CTG ATC GAG ACG TGG ATC AGT TTC AAG CGC GAA AAC GAG ATC
 gly val phe thr asn asp leu ile glu thr trp ile ser phe lys arg glu asn glu ile
 1381/461 1411/471
 GAG CCG GTC AAC ATC CCG CCG CAT CCC TAC GAA TTC GCG CTG TAC TAC GAC GTT taa
 glu pro val asn ile arg pro his pro tyr glu phe ala leu tyr tyr asp val OCH

55

(Sequence ID No. 93)

08786533-012197

23.5 KD DNA SEQUENCE

1/1 31/11
 gtg CGC ATC AAG ATC TTC ATG CTG GTC ACC GCT GTC GTT TTG CTC TGT TGT TCG GST GTG
 val arg ile lys ile phe met leu val thr ala val val leu leu cys cys ser gly val
 5 61/21 91/31
 GCC ACG GCC GCG CCC AAG ACC TAC TGC GAG GAG TTG AAA GGC ACC GAT ACC GGC CAG GCG
 ala thr ala ala pro lys thr tyr cys glu glu leu lys gly thr asp thr gly gln ala
 121/41 151/51
 TGC CAG ATT CAA ATG TCC GAC CCG GCC TAC AAC ATC AAC ATC AGC CTG CCC AGT TAC TAC
 10 cys gln ile gln met ser asp pro ala tyr asn ile asn ile ser leu pro ser tyr tyr
 181/61 211/71
 CCC GAC CAG AAG TCG CTG GAA AAT TAC ATC GCC CAG ACG CGC GAC AAG TTC CTC AGC GCG
 pro asp gln lys ser leu glu asn tyr ile ala gln thr arg asp lys phe leu ser ala
 241/81 271/91
 15 GCC ACA TCG TCC ACT CCA CGC GAA GCC CCC TAC GAA TTG AAT ATC ACC TCG GCC ACA TAC
 ala thr ser ser thr pro arg glu ala pro tyr glu leu asn ile thr ser ala thr tyr
 301/101 331/111
 CAG TCC GCG ATA CCG CCG CGT GGT ACG CAG GCC GTG GTG CTC AAG GTC TAC CAG AAC GCC
 20 gln ser ala ile pro pro arg gly thr gln ala val val leu lys val tyr gln asn ala
 361/121 391/131
 GGC GGC ACG CAC CCA ACG ACC ACG TAC AAG GCC TTC GAT TGG GAC CAG GCC TAT CGC AAG
 gly gly thr his pro thr thr thr tyr lys ala phe asp trp asp gln ala tyr arg lys
 421/141 451/151
 CCA ATC ACC TAT GAC ACG CTG TCG CAG GCT GAC ACC GAT CCG CTG CCA GTC GTC TTC CCC
 25 pro ile thr tyr asp thr leu trp gln ala asp thr asp pro leu pro val val phe pro
 481/161 511/171
 ATT GTG CAA GGT GAA CTG AGC AAG CAG ACC GGA CAA CAG GTA TCG ATA GCG CCG AAT GCC
 ile val gln gly glu leu ser lys gln thr gly gln gln val ser ile ala pro asn ala
 541/181 571/191
 30 GGC TTG GAC CCG GTG AAT TAT CAG AAC TTC GCA GTC ACG AAC GAC GGG GTG ATT TTC TTC
 gly leu asp pro val asn tyr gln asn phe ala val thr asn asp gly val ile phe phe
 601/201 631/211
 TTC AAC CCG GGG GAG TTG CTG CCC GAA GCA GCC GGC CCA ACC CAG GTA TTG GTC CCA CGT
 phe asn pro gly glu leu leu pro glu ala ala gly pro thr gln val leu val pro arg
 35 661/221
 TCC GCG ATC GAC TCG ATG CTG GCC tag
 ser ala ile asp ser met leu ala AMB

(Sequence ID No. 94)

24 KD DNA SEQUENCE

40 1/1 31/11
 ATG AAG GGT CGG TCG GCG CTG CTG CGG GCG CTC TGG ATT GCC GCA CTG TCA TTC GGG TTG
 Met lys gly arg ser ala leu leu arg ala leu trp ile ala ala leu ser phe gly leu
 61/21 91/31
 GGC GGT GTC GCG GTA GCC GCG GAA CCC ACC GCC AAG GCC GCC CCA TAC GAG AAC CTG ATG
 45 gly gly val ala val ala ala glu pro thr ala lys ala ala pro tyr glu asn leu met
 121/41 151/51
 GTG CCG TCG CCC TCG ATG GGC CGG GAC ATC CCG GTG GCC TTC CTA GCC GGT GGG CCG CAC
 val pro ser pro ser met gly arg asp ile pro val ala phe leu ala gly gly pro his
 181/61 211/71
 50 GCG GTG TAT CTG CTG GAC GCC TTC AAC GCC GGC CCG GAT GTC AGT AAC TGG GTC ACC GCG
 ala val tyr leu leu asp ala phe asn ala gly pro asp val ser asn trp val thr ala
 241/81 271/91
 GGT AAC GCG ATG AAC ACG TTG GCG GGC AAG GGG ATT TCG GTG GTG GCA CCG GCC GGT GGT
 gly asn ala met asn thr leu ala gly lys gly ile ser val val ala pro ala gly gly
 301/101 331/111
 55 GCG TAC AGC ATG TAC ACC AAC TGG GAG CAG GAT GGC AGC AAG CAG TGG GAC ACC TTC TTG
 ala tyr ser met tyr thr asn trp glu gln asp gly ser lys gln trp asp thr phe leu

5
10
15
20
25

(Sequence ID No. 95)

5
10
15

As previously discussed, following the inability of traditional Western blot analysis to consistently identify the most immunogenically specific extracellular products,

the present inventor decided to analyze the immunogenicity of the majorly abundant extracellular products based upon their abundance and consequent ease of identification and isolation. Surprisingly, it was found that these majorly abundant extracellular products induce unexpectedly effective immune responses leading this inventor to conclude that they may function as vaccines. This surprising discovery led to the development of the nonlimiting functional theory of this invention discussed above.

To demonstrate the efficacy of the present invention, additional experiments were conducted using individual majorly abundant extracellular products and combinations thereof at various exemplary dosages to induce protective immunity in art accepted laboratory models. More specifically, purified individual majorly abundant extracellular products were used to induce protective immunity in guinea pigs which were then challenged with *M. tuberculosis*. Upon showing that these proteins were capable of inducing protective immunity, combinations of five purified majorly abundant extracellular products was similarly tested using differing routes of administration. In particular the 30 KD abundant extracellular product was used to induce protective immunity in the accepted animal model as was the purified form of the 71 KD extracellular product. As with the individual exemplary majorly abundant extracellular products the combination vaccines of five majorly abundant extracellular products conferred protection against challenge with lethal doses of *M. tuberculosis* as well. Results of the various studies of these exemplary vaccines of the present invention follow.

Specific pathogen-free male Hartley strain guinea pigs (Charles River Breeding Laboratories, North Wilmington, Massachusetts) were used in all experiments involving immunogenic or aerosol challenges with *M. tuberculosis*. The animals were housed two or three to a stainless steel cage and allowed free access to standard

467937-0-EE99280

guinea pig chow and water. After arrival at the animal facility, the guinea pigs were observed for at least one week prior to the start of each experiment to ensure that they were healthy.

5 Initial experiments were conducted using individual majorly abundant extracellular products believed to comprise between 3% to 25% of the total extracellular proteins normally present. These experiments demonstrate that majorly abundant extracellular products elicit an
10 effective immune response. More particularly, isolated 30 KD and 71 KD extracellular products were shown to be individually capable of generating a cell-mediated immune response that protected guinea pigs upon exposure to lethal doses of *M. tuberculosis* as follows.

15

Example 3

Purified 30 KD Protein Skin Testing for Cell-Mediated Immunity of 30 KD Immunized Guinea Pigs

To illustrate that a measurable immune response can be induced by purified forms of abundant extracellular
20 products, a cutaneous hypersensitivity assay was performed. Guinea pigs were immunized with the exemplary majorly abundant *M. tuberculosis* 30 KD secretory product purified according to Example 2 and believed to comprise approximately 25% of the total extracellular product of
25 *M. tuberculosis*. In three independent experiments, guinea pigs were immunized three times three weeks apart with 100 μ g of substantially purified 30 KD protein in SAF adjuvant. Control animals were similarly injected with buffer in SAF. Three weeks after the last immunization the
30 guinea pigs were challenged with the exemplary 30 KD protein in a cutaneous hypersensitivity assay.

Guinea pigs were shaved over the back and injections of 0.1, 1 and 10 μ g of 30 KD protein were administered intradermally with resulting erythema (redness of the
35 skin) and induration measured after 24 hours as shown in

UCLA-VID-VACCINE\120243.APP\MAK\R\121196 11:08am

Table A below. Data are reported in terms of mean measurement values for the group \pm standard error (SE) as determined using traditional methods. ND indicates that this particular aspect of the invention was not done.

5

Table A

Erythema (mm) to 30 KD (Mean \pm SE)

	Guinea Pig Status	n	0.1 μ g	1.0 μ g	10.0 μ g
10	<u>Expt. 1</u> Immunized	6	1.2 \pm 0.5	3.9 \pm 0.8	6.9 \pm 1.0
	Controls	5	ND	ND	3.0 \pm 0.9
	<u>Expt. 2</u> Immunized	6	0.5 \pm 0.5	5.4 \pm 0.7	8.1 \pm 0.6
	Controls	3	0 \pm 0	2.5 \pm 0	1.7 \pm 0.8
15	<u>Expt. 3</u> Immunized	6	ND	1.7 \pm 1.1	6.2 \pm 0.3
	Controls	3	ND	ND	2.0 \pm 0.0

Induration (mm) to 30 KD (Mean \pm SE)

	Guinea Pig Status	n	0.1 μ g	1.0 μ g	10.0 μ g
20	<u>Expt. 1</u> Immunized	6	0 \pm 0	3.3 \pm 0.3	5.6 \pm 0.9
	Controls	5	ND	ND	1.6 \pm 1.0
	<u>Expt. 2</u> Immunized	6	0 \pm 0	3.8 \pm 0.7	4.9 \pm 1.2
	Controls	3	0 \pm 0	0.8 \pm 0.8	1.7 \pm 0.8
	<u>Expt. 3</u> Immunized	6	ND	1.1 \pm 1.1	4.7 \pm 0.4
	Controls	3	ND	0 \pm 0	0 \pm 0

30 As shown in Table A, guinea pigs immunized with the exemplary 30 KD secretory product exhibited a strong cell-mediated immune response as evidenced by marked erythema and induration. In contrast, the control animals exhibited minimal response.

To confirm the immunoreactivity of the 30 KD secretory product and show its applicability to infectious tuberculosis, nonimmunized guinea pigs were infected with *M. tuberculosis* and challenged with this protein as follows:

Example 4

Purified 30 KD Protein Testing for Cell-Mediated Immune Responses of Guinea Pigs Infected With *M. tuberculosis*

10 To obtain bacteria for use in experiments requiring the infection of guinea pigs, *M. tuberculosis* was first cultured on 7H11 agar and passaged once through a guinea pig lung to insure that they were virulent. For this purpose, guinea pigs were challenged by aerosol with a 10
15 ml suspension of bacteria in 7H9 broth containing approximately 5×10^4 bacteria/ml. After the guinea pigs became ill, the animals were sacrificed and the lungs, containing prominent *M. tuberculosis* lesions, were removed. Each lung was ground up and cultured on 7H11 agar for 7 days to
20 10 days. The bacteria were scraped from the plates, diluted in 7H9 broth containing 10% glycerol, sonicated in a water bath to obtain a single cell suspension, and frozen slowly at -70°C at a concentration of approximately 2×10^7 viable bacteria/ml. Viability of the frozen cells
25 was measured by thawing the bacterial suspension and culturing serial dilutions of the suspension on 7H11 agar. Just before a challenge, a vial of bacterial cells was thawed and diluted to the desired concentration in 7H9 broth.

30 The guinea pigs were exposed to aerosols of the viable *M. tuberculosis* in a specially designed lucite aerosol chamber. The aerosol chamber measured 14 by 13 by 24 in. and contained two 6 inch diameter portals on opposite sides for introducing or removing guinea pigs. The
35 aerosol inlet was located at the center of the chamber

ceiling. A vacuum pump (Gast Mfg. Co., Benton Harbor, Michigan) delivered air at 30 lb/in² to a nebulizer-venturi unit (Mes Inc., Burbank, California), and an aerosol was generated from a 10-ml suspension of bacilli. A 0.2 μ m breathing circuit filter unit (Pall Biomedical Inc., Fajardo, Puerto Rico) was located at one end of the chamber to equilibrate the pressure inside and outside of the assembly. Due to safety considerations, the aerosol challenges were conducted with the chamber placed completely within a laminar flow hood.

The animals were exposed to pathogenic aerosol for 30 minutes during which time the suspension of bacilli in the nebulizer was completely exhausted. Each aerosol was generated from the 10 ml suspension containing approximately 5.0 x 10⁴ bacterial particles per ml. Previous studies have shown that guinea pig exposure to this concentration of bacteria consistently produces infections in nonprotected animals. Following aerosol infection, the guinea pigs were housed in stainless steel cages contained within a laminar flow biohazard safety enclosure (Airo Clean Engineering Inc., Edgemont, Pennsylvania) and observed for signs of illness. The animals were allowed free access to standard guinea pig chow and water throughout the experiment.

In this experiment, the infected guinea pigs were sacrificed and splenic lymphocyte proliferation was measured in response to various concentrations of the 30 KD protein. More specifically, splenic lymphocytes were obtained and purified as described by Brieman and Horwitz (*J. Exp. Med.* 164:799-811) which is incorporated herein by reference. The lymphocytes were adjusted to a final concentration of 10⁷/ml in RPMI 1640 (GIBCO Laboratories, Grand Island, New York) containing penicillin (100 U/ml), streptomycin (100 μ g/ml), and 10% fetal calf serum (GIBCO) and incubated with various concentrations of purified 30 KD secretory product in a total volume of 100 μ l in

microtest wells (96-well round-bottom tissue culture plate; Falcon Labware, Oxnard, California) for 2 days at 37°C in 5% CO₂-95% air and 100% humidity. Noninfected animals were used as negative controls. At the end of the incubation period, 0.25 µCi of [³H]thymidine (New England Nuclear, Boston, Massachusetts) was added to each well and the cells were further incubated for 2 hours at 37°C in 5% CO₂-95% air at 100% humidity. A multisample automated cell harvester (Skatron Inc., Sterling, Virginia) was used to wash each well, and the effluent was passed through a filtermat (Skatron). Filtermat sections representing separate microtest wells were placed in scintillation vials, and 2 ml of Ecoscint H liquid scintillation cocktail (National Diagnostics, Manville, New Jersey) was added. Beta particle emission was measured in a beta scintillation counter (Beckman Instruments Inc., Fullerton, California).

Tissue samples from the infected and noninfected guinea pigs were assayed against 1 and 10 µg/ml of isolated 30 KD secretory protein. Samples were then monitored for their ability to incorporate [³H]thymidine. The results of these assays were tabulated and presented in Table B below.

Data are reported as a stimulation index which, for the purposes of this disclosure, is defined as:
mean [³H]thymidine incorporation of lymphocytes incubated with antigen / mean [³H]thymidine incorporation of lymphocytes incubated without antigen.

08786533-012197

Table B
Stimulation Indices to 30 KD
(Mean \pm SE)

5	<u>Guinea Pig</u> <u>Status</u>	<u>n</u>	<u>1.0 μg/ml</u>	<u>10.0 μg/ml</u>
	Infected	6	2.2 \pm 0.2	9.7 \pm 4.6
	Controls	6	1.5 \pm 0.3	2.0 \pm 0.8

As shown in Table B, the cells of the infected animals exhibited a strong response to the exemplary 30 KD protein as manifested by dose dependant splenic lymphocyte proliferation in response to exposure to this majorly abundant secretory product. Conversely, the uninfected control animals showed little lymphocyte proliferation. Accordingly, the 30 KD secretory product clearly induces a cell-mediated immune response in mammals infected with *M. tuberculosis*.

To illustrate the protective aspects of the vaccines of the present invention, guinea pigs were immunized with purified 30 KD protein and exposed to *M. tuberculosis* as follows.

Example 5

Challenge of 30 KD Immunized Guinea Pig With Aerosolized *M. tuberculosis*

As before, the animals were immunized three times at three week intervals with 100 μ g of the exemplary 30 KD secretory protein in SAF. Control guinea pigs were immunized with 120 μ g of bulk EP in SAF or sham-immunized with buffer in the same adjuvant. Three weeks after the last immunization, the animals were challenged with aerosolized *M. tuberculosis* as described in Example 4. The survival rates for the three groups of animals were monitored and are graphically presented in Fig. 4. Absolute mortality was determined 14 weeks after challenge as presented in Table C below.

Table C

<u>Status of Guinea Pigs</u>	<u>Survivors/ Challenged</u>	<u>Percent Survival</u>
30 KD Immunized	4/6	67%
5 EP Immunized	3/6	50%
Sham Immunized	1/6	17%

As shown in Fig. 4 guinea pigs immunized three times with the exemplary 30 KD protein were protected against death. Approximately 67% of the guinea pigs immunized with the 30 KD protein survived whereas only 17% of the control sham-immunized guinea pigs survived.

Weight retention of the immunized animals was also monitored (data not shown) and further illustrates the prophylactic capacity of vaccines incorporating majorly abundant extracellular products produced by pathogenic bacteria as taught by the present invention. While the immunized animals appeared to maintain their weight, the high mortality rate of the sham-immunized animals precluded the graphical comparison between the immunized animals and the control animals.

Following conclusion of the weight monitoring study, the surviving animals were sacrificed and the right lung and spleen of each animal was assayed for viable *M. tuberculosis*. The animals were soaked in 2% amphyl solution (National Laboratories, Montvale, New Jersey), and the lungs and spleen were removed aseptically. The number of macroscopic primary surface lesions in the lungs were enumerated by visual inspection. Colony forming units (CFU) of *M. tuberculosis* in the right lung and spleen were determined by homogenizing each organ in 10 ml of 7H9 with a mortar and pestle and 90-mesh Norton Alundum (Fisher), serially diluting the tissue homogenate in 7H9, and culturing the dilutions on duplicate plates of 7H11 agar by using drops of 0.1 ml/drop. All plates were kept in

modular incubator chambers and incubated 12 to 14 days at 37°C in 5% CO₂, 95% air at 100% humidity. The assay was conducted using this protocol and the results of the counts are presented in Table D below in terms of mean colony forming units (CFU) ± standard error (SE).

Table D

Guinea Pig Status	n	Mean CFU ± SE	
		Right Lung	Spleen
10 30 KD Immunized	4	$3.4 \pm 1.7 \times 10^7$	$7.7 \pm 3.9 \times 10^6$
Sham-immunized	1	1.8×10^8	8.5×10^7
Log-Difference		0.73	1.04

As shown in Table D, immunization with the exemplary 30 KD secretory protein limited the growth of *M. tuberculosis* in the lung and the spleen. Although only data from the one surviving sham-immunized animal was available for comparative purposes, the four surviving 30 KD immunized animals had 0.7 log fewer CFU in their lungs and 1 log fewer CFU in their spleen than the surviving sham-immunized animal. Based on previous demonstrations of a high correlation between CFU counts and mortality, the surviving animal likely had fewer CFU in the lungs and spleen than the animals who died before a CFU analysis could be performed. Again this reduction of CFU in the lungs and spleens of the immunized animals conclusively demonstrates the scope and operability of the present invention.

The immunoprotective potential of another majorly abundant extracellular product from *M. tuberculosis*, the 71 KD extracellular product, was tested in its isolated form to demonstrate its immunoprotective capacity.

Example 6Purified 71 KD Protein Skin Test of Guinea PigsImmunized with a Bulk Preparation of EP

To demonstrate the potential of 71 KD protein to pro-
5 voke an effective immune response in animals, this iso-
lated majorly abundant extracellular product was used to
skin test guinea pigs immunized with a bulk preparation of
M. tuberculosis extracellular proteins (EP) in a cutaneous
hypersensitivity assay. As discussed above, bulk EP will
10 impart acquired immunity against infection by *M. tubercu-*
losis but to a lesser extent than the vaccines of the
present invention.

Guinea pigs were immunized on two occasions spaced
three weeks apart, with 120 μ g of a bulk preparation of EP
15 prepared as detailed in Example 1. The vaccination was
prepared in incomplete Freund's adjuvant with sham-immu-
nized animals receiving buffer in place of EP. Three
weeks after the last vaccination the guinea pigs from each
group were shaved over the back and skin tested with an
20 intradermal injection of 0.1, 1.0 and 10 μ g of 71 KD
protein. 10.0 μ g of buffer was used as a control and all
injections were performed using a total volume of 0.1 ml.
The diameters of erythema and induration were measured
after 24 hours with the results as shown in Table E below.
25 Data are reported in terms of mean measurement values for
the group \pm standard error (SE) as determined using
traditional methods.

Table E

Erythema (mm) to 71 KD (Mean \pm SE)

	<u>Guinea Pig Status</u>	<u>n</u>	<u>0.1 μg</u>	<u>1.0 μg</u>	<u>10.0 μg</u>
5	Immunized	4	6.5 \pm 0.7	11.9 \pm 1.4	18.9 \pm 2.2
	Controls	3	2.5 \pm 1.4	5.0 \pm 2.9	11.8 \pm 2.1

Induration (mm) to 71 KD (Mean \pm SE)

	<u>Guinea Pig Status</u>	<u>n</u>	<u>0.1 μg</u>	<u>1.0 μg</u>	<u>10.0 μg</u>
10	Immunized	4	3.6 \pm 1.1	6.8 \pm 1.1	11.6 \pm 0.8
	Controls	3	0.7 \pm 0.7	3.7 \pm 0.9	7.8 \pm 1.0

The responses of the immunized animals were almost twice the response of the guinea pigs challenged with buffer alone and were comparable to those challenged with bulk EP identical to that used to immunize the animals (data not shown).

To further confirm that the purified exemplary 71 KD majorly abundant extracellular product elicits cell-mediated immune responses, the bulk EP immunized guinea pigs were sacrificed and splenic lymphocyte proliferation was measured in response to various concentrations of the 71 KD protein. Nonimmunized animals were used as controls. Following the protocol of Example 4, the lymphocytes were incubated with and without 71 KD protein for 2 days and then assayed for their capacity to incorporate [3 H]thymidine.

Data is reported in terms of stimulation indices calculated as in Example 4. The results of this 71 KD challenge are shown in Table F below.

Table F
Stimulation Indices to 71 KD (Mean \pm SE)

	<u>Guinea Pig Status</u>	<u>n</u>	<u>0.01 μg/ml</u>	<u>0.1 μg/ml</u>	<u>1.0 μg/ml</u>
5	Immunized	4	1.5 \pm 0.1	2.3 \pm 0.5	8.1 \pm 2.2
	Controls	2	1.7 \pm 0.6	1.6 \pm 0.4	2.5 \pm 0.6

Stimulation Indices to EP (Mean \pm SE)

	<u>Guinea Pig Status</u>	<u>n</u>	<u>0.01 μg/ml</u>	<u>0.1 μg/ml</u>	<u>1.0 μg/ml</u>
10	Immunized	4	1.5 \pm 0.1	2.2 \pm 0.3	5.3 \pm 1.4
	Controls	2	1.4 \pm 0.2	1.5 \pm 0.2	1.2 \pm 0.1

As shown in Table F, stimulation indices for the lymphocyte proliferation assay were comparable to the results obtained in the cutaneous hypersensitivity assay.

15 Both the 71 KD and bulk EP tested samples showed responses between two and three times higher than those obtained with the controls indicating that isolated exemplary 71 KD majorly abundant extracellular product is capable of provoking a cell-mediated immune response in animals

20 immunized with *M. tuberculosis* extracts. However, it should again be emphasized that the purified majorly abundant or principal extracellular product is free of the problems associated with prior art or bulk compositions and is more readily adaptable to synthetic and commercial

25 production making the vaccines of the present invention superior to the prior art.

More particularly the bulk preparation cannot be manufactured easily on a large scale through modern biomolecular techniques. Any commercial production of

30 these unrefined bulk preparations containing all extracellular products would involve culturing vast amounts of the target pathogen or a closely related species and harvesting the resultant supernatant fluid. Such production

methodology is highly susceptible to contamination by the target pathogen, toxic byproducts or other parasitic agents. Further, the large number of immunogenic determinants in such a preparation is far more likely to provoke
 5 a toxic immune reaction in a susceptible segment of the immunized population. Using these unrefined bulk preparations also negates the use of the most popular skin tests currently used for tuberculosis screening and control.

In direct contrast, the vaccines of the present
 10 invention can be mass-produced in relative safety using high yield transformed hosts. Similarly, the vaccines of the present invention can be produced in identical, easy to standardize batches as opposed to the wider variable production of bulk extracellular products. Moreover, as
 15 the number of immunogenic determinants presented to the host immune system is relatively small, toxic reactions and the chance of invalidating popular screening tests are greatly reduced.

Example 7

20 Purified 71 KD Protein Skin Test of 71 KD Immunized Guinea Pigs

Following demonstration that the isolated exemplary 71 KD majorly abundant extracellular product generates a cell-mediated immune response in bulk EP immunized ani-
 25 mals, it was shown that the purified form of this majorly abundant product was able to induce a cell-mediated immune response in animals immunized with 71 KD.

Guinea pigs were twice vaccinated with 100 μ g of purified 71 KD protein in SAF three weeks apart. Control
 30 animals were sham-immunized with buffer in SAF on the same schedule. Three weeks after the last immunization both sets of animals were intradermally challenged with 1 and 10 μ g of isolated 71 KD protein. The resulting erythema and indurations were measured after 24 hours with the
 35 results shown in Table G below.

Table G

Erythema (mm) to 71 KD (Mean \pm SE)

	Guinea Pig Status	n	0 μ g	1.0 μ g	10.0 μ g
5	Immunized	3	0 \pm 0	6.5 \pm 1.5	15.0 \pm 1.5
	Controls	3	0 \pm 0	2.7 \pm 1.3	6.7 \pm 1.3

Induration (mm) to 71 KD (Mean \pm SE)

	Guinea Pig Status	n	0 μ g	1.0 μ g	10.0 μ g
10	Immunized	3	0 \pm 0	3.0 \pm 1.0	9.3 \pm 0.3
	Controls	3	0 \pm 0	0 \pm 0	1.3 \pm 1.3

The extent of induration and erythema was much greater in the immunized animals than in the nonimmunized control animals demonstrating that a strong cell-mediated immune response to 71 KD protein had been initiated by the vaccination protocol of the present invention.

To further confirm the capacity of this abundant extracellular product to induce an effective immune response on its own in accordance with the teachings of the present invention, lymphocyte proliferation assays were performed. Animals immunized as in Table G were sacrificed and splenic lymphocyte proliferative assays were run using the protocol established in Example 4. The tissue samples from the 71 KD immunized guinea pigs and those from the control guinea pigs were challenged with 0.1, 1 and 10 μ g/ml of isolated 71 KD protein and monitored for their ability to incorporate [3 H]thymidine. Stimulation indices were calculated as previously described. The results of these assays are presented in Table H below.

Table H
Stimulation Indices to 71 KD (Mean \pm SE)

	<u>Guinea Pig</u> <u>Status</u>	<u>n</u>	<u>0.1 μg/ml</u>	<u>1.0 μg/ml</u>	<u>10.0 μg/ml</u>
5	Immunized	3	4.0 \pm 1.3	5.6 \pm 2.5	12.2 \pm 5.1
	Controls	3	1.3 \pm 0.3	1.3 \pm 0.3	3.2 \pm 1.5

As with the cutaneous hypersensitivity assay, the 71 KD immunized animals showed a much higher response to purified 71 KD than did the sham-immunized controls. Though expected of a foreign protein, such results clearly show that a majorly abundant extracellular product has the capacity to induce an cell-mediated immune response.

After establishing that an isolated majorly abundant extracellular protein will induce an effective cell-mediated immune response, further experiments were conducted to confirm that any such response is cross-reactive against tubercle bacilli as follows.

Example 8

Purified 71 KD Protein Challenge of Guinea Pigs

20 Infected With *M. tuberculosis*

Nonimmunized guinea pigs were infected with aerosolized *M. tuberculosis* as reported in Example 4. Purified protein derivative (PPD-CT68; Connaught Laboratories Ltd.) was employed as the positive control to ensure that the infected animals were demonstrating a cell-mediated immune response indicative of *M. tuberculosis*. Widely used in the Mantoux test for tuberculosis exposure, PPD is generally prepared by ammonium sulfate fractionation and comprises a mixture of small proteins having an average molecular weight of approximately 10 KD. Immune responses to PPD are substantially analogous to those provoked by the bulk EP fractions isolated in Example 1.

Three weeks after infection the guinea pigs were challenged intradermally with 0.1, 1 and 10 μg of the exemplary purified majorly abundant 71 KD extracellular protein. Uninfected animals used as controls were similarly challenged with the isolated protein. The extent of erythema and induration were measured 24 hours later with the results reported in Table I below.

Table I

Erythema (mm) to 71 KD (Mean \pm SE)

10	Guinea Pig				
	<u>Status</u>	<u>n</u>	<u>0.1 μg</u>	<u>1.0 μg</u>	<u>10.0 μg</u>
	Infected	7	9.5 \pm 1.7	13.4 \pm 1.3	19.7 \pm 1.3
	Controls	6	2.3 \pm 2.3	3.5 \pm 2.2	7.8 \pm 1.9

Induration (mm) to 71 KD (Mean \pm SE)

15	Guinea Pig				
	<u>Status</u>	<u>n</u>	<u>0.1 μg</u>	<u>1.0 μg</u>	<u>10.0 μg</u>
	Infected	7	5.3 \pm 1.8	8.7 \pm 1.6	13.4 \pm 1.1
	Controls	6	0 \pm 0	0.8 \pm 0.8	0 \pm 0

As shown in Table I, strong immune responses are present in the infected animals challenged with the exemplary purified majorly abundant extracellular protein of the present invention. These responses are on the order of three to four times greater for erythema and more than 10 times greater for induration than those of the uninfected animals, confirming that the prominent 71 KD extracellular protein induces a strong cell-mediated immune response in *M. tuberculosis*-infected animals.

To further corroborate these results the infected animals and uninfected animals were sacrificed and subjected to a lymphocyte proliferative assay according to the protocol of Example 4. The tissue samples from both sets of guinea pigs were assayed against 0.1, 1 and 10

UCL/20243.APP/MAK/11/12/196 11:08am

$\mu\text{g/ml}$ of isolated 71 KD protein and PPD. The samples were then monitored for their ability to incorporate [^3H]thymidine as previously described with the results of these assays presented in Table J below.

5

Table J

Stimulation Indices to 71 KD (Mean \pm SE)

Guinea Pig Status	n	0.1 $\mu\text{g/ml}$	1.0 $\mu\text{g/ml}$	10.0 $\mu\text{g/ml}$
Infected	3	2.4 \pm 0.5	6.2 \pm 1.8	29.1 \pm 16.2
10 Controls	3	1.1 \pm 0.1	2.6 \pm 0.8	18.2 \pm 6.1

Stimulation Indices to PPD (Mean \pm SE)

Guinea Pig Status	n	0.1 $\mu\text{g/ml}$	1.0 $\mu\text{g/ml}$	10.0 $\mu\text{g/ml}$
Infected	3	1.0 \pm 0.1	4.0 \pm 1.5	11.4 \pm 3.4
15 Controls	3	0.9 \pm 0.2	0.9 \pm 0.03	1.5 \pm 0.3

As with the results of the cutaneous sensitivity assay, Table J shows that the stimulation indices were much higher for the infected tissue than for the uninfected samples. More specifically, the mean peak stimulation index of infected animals was 2-fold higher to the exemplary 71 KD protein and 3-fold higher to PPD than it was to uninfected controls confirming that a strong cell-mediated immune response is induced in animals infected with *M. tuberculosis* by the exemplary majorly abundant extracellular protein vaccines of the present invention.

Following this demonstration of cross-reactivity between the exemplary purified 71 KD majorly abundant protein and *M. tuberculosis*, additional experiments were performed to demonstrate that an effective immune response could be stimulated by these exemplary purified samples of the majorly abundant extracellular products as disclosed by the present invention.

UCLAID-VACCINE/20243.APP/MAK/R/121196 11:08am

Example 9Challenge of 71 KD Immunized Guinea Pigs
With Aerosolized *M. tuberculosis*

To demonstrate the immunoprotective capacity of
 5 exemplary majorly abundant or principal extracellular
 protein vaccines, guinea pigs were immunized twice, 3
 weeks apart, with 100 μ g of the exemplary majorly abundant
 71 KD protein purified according to Example 2. Control
 animals were immunized with 120 μ g bulk EP from Example 1
 10 or buffer. All animals were immunized using the adjuvant
 SAF. Three weeks after the last immunization, guinea pigs
 immunized with the exemplary 71 KD protein were skin-
 tested with 10 μ g of the material to evaluate whether a
 cell-mediated immune response had developed. The control
 15 animals and 71 KD immunized guinea pigs were then infected
 with aerosolized *M. tuberculosis* as detailed in Example 4.
 Following infection the animals were monitored and weighed
 for six months.

The graph of Fig. 5 contrasts the weight loss experi-
 20 enced by the sham-immunized group to the relatively normal
 weight gain shown by the 71 KD and bulk EP immunized
 animals. Data are the mean weights \pm SE for each group.
 Mortality curves for the same animals are shown in the
 graph of Fig. 6. The absolute mortality rates for the
 25 study are reported in Table K below.

Table K

<u>Status of Guinea Pigs</u>	<u>Survivors/ Challenged</u>	<u>Percent Survival</u>
71 KD Immunized	3/6	50%
30 EP Immunized	5/8	62.5%
Sham Immunized	0/6	0%

Both the weight loss curves and the mortality rates
 clearly show that the majorly abundant extracellular

proteins of the present invention confer a prophylactic immune response. This is emphasized by the fact that 100% of the nonimmunized animals died before the end of the monitoring period.

5

Example 10

Challenge of 71 KD Immunized Guinea Pigs
With Aerosolized *M. tuberculosis*

A similar experiment was conducted to verify the results of the previous Example and show that the administration of an exemplary principal extracellular protein can confer a protective immune response in animals. In this experiment, guinea pigs were again immunized three times, 3 weeks apart, with 100 μ g of the 71 KD extracellular protein in SAF. Control guinea pigs were sham-immunized with buffer in SAF. Three weeks after the last immunization, the animals were challenged with aerosolized *M. tuberculosis* and weighed weekly for 13 weeks. Mean weights \pm SE for each group of 6 guinea pigs were calculated and are graphically represented in Fig. 7. This curve shows that the sham-immunized animals lost a considerable amount of weight over the monitoring period while the immunized animals maintained a fairly consistent body weight. As loss of body mass or "consumption" is one of the classical side effects of tuberculosis, these results indicate that the growth and proliferation of tubercle bacilli in the immunized animals was inhibited by the exemplary vaccine of the present invention.

Protective immunity having been developed in guinea pigs through vaccination with an abundant extracellular product in an isolated form, experiments were run to demonstrate the inter-species immunoreactivity of the vaccines of the present invention and to further confirm the validity and applicability of the guinea pig model.

Example 11**Testing Cell-Mediated Immunity of PPD Positive Humans
With Purified 71 KD Protein**

To assess the cell-mediated component of a human
5 immune response to the exemplary 71 KD majorly abundant
protein, the proliferation of peripheral blood lymphocytes
from PPD-positive and PPD-negative individuals to the
protein were studied in the standard lymphocyte prolifera-
tion assay as reported in Example 4 above. A positive
10 PPD, or tuberculin, response is well known in the art as
being indicative of previous exposure to *M. tuberculosis*.
The proliferative response and corresponding incorporation
of [³H]thymidine were measured at two and four days. Data
for these studies is shown in Figs. 8A and 8B. Fig. 8A
15 shows the response to various levels of 71 KD after two
days while Fig. 8B shows the same responses at four days.

As illustrated in Figs. 8A and 8B, the mean peak
stimulation index of PPD-positive individuals was twofold
higher to the 71 KD protein and threefold higher to PPD
20 than that of PPD negative individuals. Among PPD-positive
individuals, there was a linear correlation between the
peak stimulation indices to the exemplary 71 KD protein
and to PPD demonstrating that a strong cell-mediated
response is stimulated by the most prominent or majorly
25 abundant extracellular products of *M. tuberculosis* in
humans previously exposed to *M. tuberculosis*. This data
corresponds to the reactivity profile seen in guinea pigs
and confirms the applicability of the guinea pig model to
other mammals subject to infection.

30 Thus, as with the previously discussed 30 KD exem-
plary protein, the development of a strong immune response
to the majorly abundant 71 KD extracellular product demon-
strates the broad scope of the present invention as evi-
denced by the fact that the 71 KD product is also effec-
35 tive at stimulating cell-mediated immunity in humans.

Again, it should be emphasized that the present invention is not limited to the extracellular products of *M. tuberculosis* or to the use of the exemplary 71 KD protein. Rather the teachings of the present invention are applicable to any majorly abundant extracellular product as demonstrated in the examples.

Additional studies were performed in order to ascertain whether combinations of majorly abundant extracellular products of *M. tuberculosis* would provide protective immunity as well. In general, these studies utilized guinea pigs which were immunized either intradermally or subcutaneously with various dosages of vaccines comprising combinations of 5 purified extracellular proteins of *M. tuberculosis* in SAF three times, 3 or 4 weeks apart.

The first protein combination used for the immunization procedure, labeled Combination I, was comprised of 71 KD, 32A KD, 30 KD, 23 KD, and 16 KD proteins purified according to the protocols described in Example 2. This combination is believed to comprise up to 60% of the total extracellular protein normally present in *M. tuberculosis* culture supernatants. These proteins selected for use in Combination I, are identified with an asterisk in Fig. 2. Combination I vaccine containing 100 μ g, 20 μ g, or 2 μ g of each protein was administered intradermally with the adjuvant SAF. Combination I vaccine containing 20 μ g of each protein was also administered subcutaneously in similar experiments. Negative control guinea pigs were sham-immunized with equivalent volumes of SAF and buffer on the same schedule while positive controls were immunized using 120 μ g of the bulk extracellular protein preparation from Example 1 in SAF. All injection volumes were standardized using buffer.

2025 RELEASE UNDER E.O. 14176

Example 12

Response of Combination I Immunized Guinea Pigs to a
Challenge With Combination I Vaccine

To determine if the animals had developed a measurable immune response following vaccination with the Combination I mixture of principal extracellular products, a cutaneous hypersensitivity assay was performed. Guinea pigs were shaved over the back and injected intradermally with 1.0 μ g and 10.0 μ g of the same combination of the five purified extracellular proteins. 10.0 μ g of buffer was used as a control and all injections were performed using a total volume of 0.1 ml. The diameters of erythema and induration at skin tests sites were measured at 24 hours after injection.

The results of the measurements are presented in Table L below. Data are again reported in terms of mean measurement values for the group \pm standard error (SE) as determined using traditional methods. ND indicates that this particular aspect of the experiment was not done.

20

Table L

<u>Guinea Pig Status</u>	<u>n</u>	<u>PD</u>	<u>Erythema (mm) (Mean \pm SE)</u>	
			<u>1.0 μg</u>	<u>10.0 μg</u>
Immunized	6	0	11.4 \pm 4.6	17.4 \pm 2.6
25 Controls	6	0	ND	6.0 \pm 0.5

	<u>n</u>	<u>PD</u>	<u>Induration (mm) (Mean \pm SE)</u>	
			<u>1.0 μg</u>	<u>10.0 μg</u>
Immunized	6	0	7.3 \pm 0.8	11.6 \pm 1.2
Controls	6	0	ND	4.2 \pm 0.3

30 The data clearly demonstrate that a strong cell-mediated immune response to the Combination I extracellular proteins was generated by the vaccinated animals. The

immunized guinea pigs show erythema and induration measurements almost three times greater than the control animals.

Example 13

5 Immunoprotective Analysis of Combination I Vaccine Against Aerosolized *M. tuberculosis*

Three weeks after the last immunization, the guinea pigs used for the preceding hypersensitivity assay were challenged with aerosolized *M. tuberculosis*, Erdman strain
10 and weighed weekly for 10 weeks. This aerosol challenge was performed using the protocol of Example 4. Six animals immunized with 100 µg of the principal extracellular products of Combination I, along with equal sized groups of positive and negative controls, were challenged
15 simultaneously with aerosolized *M. tuberculosis*. Positive controls were immunized three times with 120 µg EP in SAF.

Guinea pigs that died before the end of the observation period were autopsied and examined for evidence of gross tuberculosis lesions. Such lesions were found in
20 all animals which expired during the study.

Differences between immunized and control animals in mean weight profiles after aerosol challenge were analyzed by repeated measures analysis of variance (ANOVA). Differences between immunized and control guinea pigs in
25 survival after challenge were analyzed by the two-tailed Fisher exact test. Data are the mean weights ± standard error (SE) for each group of six guinea pigs.

Results of the weekly weight determinations following challenge are shown in Fig. 9. Compared with guinea pigs
30 immunized with the combination of extracellular products, sham-immunized animals lost 15.9% of their total body weight. Weights of the positive controls were similar to those of animals immunized with the combination of five purified extracellular proteins. Body weights were
35 normalized immediately before challenge. The difference

between animals immunized with Combination I and sham-immunized controls was highly significant with $p < .0000001$ by repeated measures ANOVA.

Mortality was determined ten and one-half weeks after challenge. All three of the sham-immunized animals died within three days of each other between ten and ten and one-half weeks after challenge. The mortality results of the experiment are provided in Table M below.

Table M

10	<u>Status of Guinea Pigs</u>	<u>Survivors/ Challenged</u>	<u>Percent Survival</u>
	Combination Immunized	6/6	100%
	EP-Immunized	5/6	83%
	Sham-Immunized	3/6	50%

15 Following the conclusion of the weight monitoring study, the surviving animals were sacrificed by hypercarbia and the right lung and spleen of each animal was assayed for viable *M. tuberculosis* using the protocol of Example 5. The results of the counts, including the 3
20 animals that died the last week of the experiment, are presented in Table N below in terms of mean colony forming units (CFU) \pm standard error (SE).

Table N

25	<u>Guinea Pig Status</u>	<u>n</u>	<u>Mean CFU \pm SE</u>	<u>Right Lung</u>	<u>Spleen</u>
	Sham-immunized	6	$8.9 \pm 5.4 \times 10^7$	$1.3 \pm 0.7 \times 10^7$	
	Immunized	6	$3.4 \pm 1.7 \times 10^6$	$1.8 \pm 0.6 \times 10^6$	
	EP-immunized	6	$1.7 \pm 0.7 \times 10^7$	$5.0 \pm 2.8 \times 10^6$	

30 The log difference between the concentration of bacilli in the lung of the animals immunized with the

combination of purified proteins and that of the sham-immunized animals was 1.4 while the log difference of bacilli in the spleen was 0.9. Parallelling this, on gross inspection at autopsy immunized animals had markedly decreased lung involvement with tuberculosis compared with sham-immunized controls. Positive control animals immunized with the bulk extracellular preparation (EP) of Example 1 showed 0.7 log more bacilli in the lung and .5 log more bacilli in the spleen than animals immunized with the Combination I mixture of purified extracellular proteins.

Example 14

Immunoprotection Analysis of Combination I Vaccine at Low Doses Through Intradermal and Subcutaneous Delivery

While Example 13 confirmed that Combination I proteins demonstrated immunoprotection in animals immunized intradermally with 100 μ g of each protein (30 + 32A + 16 + 23 + 71) 3 times, 4 weeks apart, an alternative study was conducted to demonstrate the immunoprotective capacity of lower doses of Combination I proteins, specifically 20 μ g or 2 μ g of each protein. As in Example 13, guinea pigs (6 animals per group) were immunized with Combination I proteins (30 + 32A + 16 + 23 + 71) intradermally in SAF 4 times, 3 weeks apart. Animals received either 20 μ g or each protein per immunization or 2 μ g of each protein per immunization. Control animals were sham-immunized utilizing the previous protocol. Three weeks later, the animals were challenged with aerosolized *M. tuberculosis* and weights were measured weekly for 9 weeks. All immunized animals survived to the end of the experiment while one sham-immunized animal died before the end of the experiment. As the following results illustrate, doses 5 fold and even 50 fold lower than those of Example 13 protected immunized animals from aerosolized *M. tuberculosis* and

that delivery by both the intradermal and subcutaneous route was effective.

Compared with guinea pigs immunized with 20 μ g of each protein of Combination I, sham-immunized animals lost 12 % of their total body weight during the 9 weeks of the experiment (weights were normalized to just before challenge). Compared with guinea pigs immunized with 2 μ g of each protein of Combination I, sham-immunized animals lost 11% of their normalized total body weight. Thus, guinea pigs immunized intradermally with low doses of Combination I proteins were protected against weight loss after aerosol challenge with *M. tuberculosis*.

Similarly, guinea pigs immunized intradermally with low doses of Combination I proteins also were protected against splenomegaly associated with dissemination of *M. tuberculosis* to the spleen. As shown in Table O, whereas animals immunized with 20 μ g or 2 μ g of each protein of Combination I had spleens weighing an average of 4.6 ± 1.2 g and 4.0 ± 0.8 g (Mean \pm SE), respectively, sham-immunized animals had spleens weighing an average of 9.6 ± 1.8 g (Table 1), or more than twice as much.

Table O

	<u>Status of Guinea Pigs</u>	<u>n</u>	<u>Spleen Weight (g)</u>
			<u>Mean \pm SE</u>
25	Sham-Immunized	5	9.6 ± 1.8
	Immunized (20 μ g)	6	4.6 ± 1.2
	Immunized (2 μ g)	6	4.0 ± 0.8

Guinea pigs immunized intradermally with low doses of Combination I proteins also had fewer CFU of *M. tuberculosis* in their spleens. As shown in Table P, when compared with sham-immunized animals, guinea pigs immunized with 20 μ g or 2 μ g of each protein of

Combination I had an average of 0.6 and 0.4 log fewer CFU, respectively, in their spleens.

Table P

5	<u>Guinea Pig Status</u>	<u>n</u>	CFU in Spleen	<u>Log Difference</u>
			<u>Mean \pm SE</u>	
	Sham-Immunized	5	$3.1 \pm 2.3 \times 10^6$	
	Immunized (20 μ g)	6	$8.1 \pm 2.4 \times 10^5$	-0.6
	Immunized (2 μ g)	6	$1.2 \pm 0.6 \times 10^6$	-0.4

Moreover, guinea pigs immunized subcutaneously with
 10 Combination I proteins were also protected against weight
 loss, splenomegaly, and growth of *M. tuberculosis* in the
 spleen. In the same experiment described in Example 14,
 guinea pigs were also immunized subcutaneously rather than
 15 intradermally with 20 μ g of Combination I proteins, 4
 times, 3 weeks apart. These animals were protected from
 challenge almost as much as the animals immunized intra-
 dermally with 20 μ g of Combination I proteins.

Example 15

Response of Combination I and Combination II

20 Immunized Guinea Pigs to Challenge with Combination I and Combination II

Additional studies were performed to ascertain
 whether other combinations of majorly abundant extracellu-
 lar products of *M. tuberculosis* would provide protective
 25 immunity as well. One study utilized guinea pigs which
 were immunized with a vaccine comprising two combinations
 - Combination I (71, 32A, 30, 23, and 16) and Combination
 II (32A, 30, 24, 23, and 16). Combination II is believed
 to comprise up to 62% of the total extracellular protein
 30 normally present in *M. tuberculosis* supernatants. Animals
 (6 per group) were immunized four times with 100 μ g of
 each protein in Combination I or II in SAF, 3 weeks apart.

Negative control animals were sham-immunized with equivalent volumes of SAF and buffer on the same schedule.

As in Example 12, the animals were tested for cutaneous delayed-type hypersensitivity to determine if the animals developed a measurable immune response following vaccination. Animals immunized with Combination II had $16.8 \pm 1.3\text{mm}$ (Mean \pm SE) erythema and $12.8 \pm 1.2\text{mm}$ induration in response to skin-testing with Combination II whereas sham-immunized animals had only $1.3 \pm 0.8\text{mm}$ erythema and $0.3 \pm 3\text{mm}$ induration in response to Combination II. Thus, animals immunized with Combination II had greater than 12 fold more erythema and greater than 40 fold more induration than controls. By way of comparison, animals immunized with Combination I had $21.3 \pm 2.0\text{mm}$ erythema and $15.8 \pm 0.1\text{mm}$ induration in response to skin-testing with Combination I, whereas sham-immunized animals had only $6.4 \pm 0.8\text{mm}$ erythema and $2.6 \pm 0.7\text{mm}$ induration in response to Combination I. Thus, animals immunized with Combination I had greater than 3 fold more erythema and greater than 6 fold more induration than controls. The difference from controls for Combination II proteins was even greater than that for Combination I proteins.

In the same experiment, animals immunized with a lower dose of Combination II proteins ($20 \mu\text{g}$ of each protein vs. $100 \mu\text{g}$) also developed strong cutaneous hypersensitivity to Combination II. They had $21.0 \pm 2.0\text{mm}$ erythema and $15.3 \pm 0.9\text{mm}$ induration in response to Combination II, whereas the sham-immunized animals had only $1.3 \pm 0.8\text{mm}$ erythema and $0.3 \pm 0.3\text{mm}$ induration, as noted above. Thus, animals immunized with a lower dose of Combination II proteins had greater than 16 fold erythema and greater than 50 fold more induration than controls, a difference that was even greater than for animals immunized with the higher dose of Combination II proteins.

Example 16**Immunoprotective Analysis of Combination I and II
Vaccine Against Aerosolized *M. tuberculosis***

Three weeks after the last immunization, the guinea
5 pigs used for the preceding hypersensitivity assay were
challenged with aerosolized *M. tuberculosis*, Erdman strain
as in Example 13 and weighed weekly for 7 weeks. As in
Example 13, 6 animals were in each group. During the
first 7 weeks after challenge, sham-immunized animals lost
10 an average of 19.5g. In contrast, animals immunized with
Combination II (100 μ g of each protein) gained 52.4 g and
animals immunized with Combination II at a lower dose
(20 μ g of each protein) gained an average of 67.2g. By
way of contrast, animals immunized with Combination I
15 gained 68g. Thus, compared with guinea pigs immunized
with Combination II (100 μ g), sham-immunized animals
lost 11% of their total body weight. Compared with guinea
pigs immunized with Combination II at a lower dose (20
 μ g), sham-immunized animals lost 14% of their total body
20 weight. Compared with animals immunized with Combination
I, sham-immunized animals also lost 14% of their total
body weight.

Example 17**Response of Guinea Pigs Immunized with Combinations III
25 through XII to a Challenge with the Same Vaccine
or Its Components**

Additional experiments were performed to demonstrate
the effectiveness of various combinations of *M. tubercu-*
losis majorly abundant extracellular products. In these
30 studies, Hartley type guinea pigs were immunized intra-
dermally with vaccines comprising combinations of 2 or
more majorly abundant extracellular products purified as
in Example 2. The purified extracellular products are
identified using their apparent molecular weight as deter-
35 mined by SDS-PAGE. The guinea pigs were immunized with

the following combinations of majorly abundant extra-cellular products.

	<u>Combination</u>	<u>Protein Constituents</u>
	III	30 + 32A + 32B + 16 + 23
5	IV	30 + 32A
	V	30 + 32B
	VI	30 + 16
	VII	30 + 23
	VIII	30 + 71
10	IX	30 + 23.5
	X	30 + 12
	XI	30 + 24
	XII	30 + 58

Each combination vaccine included 100 μ g of each listed protein. The combination vaccines were volumetrically adjusted and injected intradermally in the adjuvant SAF. As before the guinea pigs were immunized four times, three weeks apart.

A cutaneous hypersensitivity assay was performed to determine if the animals had developed a measurable immune response following vaccination with the Combinations III to XII. Groups of six guinea pigs were shaved over the back and injected intradermally with the same combination of purified extracellular products to which they were immunized. For this challenge 10 μ g of each of the proteins in the combination were injected. All injections were performed using a total volume of 0.1 ml. Sham-immunized controls, which had been immunized with SAF only were also skin-tested with Combinations III to XII, again using 10 μ g of each protein in the respective combination. The diameters of erythema and induration at skin tests sites were measured 24 hours after injection as described in Example 3.

The results of these measurements are presented in Table Q below. Data are again reported in terms of mean measurement values for the group \pm standard error (SE) as determined using traditional methods.

5

Table Q

	<u>Vaccine Combination</u>	<u>Skin Test Combination</u>	<u>Diameter of Skin Reaction (mm)</u>	
			<u>Erythema</u>	<u>Induration</u>
10	III	III	12.2 \pm 2.0	6.8 \pm 0.8
	IV	IV	9.9 \pm 0.5	6.3 \pm 0.2
	V	V	13.0 \pm 1.1	8.1 \pm 0.7
	VI	VI	19.2 \pm 1.2	12.4 \pm 0.5
	VII	VII	14.3 \pm 1.0	8.7 \pm 0.4
	VIII	VIII	18.9 \pm 1.1	12.6 \pm 0.8
	IX	IX	17.0 \pm 0.9	12.1 \pm 0.9
15	X	X	19.3 \pm 1.4	13.6 \pm 1.2
	XI	XI	18.3 \pm 1.2	12.4 \pm 0.8
	XII	XII	17.7 \pm 0.9	14.0 \pm 1.2
20	Sham	III	4.8 \pm 0.9	2.0 \pm 0.0
	Sham	IV	4.3 \pm 1.1	2.0 \pm 0.0
	Sham	V	5.0 \pm 0.5	2.0 \pm 0.0
	Sham	VI	4.5 \pm 0.3	2.0 \pm 0.0
	Sham	VII	4.5 \pm 0.3	2.0 \pm 0.0
	Sham	VIII	3.3 \pm 0.3	2.3 \pm 0.3
	Sham	IX	3.7 \pm 0.3	2.0 \pm 0.0
25	Sham	X	3.7 \pm 0.4	2.0 \pm 0.0
	Sham	XI	3.7 \pm 0.2	2.0 \pm 0.0
	Sham	XII	3.8 \pm 0.2	2.0 \pm 0.0

The results clearly demonstrate that a strong cell-mediated immune response was generated to each of the combinations of purified extracellular proteins. The immunized guinea pigs showed erythema at least twice and usually 3 fold or more that of controls for all combinations. Further, the immunized guinea pigs showed induration at least 3 fold that of controls for all combinations.

Example 18**Immunoprotective Analysis of Combinations III-XII**
Against Aerosolized *M. tuberculosis*

To demonstrate the prophylactic efficacy of these
5 exemplary combinations of purified extracellular products,
guinea pigs immunized with Combinations III through XII
were challenged with *M. tuberculosis* three weeks after the
last immunization using the protocol of Example 4.

Consistent with earlier results guinea pigs immunized
10 with Combinations III through XII were all protected
against death after challenge. At 4 weeks afte^F^PB

08786633-012197

Zr challenge, 2 of 6 sham-immunized animals (33%) died compared with 0 animals in groups immunized with Combinations IV-XII and 1 of 6 animals (17%) in the group immunized with Combination III. At 10 weeks after challenge, 50% of the sham-immunized animals had died compared with 0 deaths in the animals in groups immunized with Combinations IX and XII (0%), 1 of 6 deaths (17%) in the animals in the groups immunized with Combination III, IV, V, VI, X, and XI, 1 of 5 deaths (20%) in the animals immunized with Combination VIII, and 2 of 6 deaths (33%) in the animals immunized with Combination VII.

Guinea pigs that died before the end of the observation period were autopsied and examined for evidence of gross tuberculosis lesions. Lesions were found in all animals which expired during the study.

Following the conclusion of the mortality study, the surviving animals were sacrificed by hypercarbia and the spleen of each animal was assayed for viable *M. tuberculosis* using the protocol of Example 5. The results are presented in Table R below in terms of mean colony forming units (CFU) along with the log decrease from the sham immunized animals. An asterisk next to the CFU value indicates that spleen counts were zero on one animal in each group. For purposes of calculation, zero counts were treated as 10^3 CFU per spleen or 3 logs.

0378533-012197

Table R

	Vaccine Group	CFU in Spleen (Mean Log)	Log Decrease from Sham
5	III	5.99	.5
	IV	5.41	1.1
	V	6.27	.3
	VI	<5.80*	>.7
	VII	<5.61*	>.9
10	VIII	6.47	.1
	IX	<5.85*	>.7
	XXI	<5.74*	>.8
	XII	5.93	.6
		6.03	.5
	Sham	6.53	--

Animals immunized with Combinations III, IV, VI, VII, IX, X, XI, and XII had at least 0.5 log fewer colony forming units of *M. tuberculosis* in their spleens on the average than the sham-immunized controls. In particular, combinations IV and VII proved to be especially effective, reducing the average number of colony forming units by roughly a factor of ten. Animals immunized with Combinations V and VIII had 0.3 and 0.1 log fewer colony forming units (CFU), respectively, in their spleens on average, than sham-immunized controls. This dramatic reduction in colony forming units in the animals immunized in accordance with the teachings of the present invention once again illustrates the immunoprotective operability of the present invention.

Example 19

Response of Guinea Pigs Immunized with 3 Different Dosages of Combination XIII to a Challenge with Combination XIII

To further define the operability and scope of the present invention as well as to demonstrate the efficacy of additional combinations of purified extracellular products, guinea pigs were immunized as before using

alternative vaccination dosages. Specifically, 50 μ g, 100 μ g and 200 μ g of an alternative combination of 3 majorly abundant extracellular products identified as Combination XIII and comprising the 30 KD, 32(A) KD, and 16 KD proteins. As with the preceding examples, groups of animals were immunized intradermally 4 times, 3 weeks apart with the alternative dosages of Combination XIII in SAF.

A cutaneous hypersensitivity assay was performed to determine if the animals had developed a measurable immune response following vaccination. The animals were shaved over the back and injected intradermally with Combination XIII containing 10.0 μ g of each of the purified extracellular products. All injections were performed using a total volume of 0.1 ml. Sham-immunized controls were also skin-tested with the same dosage of Combination XIII. The diameters of erythema and induration at skin-test sites were measured 24 hours after injection.

The results are presented in Table S below in terms of mean measurement values for the group \pm standard error (SE) as determined using traditional methods

Table S

	Vaccine Combination	Vaccine Dose (μ g)	Diameter of Skin Reaction (mm)	
			<u>Erythema</u>	<u>Induration</u>
25	XIII	50	17.8 \pm 1.3	13.2 \pm 1.0
	XIII	100	11.2 \pm 0.9	7.3 \pm 0.4
	XIII	200	10.0 \pm 0.7	7.0 \pm 0.4
	Sham	0	5.7 \pm 0.5	0.2 \pm 0.2

Once again, these results clearly demonstrate that a strong cell-mediated immune response to Combination XIII was generated in animals immunized with each of the three dosages of Combination XIII. The immunized animals exhibited erythema about two to three times that of controls. Even more strikingly, the immunized animals

exhibited induration at least 35 fold that of control animals which exhibited a minimal response in all cases.

Example 20

Immunoprotective Analysis of Combination XIII in Three Different Dosages Against Aerosolized *M. tuberculosis*

To further demonstrate the protective immunity aspects of the vaccines of the present invention at various dosages, the immunized guinea pigs (6 per group) used for the preceding cutaneous hypersensitivity assay were challenged with aerosolized *M. tuberculosis* three weeks after the last immunization. The aerosol challenge was performed using the protocol detailed in Example 4. A control group of 12 sham-immunized animals was challenged simultaneously.

Results of the weekly weight determinations following challenge are graphically represented in Fig. 10 and distinctly show guinea pigs immunized with each of the three dosages of Combination XIII were protected from weight loss. Animals immunized with the higher dosages of Combination XIII (100 and 200 μ g) actually showed a net gain in weight and animals immunized with the lower dosage (50 μ g) showed a relatively small loss in weight. In contrast, the sham immunized animals lost approximately 22% of their total body weight in the weeks immediately after challenge and averaged a loss of 182 g over the 10 week observation period.

Table U below illustrates the percent weight change for immunized and control animals as determined by taking the mean weight at the end of the challenge, subtracting the mean weight at the start of the challenge and dividing the result by the mean weight at the start of the challenge. Similarly, the percent protection was determined by subtracting the mean percent weight loss of the controls from the mean percent weight gain or loss of the immunized animals.

Table U

	<u>Immunogen</u>	<u>Dosage</u>	<u>% Weight Change</u>	<u>% Protection from Weight Loss</u>
	Combination XIII	50	-4%	18%
	Combination XIII	100	+7%	29%
5	Combination XIII	200	+5%	27%
	Sham	Sham	-22%	-

Table U shows that the sham-immunized animals lost a considerable amount of weight (18% - 29%) over the monitoring period compared with the immunized animals. Fig. 10 provides a more graphic illustration of the net weight loss for each group of immunized animals versus sham-control animals plotted at weekly intervals over the ten week monitoring period. As loss of body mass or "consumption" is one of the classical side effects of tuberculosis, these results indicate that the growth and proliferation of tubercle bacilli in the immunized animals was inhibited by the three different dosages of the exemplary combination vaccine of the present invention.

Example 21

Immunoprotective Analysis of Combinations XIV-XVIII against Challenge with Combinations XIV-XVIII

To further demonstrate the scope of the present invention and the broad range of effective vaccines which may be formulated in accordance with the teachings thereof, five additional combination vaccines, Combinations XIV through XVIII, were tested in guinea pigs. Identified by the apparent molecular weight of the purified extracellular products determined using SDS-PAGE, the composition of each of the combination vaccines is given below.

	<u>Combination</u>	<u>Protein Constituents</u>
	XIV	30, 32A, 16, 32B, 24, 23, 45
	XV	30, 32A, 16, 32B, 24, 23, 45, 23.5, 12
	XVI	30, 32A, 16, 32B, 24, 23
5	XVII	30, 32A, 16, 32B, 24, 71
	XVIII	30, 32A, 32B
	I	30, 32A, 16, 23, 71

In addition to the new combination vaccines and appropriate controls, Combination I was also used in this series of experiments. Guinea pigs were immunized intradermally with 50 μ g of each protein of Combination XIV or XV and with 100 μ g of each protein of Combinations I, XVI, XVII, and XVIII all in SAF adjuvant. The animals were immunized a total of four times, with each injection three weeks apart.

A cutaneous hypersensitivity assay was performed to determine if the animals had developed a measurable immune response following vaccination using the previously discussed protocol. Guinea pigs were shaved over the back and injected intradermally with the same combination of purified extracellular proteins to which they were immunized. For each challenge the appropriate combination vaccine containing 10 μ g of each protein was injected. All injections were performed using a total volume of 0.1 ml. Sham-immunized controls were also skin-tested with the same dosage of each combination. The diameters of erythema and induration at skin test sites were measured at 24 hours after injection as described in Example 3.

The results of these measurements are presented in Table V below, reported in terms of mean measurement values for the group \pm standard error (SE) as determined using traditional methods.

Table V

	Vaccine Combination	Skin Test Combination	Diameter of Skin Reaction (mm)	
			Erythema	Induration
5	XIV	XIV	13.3 \pm 0.7	9.1 \pm 0.4
	XV	XV	10.4 \pm 0.4	6.5 \pm 0.4
	XVI	XVI	8.0 \pm 1.8	5.1 \pm 1.0
	XVII	XVII	9.4 \pm 0.9	6.1 \pm 1.1
	XVIII	XVIII	13.6 \pm 1.2	8.7 \pm 0.7
	I	I	10.0 \pm 0.3	6.7 \pm 0.2
10	Sham	XIV	5.5 \pm 1.6	0.4 \pm 0.2
	Sham	XV	6.1 \pm 0.5	0.4 \pm 0.2
	Sham	XVI	4.6 \pm 1.4	0.4 \pm 0.2
	Sham	XVII	5.7 \pm 1.2	0.2 \pm 0.2
	Sham	XVIII	2.1 \pm 1.1	0 \pm 0
15	Sham	I	6.0 \pm 1.2	0.6 \pm 0.2

These results clearly demonstrate that a strong cell-mediated immune response was generated to Combinations XIV through XVIII, and, as before, to Combination I. Immunized animals exhibited erythema about twice that of controls. Even more strikingly, the immunized animals exhibited induration at least 10 fold greater than the sham-immunized controls which exhibited a minimal response in all cases.

Example 22

Immunoprotective Analysis of Combinations XIV-XVIII and Combination I Against Aerosolized *M. tuberculosis*

To confirm the immunoreactivity of the combination vaccines of Example 21 and to demonstrate their applicability to infectious tuberculosis, the immunized guinea pigs used for the preceding cutaneous hypersensitivity assay were challenged with aerosolized *M. tuberculosis* three weeks after the last immunization and monitored using the protocol of Example 4. A control group of 12 sham-immunized animals, the same as used in Example 20, was similarly challenged. The results of these challenge are graphically represented in Fig.11 and shown in Table W directly below.

Percent weight change was determined by taking the mean weight at the end of the challenge, subtracting the mean weight at the start of the challenge and dividing the result by the mean weight at the start of the challenge.

- 5 Similarly, the percent protection was determined by subtracting the mean percent weight loss of the controls from the mean percent weight gain or loss of the immunized animals.

Table W

10	<u>Immunogen</u>	<u>% Weight Change</u>	<u>% Protection from Weight Loss</u>
	Combination XIV	3%	25%
	Combination XV	- 4%	18%
	Combination XVI	-15%	7%
	Combination XVII	-11%	11%
15	Combination XVIII	-12%	10%
	Combination I	-11%	11%
	Sham	-22%	

As shown in Table W, guinea pigs immunized with each of the combination vaccines were protected from weight loss. Sham-immunized animals lost approximately 22% of their total combined body weight. In contrast the prophylactic effect of the combination vaccines resulted in actual weight gain for one of the test groups and a reduced amount of weight loss in the others. Specifically, animals immunized with Combination XIV evidenced a 3% weight gain while those animals immunized with the other combinations lost only 4% to 15% of their total combined weight.

These results are shown graphically in Fig.11 which plots weekly weight determinations in terms of net weight gain or loss for each group of animals following aerosolized challenge. This statistically significant difference between the net weight loss for the immunized animals and the sham-immunized controls shown in Fig.11 provides fur-

ther evidence for the immunoprophylactic response generated by the combination vaccines of the present invention.

Example 23

Cell-Mediated Immunity in Guinea Pigs Immunized with

5 Three Different Adjuvants

In order to further demonstrate the broad applicability and versatility of the vaccine formulations of the present invention, immunogenic studies were conducted using different adjuvants. Specifically three different
10 immunogens, purified 30 KD protein, Combination I (30, 32A, 16, 23, 71) and Combination XIII (30, 32A, 16) were each formulated using three different adjuvants, Syntex Adjuvant Formulation I (SAF), incomplete Freund's adjuvant (IFA) and Monophosphoryl Lipid A containing adjuvant
15 (MPL). Such adjuvants are generally known to enhance the immune response of an organism when administered with an immunogen.

Guinea pigs were immunized intradermally with 100 μ g of each protein comprising Combinations I and XIII and
20 approximately 100 μ g of purified 30 KD protein in each of the three different adjuvant formulations. The guinea pigs were immunized with each formulation a total of three times with injections three weeks apart.

Following immunization, a cutaneous hypersensitivity
25 assay was performed to determine if the guinea pigs had developed a measurable immune response. Guinea pigs were shaved over the back and injected intradermally with the same immunogen to which they had been immunized. For the challenge, 10 μ g of each protein in Combinations I and
30 XIII or 10 μ g of purified 30 KD protein was injected in a total volume of 100 μ l. Sham-immunized guinea pigs, vaccinated with one of the three adjuvants, were skin-tested with each of the immunogen formulations containing the same adjuvant. The diameters of erythema and induration

at skin test sites were measured 24 hours after challenge as described in Example 3.

The results of these measurements are presented in Table X below. As previously discussed data are reported
5 in terms of mean measurement values for the group \pm standard error as determined using accepted statistical techniques.

Table X

	Vaccine	Adjuvant	Skin Test Reagent	Diameter of Skin Reaction (mm)	
				Erythema	Induration
10	30	SAF	30	10.7 \pm 1.6	5.8 \pm 1.5
	30	IFA	30	8.8 \pm 0.7	4.6 \pm 0.7
	30	MPL	30	10.2 \pm 1.7	5.3 \pm 1.5
15	XIII	SAF	XIII	7.3 \pm 0.5	4.1 \pm 0.5
	XIII	IFA	XIII	6.8 \pm 0.9	3.5 \pm 0.5
	XIII	MPL	XIII	6.3 \pm 0.4	3.4 \pm 0.3
	I	SAF	I	6.9 \pm 0.6	4.0 \pm 0.3
	I	IFA	I	6.8 \pm 0.2	3.6 \pm 0.3
	I	MPL	I	7.4 \pm 0.4	3.9 \pm 0.5
20	Sham	SAF	30	0.7 \pm 0.7	1.0 \pm 0
	Sham	IFA	30	0 \pm 0	0 \pm 0
	Sham	MPL	30	0 \pm 0	0 \pm 0
	Sham	SAF	XIII	1.0 \pm 1.0	1.0 \pm 0
	Sham	IFA	XIII	0 \pm 0	0.3 \pm 0.3
	Sham	MPL	XIII	0 \pm 0	0 \pm 0
25	Sham	SAF	I	4.7 \pm 0.3	1.0 \pm 0
	Sham	IFA	I	2.0 \pm 1.0	0.7 \pm 0.3
	Sham	MPL	I	1.0 \pm 1.0	0.7 \pm 0.3

As shown in the data presented in Table X, the combination vaccines and purified extracellular products
30 of the present invention provide a strong cell-mediated immunogenic response when formulated with different adjuvants. Moreover, each one of the three adjuvants provided about the same immunogenic response for each respective immunogen. In general, the immunized guinea
35 pigs exhibited erythema diameters approximately seven to

08786533-0119

ten times that of the sham-immunized guinea pigs while indurations were approximately four to six times greater than measured in the control animals.

The ability of the present invention to provoke a strong immunogenic response in combination with different adjuvants facilitates vaccine optimization. That is, adjuvants used to produce effective vaccine formulations in accordance with the teachings herein may be selected based largely on consideration of secondary criteria such as stability, lack of side effects, cost and ease of storage. These and other criteria, not directly related to the stimulation of an immune response, are particularly important when developing vaccine formulations for widespread use under relatively primitive conditions.

Example 24

Immunoprotective Analysis of Combinations XIX-XXVIII against Challenge with Combinations XIX-XXVIII

The broad scope of the present invention was further demonstrated through the generation of an immune response using ten additional combination vaccines, Combinations XIX through XXVIII. In addition to the new combination vaccines and appropriate controls, Combinations IV and XIII were also used as positive controls to provoke an immune response in guinea pigs. Identified by the apparent molecular weight of the purified extracellular products determined using SDS-PAGE, the composition of each of the combination vaccines is given below.

<u>Combination</u>	<u>Protein Constituents</u>
XIX	30, 32A, 23
XX	30, 32A, 23.5
XXI	30, 32A, 24
XXII	30, 32A, 71
XXIII	30, 32A, 16, 23
XXIV	30, 32A, 16, 23.5

	XXV	30, 32A, 16, 24
	XXVI	30, 32A, 16, 71
	XXVII	30, 32A, 16, 32B
	XXVIII	30, 32A, 16, 45
5	IV	30, 32A
	XIII	30, 32A, 16

The guinea pigs were immunized a total of four times, with each injection three weeks apart. Each combination vaccine used to immunize the animals consisted of 100 μ g of each protein in SAF adjuvant to provide a total volume of 0.1 ml.

Using the protocol discussed in Example 3, a cutaneous hypersensitive assay was performed to determine if the animals had developed a measurable immune response following vaccination with the selected combination vaccine. The guinea pigs were shaved over the back and injected intradermally with the same combination of purified extracellular proteins with which they were immunized. The protein combinations used to challenge the animals consisted of 10 μ g of each protein. Sham immunized controls were also skin-tested with the same dosage of each combination. As in Example 3, the diameters of erythema and induration at the skin test sites were measured at 24 hours after injection.

The results of these measurements are presented in Table Y below, reported in terms of mean measurement values for the group of animals \pm standard error.

Table Y

		<u>Diameter of Skin Reaction (mm)</u>	
<u>Vaccine Combination</u>	<u>Skin Test Combination</u>	<u>Erythema</u>	<u>Induration</u>
5	XIX	8.5 \pm 0.6	3.9 \pm 0.3
	XX	8.2 \pm 0.3	3.7 \pm 0.3
	XXI	11.1 \pm 1.1	4.5 \pm 0.4
	XXII	9.4 \pm 0.8	4.3 \pm 0.4
	XXIII	8.3 \pm 1.1	3.0 \pm 0.3
10	XXIV	8.5 \pm 0.9	3.4 \pm 0.5
	XXV	7.9 \pm 0.5	3.2 \pm 0.4
	XXVI	8.9 \pm 0.7	3.3 \pm 0.5
	XXVII	7.2 \pm 1.0	2.8 \pm 0.5
	XXVIII	8.5 \pm 0.5	2.8 \pm 0.3
15	IV	9.0 \pm 0.9	4.1 \pm 0.3
	XIII	9.4 \pm 0.9	4.3 \pm 0.3
	Sham	4.0 \pm 2.6	1.0 \pm 0
	Sham	1.3 \pm 1.3	1.0 \pm 0
	Sham	3.5 \pm 1.0	1.3 \pm 1.3
20	Sham	1.3 \pm 1.3	1.0 \pm 1.0
	Sham	0 \pm 0	1.0 \pm 0
	Sham	0 \pm 0	1.0 \pm 0
	Sham	0 \pm 0	1.0 \pm 0
	Sham	2.3 \pm 2.3	2.0 \pm 1.0
25	Sham	0 \pm 0	1.0 \pm 0
	Sham	2.0 \pm 1.2	1.0 \pm 0
	Sham	2.8 \pm 1.6	1.0 \pm 0
	Sham	1.5 \pm 1.5	1.0 \pm 0
	Sham		

The results presented in Table Y explicitly show that a strong cell-mediated immune response was generated to combinations XIX through XXVIII when challenged with the same immunogens. As before, a strong cell-mediated immune response was also provoked by combinations IV and XIII. The erythema exhibited by the immunized guinea pigs was at least twice, and generally proved to be and more than four fold greater than, the reaction provoked in the corresponding sham immunized control animals. Similarly, the induration exhibited by the immunized animals was at least twice, and generally three to four times greater than, that of the nonimmunized controls. The substantially stronger immune response generated among the animals immunized in accordance with the teachings of the

present invention once again illustrates the immunoprotective operability of the combination vaccines of the present invention.

Those skilled in the art will also appreciate
5 additional benefits of the vaccines and methods of the present invention. For example, because individual compounds or selected combinations of highly purified molecular species are used for the subject vaccines rather than whole bacteria or components thereof, the vaccines of
10 the present invention are considerably less likely to provoke a toxic response when compared with prior art attenuated or killed bacterial vaccines. Moreover, the molecular vaccines of the present invention are not life threatening to immunocompromised individuals. In fact,
15 the compositions of the present invention may be used therapeutically to stimulate a directed immune response to a pathogenic agent in an infected individual.

Selective use of majorly abundant extracellular products or their immunogenic analogs also prevents the
20 development of an opsonizing humoral response which can increase the pathogenesis of intracellular bacteria. As the protective immunity generated by this invention is directed against unbound proteins, any opsonic response will simply result in the phagocytosis and destruction of
25 the majorly abundant extracellular product rather than the expedited inclusion of the parasitic bacteria. Moreover, the selective use of purified extracellular products reduces the potential for generating a response which precludes the use of widely used screening and control
30 techniques based on host recognition of immunogenic agents. Unlike prior art vaccines, the screening tests could still be performed using an immunoreactive molecule that is expressed by the pathogen but not included in the vaccines made according to the present invention. The use
35 of such an immunogenic determinant would only provoke a response in those individuals which had been exposed to

the target pathogen allowing appropriate measures to be taken.

Another advantage of the present invention is that purified extracellular products are easily obtained in large quantities and readily isolated using techniques well known in the art as opposed to the attenuated bacteria and bacterial components of prior art vaccines. Since the immunoreactive products of the present invention are naturally released extracellularly into the surrounding media for most organisms of interest, removal of intracellular contaminants and cellular debris is simplified. Further, as the most prominent or majorly abundant extracellular products or immunogenic analogs thereof are used to stimulate the desired immune response, expression levels and culture concentrations of harvestable product is generally elevated in most production systems. Accordingly, whatever form of production is employed, large scale isolation of the desired products is easily accomplished through routine biochemical procedures such as chromatography or ultrafiltration. These inherent attributes and molecular characteristics of the immunogenic determinants used in the present invention greatly facilitate the production of a consistent, standardized, high quality composition for use on a large scale.

Alternatively, the use of purified molecular compounds based on the immunogenic properties of the most prominent or majorly abundant extracellular products of target pathogens also makes the large scale synthetic generation of the immunoactive vaccine components of the present invention relatively easy. For instance, the extracellular products of interest or their immunogenic analogs may be cloned into a nonpathogenic host bacteria using recombinant DNA technology and harvested in safety. Molecular cloning techniques well known in the art may be used for isolating and expressing DNA corresponding to the extracellular products of interest, their homologs or any

03786533-01249

segments thereof in selected high expression vectors for insertion in host bacteria such as *Escherichia coli*. Exemplary techniques may be found in II R. Anon, *Synthetic Vaccines* 31-77 (1987), Tam et al., *Incorporation of T and B Epitopes of the Circumsporozoite Protein in a Chemically Defined Synthetic Vaccine Against Malaria*, 171 J. Exp. Med. 299-306 (1990), and Stover et al., *Protective Immunity Elicited by Recombinant Bacille Calmette-Guerin (BCG) Expressing Outer Surface Protein A (OspA) Lipoprotein: A Candidate Lyme Disease Vaccine*, 178 J. Exp. Med. 197-209 (1993).

The present invention involves a process for using a host cell to produce a majorly abundant extracellular product selected from the group consisting of *M. tuberculosis* 110 KD protein, 80 KD protein, 71 KD protein, 58 KD protein, 45 KD protein, 32A KD protein, 32B KD protein, 30 KD protein, 24 KD protein, 23.5 KD protein, 23 KD protein, 16 KD protein, 14 KD protein, 12 KD protein and respective analogs, homologs, and subunits thereof. Examples of practice demonstrating preferred methods for expressing the extracellular proteins of the present invention are as follows:

Example 25

Expression Of Recombinant 30 KD Protein

For the expression of the mature 30 KD protein, the gene encoding the 30 KD protein was engineered such that the initiator phenylalanine of the mature protein was fused to a glycine residue artificially inserted at the NcoI site or carboxyl terminus of the pelB leader sequence in pET22b (Novagen, Madison, WI) (see Fig. 14). This strategy provided a fusion molecule from which the mature 30 KD protein could be easily released and led to the expression of relatively large quantities of recombinant 30 KD protein over a period of 4 hours. Thereafter, expression of recombinant protein reached a plateau.

Expression of the recombinant molecules continued for up to 8 hours without exerting serious detrimental effects on the bacterial culture. A typical yield from 1 liter of *E. coli* culture was approximately 50 mg, amounting to nearly 25% of the total cell protein.

To achieve expression of recombinant 30 KD protein in its full-length or truncated version, constructs in pET22b were expressed in *E. coli* BL21(DE3)pLysS upon induction with 1 mM isopropyl- β -D-thiogalactopyranoside (IPTG). Samples of induced cultures were taken at hourly intervals for up to 8 hours and aliquots of the culture supernatants and cell pellets were run on 12.5% denaturing polyacrylamide gels and stained with Coomassie brilliant blue R. Recombinant protein was purified as described by Horwitz, M.A., Lee, B.-W.E., Dillon, B.J., and Harth, G. (1995) Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of *Mycobacterium tuberculosis*. *Proc Natl Acad Sci USA* 92:1530-1534, with the exception that all chromatography steps included the addition of 8 M urea to the buffers. The purified recombinant protein was dialyzed against phosphate buffered saline and remained soluble.

The mature 30 KD protein was expressed in the pET22b vector either with its own or the plasmid encoded pelB leader peptide. The results of the electrophoresis of the cell pellets are shown in Fig. 15. Lanes A and B show Coomassie stained protein extracts upon IPTG induction of bacteria carrying the pET22b vector with the mature 30 KD protein gene fused to the pelB leader DNA sequence (A) and the pET22b vector with the full-length 30 KD protein gene (B). Lane C shows mature 30 KD protein isolated from *M. tuberculosis* culture filtrates as a reference. Lanes D, E, and F show a Western blot analysis of the same proteins as in A, B, and C probed with anti-30/32A-B KD complex specific antibodies. Lane G, protein extract from *E. coli* cultures carrying the pET22b vector alone, probed

with the same antibodies. Positions of full-length and mature 30 KD proteins are marked 30W and 30M, respectively, and these recombinant proteins are further identified by their first 5 or 7 N-terminal amino acids.

5 Numbers on the left refer to molecular mass standards in KD.

EXAMPLE 26

Expression Of Soluble, Processed, Extracellular, *M. tuberculosis* 30 KD Major Secretory Protein Using The Plasmid pSMT3 in *Mycobacterium smegmatis* and *Mycobacterium vaccae*

This example is directed to demonstrating the expression and secretion of the *M. tuberculosis* 30 KD major secretory protein in a mycobacterium. We used the pSMT3 plasmid (Dr. Douglas B. Young, Dept. Medical Microbiology, St. Mary's Hospital Medical School, Norfolk Place, London, W2 1PG, United Kingdom, a 5.7 kb (kilo basepairs) plasmid with both *E. coli* (col E1 ori) and mycobacterium (*Mycobacterium fortuitum* plasmid pAL5000 ori) origins of replication, a hygromycin resistance marker, a hsp60 promoter (*Mycobacterium bovis* BCG heat shock protein promoter sequence), and a multicloning site downstream of the hsp60 promoter. The expression system is shown diagrammatically in Fig. 16.

The insert consisted of a 4.7 kb HindIII - BamHI genomic DNA fragment from *M. tuberculosis* Erdman strain containing the sequence for the 30 KD protein. The insert was cloned into pSMT3 in *E. coli* DH5 α and recombinant plasmid DNA was transformed into *M. smegmatis* 1-2c and *M. vaccae* R877R (National Collection of Type Cultures (NCTC) 11659) by electroporation at a setting of 6250 V/cm and 25 μ Farad. *M. smegmatis* 1-2c is a cured isolate of strain *M. smegmatis* mc²6, which is a single cell isolate of ATCC 607 (American Type Culture Collection) which was prepared from

M. smegmatis mc²6 by the procedure described in: Zhang, Y., Lathigra, R., Grabe, T., Catty, D., and Young, D., 1991, *Molecular Microbiology* 5(2):381-391. *M. smegmatis* mc²6 was isolated from ATCC 607 by the procedure described
 5 in: Jacobs, W.R., Tuckman, M., and Bloom, B.R., 1987, *Nature*, 327:532-535. Using 1 μ g of recombinant plasmid DNA and approximately 4 x 10⁹ CFU of mycobacteria, this method yielded 100-200 hygromycin-resistant transformants. The transformants were stable in broth culture and
 10 constitutively expressed the *M. tuberculosis* 30 KD protein, yielding approximately 10 mg processed protein/L of culture. Most importantly, the protein was soluble and approximately 90% of the expressed protein was secreted in the culture supernatant (see Fig. 17).

15 The electrophoresis results shown in Fig. 17 were obtained as follows. Supernatant fluid from each of 5 recombinant *M. smegmatis* clones containing the pSMT3 construct with the *M. tuberculosis* 30 KD gene was subjected to SDS-PAGE (sodium dodecyl sulfate-
 20 polyacrylamide gel electrophoresis) analysis (5 right most lanes). The major protein (arrow in Fig. 17) is the recombinant mature *M. tuberculosis* 30 KD major secretory protein. The left most lane depicts molecular mass standards (66, 45, 36, 29, 24, 20, 14 KD). The
 25 recombinant protein migrates just above the 29 KD marker.

Western blot analysis was used to confirm that the major extracellular protein in the culture supernatant was the recombinant mature *M. tuberculosis* 30 KD major secretory protein. The results are shown in Fig. 18. In
 30 Fig. 18, the proteins depicted in the four rightmost lanes of Fig. 17 were subjected to SDS-PAGE and blotted onto nitrocellulose (4 right most lanes). The blot was probed with rabbit polyclonal antibody specific to the *M. tuberculosis* 30/32 KD protein complex. Only the recombinant
 35 *M. tuberculosis* 30 KD protein is stained (arrow). The lane to the left contains prestained molecular mass

markers (106, 80, 49.5, 32.5, 27.5, and 18.5 KD). The recombinant protein migrates between the 32.5 and 27.5 KD mass standards.

In addition, N-terminal sequence analysis of the first
 5 6 N-terminal amino acids yielded FSRPGL, confirming that the N-terminal sequence was identical to that of the mature *M. tuberculosis* 30 KD protein.

Two constructs in pET20 (Novagen, Madison, WI), one for the mature 30 KD protein and the other for the 32A KD
 10 protein, failed to yield expression of either protein in *E. coli*. The isolation of pKK233 is described by Amann, E. and Brosius, J. (1985) *Gene*, 40:183-190. pTrc99A (Pharmacia Biotech, Sweden) may be used in place of the pKK233 vector. Three different constructs in pKK233 - one
 15 for the full-length 30 KD protein, one for the full-length 32 KD protein, and one for the mature 30 KD protein - failed to yield expression of any of the proteins in *E. coli*.

One construct in pRSET-A for the mature 30 KD protein
 20 yielded a fusion protein in *E. coli*, but the 30 KD protein could not be cleaved free of this fusion protein with enterokinase. Similarly, two constructs in pTrx-Fus, one for the mature 30 KD protein and one for the mature 32 KD protein, yielded fusion proteins in *E. coli* from which the
 25 *M. tuberculosis* proteins could not be efficiently cleaved with enterokinase. A summary of the suitability of various expression systems is set forth in Table Z. All of the inserts are for the 32A KD protein.

08786533-01219

TABLE 2

PLASMID	INSERT	JUNCTIONS	HOST STRAIN	EXPRESSION	SOLUBILITY/YIELD	COMMENTS
pET22b	Full-length 30K	5'-NdeI-ATG-30K(F-L)-TGA--N--EcoRI-Vector-3'	BL21(DE3)/pLys unstable	Yes, no Fusion 100 mg/L	insoluble (pellet) 1 mg/L; purified	40% Processing F-L/mature/ mature+2aa
pET22b	Full-length 32K	5'-NdeI-ATG-32K(F-L)-TGA--N--EcoRI-Vector-3'	BL21(DE3)/pLysS unstable	Yes, no Fusion 100 mg/L	insoluble (pellet) 1 mg/L; purified	90% Processing F-L/mature+2aa
pET22b	Mature 30K	5'-NdeI-pelB-NcoI-GGG-TTC-30K(M)-TGA-N-EcoRI-Vector-3'	BL21(DE3)/pLysS unstable	Yes, pelB-Fusion 120 mg/L	insoluble (pellet) 1 mg/L; purified	50% Processing pelB+/mature/ mature+2aa
pET22b	Mature 32K	5'-NdeI-pelB-NcoI-GGG-TTT-32K(M)-TAG-N-EcoRI-Vector-3'	BL21(DE3)/pLysS unstable	Yes, pelB-Fusion 150mg/L	insoluble (pellet) 1 mg/L; purified	60% Processing pelB+/mature/mature+2aa
pET22b	Mature 30K	5'-NdeI-TTC-30K(M)-TGA--N--EcoRI-Vector-3'	BL21(DE3)/pLysS	No		
pET22b	Mature 32K	5'-NdeI-TTT-32K(M)-TAG--N--EcoRI-Vector-3'	BL21(DE3)/pLysS	No		
pET20	Mature 30K	5'-NdeI-TTC-30K(M)-TGA--N--EcoRI-Vector-3'	BL21(DE3)/pLysS	No		
pET20	Mature 32K	5'-NdeI-TTT-32K(M)-TAG--N--EcoRI-Vector-3'	BL21(DE3)/pLysS	No		
pSMT3	Full-length 30K	5'-phsp60--MCS-BHI-4.7kb gen. 30K-HdIII-MCS--Vector-3'	<i>M. smegmatis</i> 1-2c	Yes, no Fusion 10 mg/L	soluble (supernatant)	90% Processing
pSMT3	Full-length 30K	5'-phsp60--MCS-BHI-4.7kb gen. 30K-HdIII-MCS--Vector-3'	<i>M. vaccae</i> R877R NCTC11659	Yes, no Fusion 10 mg/L	soluble (supernatant)	90% processing
pRSET-A	Mature 30K	5'-MCS-(EK)-KpnI-TTC-30K(M)-TGA-N-EcoRI-Vector-3'	BL21(DE3)/pLysS stable	Yes, Fusion 100 mg/L	insoluble (pellet) not purified	No EK cleavage mature+2aa
pTrxFus	Mature 30K	5'-Trx-(EK)-KpnI-TTC-30K(M)-TGA-N--BamHI-Vector-3'	GI724 & GI698 stable in GI698	Yes, Trx-Fusion 50 mg/L	soluble (cytoplasm) not purified	10% EK cleavage mature+2aa
pTrxFus	Mature 32K	5'-Trx-(EK)-KpnI-TTT-32K(M)-TAG-N--BamHI-Vector-3'	GI724 & GI698 stable in GI698	Yes, Trx-Fusion 50 mg/L	soluble (cytoplasm) not purified	10% EK cleavage mature+2aa
pKK233	Full-length 30K	5'-NcoI-N-ATG-30K(F-L)-TGA-N-EcoRI(bI)-Vector-3'	JM109	No		
pKK233	Full-length 32K	5'-NcoI-N-ATG-32K(F-L)-TAG-N-EcoRI(bI)/HindIII(bI)-Vector-3'	JM109	No		
pKK233	Mature 30K	5'-NcoI(bIunt)-TTC---30K(M)---TGA--N--HindIII-Vector-3'	JM109	No		
pBK33	Mature 30K	5'-sacB-BamHI-TTC-30K(M)-TGA-N--BamHI-Vector-3'	<i>B. subtilis</i> BD168 & 170	No		
pBK33	Mature 32K	5'-sacB-BamHI-TTT-32K(M)-TAG--N-BamHI-Vector-3'	<i>B. subtilis</i> BD168 & 170	No		
pPL608	Full-length 30K	5'-SmaI-200N-ATG-30K(F-L)-TGA-200N-HincII-Vector-3'	<i>B. subtilis</i> Bd168 &170	No		

As can be seen from Table Z, not all constructs resulted in protein expression. A leader sequence in front of the structural gene was required for expression. Thus, one pET22b construct containing the mature 30 KD protein gene and one construct containing the mature 32A KD protein gene failed to express either protein. Successful expression in pET22b of the 30 and 32A KD *M. tuberculosis* proteins was obtained by adding the respective leader sequence of the protein in front of the structural gene. For both proteins, this resulted in expression of both the full-length and processed protein. These constructs were relatively stable in *E. coli*, i.e. they expressed the recombinant proteins after 2 or 3 subcultures but not after additional subculturing.

Successful expression in pET22b of the 30 and 32A KD *M. tuberculosis* proteins was also obtained by adding the *E. coli*-derived pelB leader sequence in front of the structural gene for each protein. Expression levels in these constructs were even higher than in those utilizing the respective leader sequences of the 30 or 32A KD proteins. However, a drawback of the pelB constructs was their instability. These constructs lost their ability to express any recombinant protein after one subculture

Previously, expression and secretion of the *M. tuberculosis* 32A KD protein had been achieved in *Mycobacterium smegmatis* and *Mycobacterium vaccae* using pSMT3 based expression constructs containing a ~4.5 kb DNA fragment which was flanked by *EcoRV* restriction sites and which encoded the full-length 32A protein gene. However, in contrast to the case with the *M. tuberculosis* 30 KD major extracellular protein and the *M. tuberculosis* 16 KD major extracellular protein, use of these constructs resulted in the intracellular accumulation of *M. tuberculosis* 32A KD protein and did not yield high-level secretion of the *M. tuberculosis* 32A KD protein.

UCLAID-VACCINE\120243.APP\MAK/R/121196 11:08am

The present invention functions by culturing the recombinant strains of *Mycobacterium smegmatis* containing DNA fragments encoding the full-length 32A KD major extracellular protein at 28°C rather than 37°C, the usual temperature for culturing these bacteria. When cultured at 28°C, the recombinant mycobacterium expresses and secretes large quantities of the 32A KD protein. The secreted protein can then be purified from the culture supernatant fluid by conventional purification techniques.

Prior to the present invention, only small amounts of recombinant *M. tuberculosis* 32A KD protein could be obtained from recombinant mycobacteria expressing the protein. The invention allows large amounts of recombinant 32A protein to be obtained from the culture filtrate of recombinant mycobacteria, which secrete the 32A KD protein into the culture medium. Thus, the cost-effective production of recombinant 32A KD protein becomes possible.

Example 27

The gene from the *M. tuberculosis* 32A KD major extracellular protein was cloned into *Mycobacterium smegmatis* using a pSMT3-based expression construct containing an ~4.5 kb DNA fragment, flanked by *EcoRV* restriction sites, that encoded the full-length 32A KD protein (Construct A in Fig. 19). The recombinant *M. smegmatis* was cultured in 7H9 medium containing 2% glucose at 37°C and 28°C. The culture filtrate of each organism was then collected and subjected to SDS-PAGE analysis. When *M. smegmatis* containing the pSMT3 vector with the full-length 32A KD protein gene was cultured at 37°C, virtually no 32A KD protein was present in the culture filtrate (Lane 2 of Fig. 20). However, when the same *M. smegmatis* strain was cultured at 28°C, a large amount of 32A KD protein was secreted and present in the culture filtrate (Lane 3, arrowhead). Lane 1 shows molecular weight standards, the

molecular weight $\times 10^{-3}$ being noted to the left of the standards. Lane 2 shows filtrate from *M. smegmatis* containing the pSMT3 vector with the full-length *M. tuberculosis* 32A KD protein gene that was cultured at 37°C. Lane 3 shows filtrate from *M. smegmatis* containing pSMT3 vector with the full-length *M. tuberculosis* 32A KD protein gene that was cultured at 28°C.

M. smegmatis containing constructs B, D, E, and G also expressed and secreted large amounts of recombinant *M. tuberculosis* 32A KD protein when cultured at 28°C.

An N-terminal amino acid analysis of recombinant *Mycobacterium tuberculosis* 32A KD protein expressed and secreted by *Mycobacterium smegmatis* at 28°C gives the following sequence:

15 1 6
 F S R P G L P

Two recombinant *M. smegmatis* strains (Constructs A and D) containing the full length *M. tuberculosis* 32A KD protein gene were cultured at 28°C. The culture filtrate of each organism was obtained and an aliquot subjected to denaturing SDS-PAGE analysis. The proteins were transferred to polyvinylidene fluoride (PVDF) membranes and the Coomassie blue R stained band migrating at 32 KD was cut out and subjected to automated amino acid sequence determination. The sequence shown above is in the conventional one-letter code.

The N-terminal sequence of the recombinant protein secreted by *M. smegmatis* containing either Construct A or D is identical to the native *M. tuberculosis* 32A KD protein, confirming that the recombinant *M. tuberculosis* 32A KD protein in *M. smegmatis* is processed the same way as the native *M. tuberculosis* 32A KD in *M. tuberculosis*.

Similarly, the extracellular proteins, their analogs, homologs or immunoreactive protein subunits may be chemically synthesized on a large scale in a relatively pure form using common laboratory techniques and automated

sequencer technology. This mode of production is particularly attractive for constructing peptide subunits or lower molecular weight analogs corresponding to antigenic determinants of the extracellular products. Exemplary techniques for the production of smaller protein subunits are well known in the art and may be found in II R. Anon, *Synthetic Vaccines* 15-30 (1987), and in A. Streitwieser, Jr., *Introduction to Organic Chemistry* 953-55 (3rd ed. 1985). Alternative techniques may be found in Gross et al., "Nonenzymatic Cleavage of Peptide Bonds: The Methionine Residues in Bovine Pancreatic Ribonuclease," 237 *The Journal of Biological Chemistry* No. 6 (1962), Mahoney, "High-Yield Cleavage of Tryptophanyl Peptide Bonds by o-Iodosobenzoic Acid," 18 *Biochemistry* No. 17 (1979), and Shoolnik et al., "Gonococcal Pili," 159 *Journal of Experimental Medicine* (1984). Other immunogenic techniques such as anti-idiotyping or directed molecular evolution using peptides, nucleotides or other molecules such as mimetics can also be employed to generate effective, immunoreactive compounds capable of producing the desired prophylactic response.

Nucleic acid molecules useful for the practice of the present invention may be expressed from a variety of vectors, including, for example, viral vectors such as herpes viral vectors (e.g., U.S. Patent No. 5,288,641), retroviruses (e.g., EP 0,415,731; WO 90/07936, WO 91/0285, WO 94/03622; WO 93/25698; WO 93/25234; U.S. Patent No. 5,219,740; WO 89/09271; WO 86/00922; WO 90/02797; WO 90/02806; U.S. Patent No. 4,650,764; U.S. Patent No. 5,124,263; U.S. Patent No. 4,861,719; WO 93/11230; WO 93/10218; Vile and Hart, *Cancer Res.* 53:3860-3864, 1993; Vile and Hart, *Cancer Res.* 53:962-967, 1993; Ram et al., *Cancer Res.* 53:83-88, 1993; Takamiya et al., *J. Neurosci. Res.* 33:493-503, 1992; Baba et al., *J. Neurosurg.* 79:729-735, 1993), pseudotyped viruses, adenoviral vectors (e.g., WO 94/26914, WO 93/9191; Kolls

et al., *PNAS* 91(1):215-219, 1994; Kass-Eisler et al., *PNAS* 90(24):11498-502, 1993; Guzman et al., *Circulation* 88(6):2838-48, 1993; Guzman et al., *Cir. Res.* 73(6):1202-1207, 1993; Zabner et al., *Cell* 75(2):207-216, 1993; Li et al., *Hum. Gene Ther.* 4(4):403-409, 1993; Caillaud et al., *Eur. J. Neurosci.* 5(10):1287-1291, 1993; Vincent et al., *Nat. Genet.* 5(2):130-134, 1993; Jaffe et al., *Nat. Genet.* 1(5):372-378, 1992; and Levrero et al., *Gene* 101(2):195-202, 1991), adenovirus-associated viral vectors (Flotte et al., *PNAS* 90(22):10613-10617, 1993), parvovirus vectors (Koering et al., *Hum. Gene Therap.* 5:457-463, 1994), and pox virus vectors (Panicali and Paoletti, *PNAS* 79:4927-4931, 1982). Typical expression vectors are disclosed in copending application Serial No. 08/545,926, filed October 20, 1995, the disclosure of which is incorporated herein by reference.

The nucleic acid molecules (or vectors, i.e., an assembly capable of directing the expression of a sequence of interest) may be introduced into host cells by a wide variety of mechanisms, including, for example, transfection, including, for example, DNA linked to killed adenovirus (Michael et al., *J. Biol. Chem.* 268(10):6866-6869, 1993; and Curiel et al., *Hum. Gene Ther.* 3(2):147-154, 1992), cytotfectin-mediated introduction (DMRIE-DOPE, Vical, Calif.), direct DNA injection (Acsadi et al., *Nature* 352:815-818, 1991); DNA ligand (Wu et al., *J. of Biol. Chem.* 264:16985-16987, 1989); lipofection (Felgner et al., *Proc. Natl. Acad. Sci, USA* 84:7413-7417, 1989); liposomes (Pickering et al., *Circ.* 89(1):13-21, 1994; and Wang et al., *PNAS* 84:7851-7855, 1987); microprojectile bombardment (Williams et al., *PNAS* 88:2726-2730, 1991); and direct delivery of nucleic acids which encode the enzyme itself, either alone (Vile and Hart, *Cancer Res.* 53:3860-3864, 1993), or utilizing PEG-nucleic acid complexes (see also WO 93/18759; WO 93/04701; WO 93/07283 and WO 93/07282).

As an additional alternative, DNA or other genetic material encoding one or more genes capable of inducing the expression of one or more of the extracellular products, homologs, analogs, or subunits of the present invention can be directly injected into a mammalian host utilizing so called "naked DNA" techniques. Following the *in vivo* introduction and the resultant uptake of the genetic construct by the host's cells the host will begin the endogenous production of the one or more encoded immunoreactive products engendering an effective immune response to subsequent challenge. As those skilled in the art will appreciate, coupling the genetic construct to eucaryotic promoter sequences and/or secretion signals may facilitate the endogenous expression and subsequent secretion of the encoded immunoreactive product or products. Exemplary techniques for the utilization of naked DNA as a vaccine can be found in International Patent No. WO 9421797 A (Merck & Co. Inc. and ViCal Inc.), International Patent Application No. WO 9011092 (ViCal Inc.), and Robinson, *Protection Against a Lethal Influenza Virus Challenge by Immunization with a Hemagglutinin-Expressing Plasmid DNA*, 11 Vaccine 9 (1993), and in Ulmer et al., *Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein*, 259 Science (1993), incorporated by reference herein.

Alternatively, techniques for the fusion of a strongly immunogenic protein tail have been disclosed in Tao et al., *Idiotypic/Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein as a Vaccine for B-Cell Lymphoma*, 362 Nature (1993), and for T-cell epitope mapping in Good et al., *Human T-Cell Recognition of the Circumsporozoite Protein of Plasmodium falciparum: Immunodominant T-Cell Domains Map to the Polymorphic Regions of the Molecule*, 85 Proc. Natl. Acad. Sci. USA (1988), and Gao et al., *Identification and Characterization of T Helper Epitopes in the Nucleoprotein of*

Influenza A Virus, 143 *The Journal of Immunology* No. 9 (1989).

As many bacterial genera exhibit homology, the foregoing examples are provided for the purposes of illustration and are not intended to limit the scope and content of the present invention or to restrict the invention to the genus *Mycobacterium* or to particular species or serogroups therein or to vaccines against tuberculosis alone. It should also be reemphasized that the prevalence of interspecies homology in the DNA and corresponding proteins of microorganisms enables the vaccines of the present invention to induce cross-reactive immunity. Because the immunodominant epitopes of the majorly abundant extracellular products may provide cross-protective immunity against challenge with other serogroups and species of the selected genera, those skilled in the art will appreciate that vaccines directed against one species may be developed using the extracellular products or immunogenic analogs of another species.

For example, *M. bovis* is between 90% and 100% homologous with *M. tuberculosis* and is highly cross-reactive in terms of provoking an immune response. Accordingly, vaccines based on abundant extracellular products of *M. bovis* or other *Mycobacterium* can offer various degrees of protection against infection by *M. tuberculosis* and vice versa. Thus, it is contemplated as being within the scope of the present invention to provide an immunoprophylactic response against several bacterial species of the same genera using an highly homologous immunogenic determinant of an appropriate majorly abundant extracellular product.

It should also be emphasized that the immunogenic determinant selected to practice the present invention may be used in many different forms to elicit an effective protective or immunodiagnostic immune response. Thus the mode of presentation of the one or more immunogenic determinants of selected majorly abundant extracellular

products to the host immune system is not critical and may be altered to facilitate production or administration. For example, the vaccines of the present invention may be formulated using whole extracellular products or any immunostimulating fraction thereof including peptides, protein subunits, immunogenic analogs and homologs as noted above.

In accordance with the teachings of the present invention, effective protein subunits of the majorly abundant extracellular products of *M. tuberculosis* can be identified in a genetically diverse population of a species of mammal. The resultant immunodominant T-cell epitopes identified should be recognized by other mammals including humans and cattle. These immunodominant T-cell epitopes are therefore useful for vaccines as well as for immunodiagnostic reagents. An exemplary study identifying the immunodominant T-cell epitopes of the 30 KD major secretory protein of *M. tuberculosis* was conducted as follows.

20

Example 28

Immunodominant Epitope Mapping of the 30 KD Protein

Fifty-five synthetic peptides (15-mers) covering the entire native 30 KD protein and overlapping by 10 amino acids were used for splenic lymphocyte proliferation assays to identify the immunodominant T-cell epitopes of the 30 KD major secretory protein of *M. tuberculosis*. The sequence of each 15-mer synthetic peptide utilized is given below in conjunction with an identification number (1-55) corresponding to the antigen peptide sequence numbers in Figs. 12a and b as well as an identification of the amino acid residues and relative position of each sequence.

No.	Residues	Peptide Sequence	Seq ID
No.			
1	1 - 15	F S R P G L P V E Y L Q V P S	37
2	6 - 20	L P V E Y L Q V P S P S M G R	38
5 3	11 - 25	L Q V P S P S M G R D I K V Q	39
4	16 - 30	P S M G R D I K V Q F Q S G G	40
5	21 - 35	D I K V Q F Q S G G N N S P A	41
6	26 - 40	F Q S G G N N S P A V Y L L D	42
7	31 - 45	N N S P A V Y L L D G L R A N Q	43
10 8	36 - 50	V Y L L D G L R A Q D D Y N G	44
9	41 - 55	G L R A Q D D Y N G W D I N T	45
10	46 - 60	D D Y N G W D I N T P A F E W	46
11	51 - 65	W D I N T P A F E W Y Y Q S G	47
12	56 - 70	P A F E W Y Y Q S G L S I V M	48
15 13	61 - 75	Y Y Q S G L S I V M P V G G Q	49
14	66 - 80	L S I V M P V G G Q S S F Y S	50
15	71 - 85	P V G G Q S S F Y S D W Y S P	51
16	76 - 90	S S F Y S D W Y S P A C G K A	52
17	81 - 95	D W Y S P A C G K A G C Q T Y	53
20 18	86 - 100	A C G K A G C Q T Y K W E T F	54
19	91 - 105	G C Q T Y K W E T F L T S E L	55
20	96 - 110	K W E T F L T S E L P Q W L S	56
21	101 - 115	L T S E L P Q W L S A N R A V	57
22	106 - 120	P Q W L S A N R A V K P T G S	58
25 23	111 - 125	A N R A V K P T G S A A I G L	59
24	116 - 130	K P T G S A A I G L S M A G S	60
25	121 - 135	A A I G L S M A G S A M I L P	61
26	126 - 140	S M A G S A M I L A A Y H P Q	62
27	131 - 145	S A M I L A A Y H P Q Q F I Y	63
30 28	136 - 150	A A Y H P Q Q F I Y A G S L S	64
29	141 - 155	Q Q F I Y A G S L S A L L D P	65
30	146 - 160	A G S L S A L L D P S Q G M G	66
31	151 - 165	A L L D P S Q G M G P S L I G	67
32	156 - 170	S Q G M G P S L I G L A M G D	68
35 33	161 - 175	P S L I G L A M G D A G G Y K	69
34	166 - 180	L A M G D A G G Y K A A D M W	70
35	171 - 185	A G G Y K A A D M W G P S S D	71
36	176 - 190	A A D M W G P S S D P A W E R	72
37	181 - 195	G P S S D P A W E R N D P T Q	73
40 38	186 - 200	P A W E R N D P T Q Q I P K L	74
39	191 - 205	N D P T Q Q I P K L V A N N T	75
40	196 - 210	Q I P K L V A N N T R L W V Y	76
41	201 - 215	V A N N T R L W V Y C G N G T	77
42	206 - 220	R L W V Y C G N G T P N E L G	78
45 43	211 - 225	C G N G T P N E L G G A N I P	79
44	216 - 230	P N E L G G A N I P A E F L E	80
45	221 - 235	G A N I P A E F L E N F V R S	81
46	226 - 240	A E F L E N F V R S S N L K F	82
47	231 - 245	N F V R S S N L K F Q D A Y N	83
50 48	236 - 250	S N L K F Q D A Y N A A G G H	84
49	241 - 255	Q D A Y N A A G G H N A V F N	85
50	246 - 260	A A G G H N A V F N F P P N G	86
51	251 - 265	N A V F N F P P N G T H S W E	87
52	256 - 270	F P P N G T H S W E Y W G A Q	88
55 53	261 - 275	T H S W E Y W G A Q L N A M K	89
54	266 - 280	Y W G A Q L N A M K G D L Q	90
55	271 - 285	L N A M K G D L Q S S L G A G	91

08786533-012199

Splenic lymphocytes were obtained from outbred male Hartley strain guinea pigs (Charles River Breeding Laboratories) that had been immunized intradermally 3-4 times with 100 μg of purified 30 KD protein emulsified in SAF (Allison and Byars, 1986). Control animals received phosphate buffered saline in SAF. Cell mediated immune responses were evaluated by skin testing as described above. Lymphocytes were seeded in 96-well tissue culture plates (Falcon Labware) and incubated in triplicate with the synthetic 15-mer peptides at 20 $\mu\text{g ml}^{-1}$, purified 30 KD protein at 20 $\mu\text{g ml}^{-1}$, purified protein derivative [(PPD); Connaught Laboratories LTD] at 20 $\mu\text{g ml}^{-1}$, or concanavalin A at 10 $\mu\text{g ml}^{-1}$ for 2 days in the presence of 10 U polymyxin B. Subsequently, cells were labeled for 16 h with 1 μCi [^3H] thymidine (New England Nuclear) and then harvested (Breiman and Horwitz, 1987). A positive proliferative response was defined as follows: (dpm of antigen) - (dpm of medium) \geq 1 500 and (dpm of antigen)/(dpm of medium) \geq 1.2. Immunodominant epitopes recognized by greater than 25% of the guinea pigs immunized with purified *M. tuberculosis* 30 KD protein are presented in Table AA below and graphically illustrated in Figs. 12a and 12b.

0878653-01349

Table AA

<u>Peptide No.</u>	<u>Inclusive Amino Acids for Mature Protein</u>	<u>Seq. ID No.</u>
1	1 - 15	37
2	6 - 20	38
3	11 - 25	39
5	21 - 35	41
6	26 - 40	42
13	61 - 75	49
21	101 - 115	57
10	126 - 140	62
27	131 - 145	63
31	151 - 165	67
33	161 - 175	69
36	176 - 190	72
15	181 - 195	73
41	201 - 215	77
45	221 - 235	81
49	241 - 255	85
53	261 - 275	89

20 The results presented in Table AA identify the immunodominant T-cell epitopes of the 30 KD major secretory protein of *M. tuberculosis*. Those skilled in the art will appreciate that earlier investigators have studied the 30 KD protein of *M. bovis* which is highly related to

25 *M. tuberculosis* protein. However, these earlier studies of the *M. bovis* protein differ markedly from the foregoing study in that the prior art studied actual patients, BCG vaccinees, patients with tuberculosis, or PPD-positive individuals. Because the response to this protein in such

30 individuals is often weak, the prior art epitope mapping studies were difficult and of questionable accuracy. In contrast, the study of Example 25 utilized outbred guinea pigs immunized with purified protein, thereby focusing the immune system on this single protein and producing a very

35 strong cell-mediated immune response. Moreover, these guinea pigs were studied within a few weeks of immunization, at the peak of T-cell responsiveness.

Previously, two types of studies aimed at identifying epitopes of the *M. tuberculosis* 32A KD protein have been

conducted. The first type examined the T-cell responses to peptides (overlapping the entire sequence of the protein) of humans who were a) tuberculin (PPD) positive; in part as a result of vaccination with BCG; b) lepromin positive; c) had TB; or d) had leprosy. (P. Launois, R. Deleys, M.N. Niang, A. Drowart, M. Adrien, P. Deirckx, J.-L. Cartel, J.-L. Sarthou, J.-P. van Vooren, and K. Huygen, 1994, "T-Cell epitope mapping of the major secreted mycobacterial antigen AG85A in tuberculosis and leprosy", *Infect. and Immun.* 62:3679-3687.) The response to this protein in these people is often weak, making it difficult to map epitopes accurately. In order to overcome these difficulties, outbred guinea pigs were immunized with purified protein, focusing the immune system on this single protein and producing a very strong cell-mediated immune response. The response was studied at the peak of T-cell responsiveness, i.e., within a few weeks of immunization.

The second type of previous study examined T-cell responses to peptides of inbred mice infected with BCG. (K. Huygen, E. Lozes, B. Gilles, A. Drowart, K. Palfliet, F. Jurion, I. Roland, M. Art, M. DuFaux, J. Nyabenda, J. De Bruyn, J.-P. van Vooren, and R. Deleys, 1994, "Mapping of TH1 helper T-cell epitopes on major secreted mycobacterial antigen 85A in mice infected with live *Mycobacterium bovis* BCG", *Infect. and Immun.*, 62:363-370.) Such a study is unlikely to yield results predictive of the diverse responses of multiple MHC types found in humans.

To obtain predictive results, in accordance with the present invention, a large number of outbred guinea pigs with a wide diversity of HLA types were studied. The epitopes of the 32A KD protein recognized by 25% or more of the guinea pigs therefore are strongly immunodominant and recognized by multiple HLA types. Hence, they are likely to be generally recognized by HLA molecules of other

species including humans, cattle, and other mammals. Such study should be highly predictive of immunodominant epitopes recognized by humans and other mammals. In addition, the mouse study referred to above relied on responses of BCG-infected animals. Such animals may a) not reflect *M. tuberculosis*-infected animals and b) not develop as strong a response to a specific protein--in this case, the 32A KD protein--as animals without active disease.

Example 29

Immunodominant Epitope Mapping of the 32A KD Protein

The procedure of Example 28 was repeated except that the fifty-seven synthetic peptides (15-mers) covering the entire native 32A KD proteins were used. The sequence of each 15-mer targeted is shown in Table AB:

Table AB

No.	Residues	Peptide Sequence	Seq. ID No.
1	1-15	F S R P G L P V E Y L Q V P S	96
2	6-20	L P V E Y L Q V P S P S M G R	97
3	11-25	L Q V P S P S M G R D I K V Q	98
4	16-30	P S M G R D I K V Q F Q S G G	99
5	21-35	D I K V Q F Q S G G A N S P A	100
6	26-40	F Q S G G A N S P A L Y L L D	101
7	31-45	A N S P A L Y L L D G L R A Q	102
8	36-50	L Y L L D G L R A Q D D F S G	103
9	41-55	G L R A Q D D F S G W D I N T	104
10	46-60	D D F S G W D I N T P A F E W	105
11	51-65	W D I N T P A F E W Y D Q S G	106
12	56-70	P A F E W Y D Q S G L S V V M	107
13	61-75	Y D Q S G L S V V M P V G G Q	108
14	66-80	L S V V M P V G G Q S S F Y S	109
15	71-85	P V G G Q S S F Y S D W Y Q P	110

	No.	Residues	Peptide Sequence	Seq. ID No.
	16	76-90	S S F Y S D W Y Q P A C G K A	111
	17	81-95	D W Y Q P A C G K A G C Q T Y	112
	18	86-100	A C G K A G C Q T Y K W E T F	113
	19	91-105	G C Q T Y K W E T F L T S E L	114
5	20	96-110	K W E T F L T S E L P G W L Q	115
	21	101-115	L T S E L P G W L Q A N R H V	116
	22	106-120	P G W L Q A N R H V K P T G S	117
	23	111-125	A N R H V K P T G S A V V G L	118
	24	116-130	K P T G S A V V G L S M A A S	119
10	25	121-135	A V V G L S M A A S S A L T L	120
	26	126-140	S M A A S S A L T L A I Y H P	121
	27	131-145	S A L T L A I Y H P Q Q F V Y	122
	28	136-150	A I Y H P Q Q F V Y A G A M S	123
	29	141-155	Q Q F V Y A G A M S G L L D P	124
15	30	146-160	A G A M S G L L D P S Q A M G	125
	31	151-165	G L L D P S Q A M G P T L I G	126
	32	156-170	S Q A M G P T L I G L A M G D	127
	33	161-175	P T L I G L A M G D A G G Y K	128
	34	166-180	L A M G D A G G Y K A S D M W	129
20	35	171-185	A G G Y K A S D M W G P K E D	130
	36	176-190	A S D M W G P K E D P A W Q R	131
	37	181-195	G P K E D P A W Q R N D P L L	132
	38	186-200	P A W Q R N D P L L N V G K L	133
	39	191-205	N D P L L N V G K L I A N N T	134
25	40	196-210	N V G K L I A N N T R V W V Y	135
	41	201-215	I A N N T R V W V Y C G N G K	136
	42	206-220	R V W V Y C G N G K P S D L G	137
	43	211-225	C G N G K P S D L G G N N L P	138
	44	216-230	P S D L G G N N L P A K F L E	139
30	45	221-235	G N N L P A K F L E G F V R T	140
	46	226-240	A K F L E G F V R T S N I K F	141
	47	231-245	G F V R T S N I K F Q D A Y N	142

	<u>No.</u>	<u>Residues</u>	<u>Peptide Sequence</u>	<u>Seq. ID No.</u>
	48	236-250	S N I K F Q D A Y N A G G G H	143
	49	241-255	Q D A Y N A G G G H N G V F D	144
	50	246-260	A G G G H N G V F D F P D S G	145
	51	251-265	N G V F D F P D S G T H S W E	146
5	52	256-270	F P D S G T H S W E Y W G A Q	147
	53	261-275	T H S W E Y W G A Q L N A M K	148
	54	266-280	Y W G A Q L N A M K P D L Q R	149
	55	271-285	L N A M K P D L Q R A L G A T	150
	56	276-290	P D L Q R A L G A T P N T G P	151
10	57	281-295	A L G A T P N T G P A P Q G A	152

As shown in the following table, for technical reasons, synthetic peptide numbers 1A, 5A, 15A, 26A, 29A, 43A, and 56A differed slightly from the corresponding 15-mers targeted.

15

Table AC

	<u>No.</u>	<u>Residues</u>	<u>Peptide Sequence</u>	<u>Seq. ID No.</u>
	1A	1-18	F S R P G L P V E Y L Q V P S P S M	153
	5A	21-36	D I K V Q F Q S G G A N S P A L	154
	15A	71-87	P V G G Q S S F Y S D W Y Q P A C	155
20	26A	126-142	S M A A S S A L T L A I Y H P Q Q	156
	29A	140-157	P Q Q F V Y A G A M S G L L D P S Q	157
	43A	211-227	C G N G K P S D L G G N N L P A K	158
	49A	240-255	F Q D A Y N A G G G H N G V F D	159
	56A	276-289	P D L Q R A L G A T P N T G	160

25

Immunodominant T-cell epitopes of the 32A KD major secretory protein of *M. tuberculosis* recognized by greater than 25% of the guinea pigs immunized with purified *M. tuberculosis* 32A KD protein are presented in Table AD below and graphically illustrated in Fig. 13.

Table AD

	<u>Peptide*</u>	<u>Inclusive Amino Acids for Mature Protein</u>	<u>Sequence ID No.</u>
	9	41 - 55	104
	11	51 - 65	106
5	12	56 - 70	107
	15	71 - 85	110
	19	91 - 105	114
	20	96 - 110	115
	23	111 - 125	118
10	25	121 - 135	120
	27	131 - 145	122
	28	136 - 150	123
	29	141 - 155	124
	31	151 - 165	126
15	32	156 - 170	127
	39	191 - 205	134
	40	196 - 210	135
	41	201 - 215	136
	43	211 - 225	138

20 In accordance with the teachings of the present invention one or more of the immunodominant epitopes identified above can be incorporated into a vaccine against tuberculosis. For example, individual immuno-

25 dominant epitopes can be synthesized and used individually or in combination in a multiple antigen peptide system. Alternatively, two or more immunodominant epitopes can be linked together chemically. The peptides, either linked together or separately, can be combined with an appropriate adjuvant and used in subunit vaccines for humans or

30 other mammals. In addition, the immunodominant epitopes can be used in new immunodiagnostic reagents such as new skin tests.

Specific exemplary adjuvants used in the instant invention to enhance the activity of the selected immunogenic determinants are SAF, adjuvants containing Monophosphoryl Lipid A (MPL), Freund's incomplete 5 adjuvant, Freund's complete adjuvant containing killed bacteria, gamma interferons (Radford et al., *American Society of Hepatology* 2008-2015, 1991; Watanabe et al., *PNAS* 86:9456-9460, 1989; Gansbacher et al., *Cancer Research* 50:7820-7825, 1990; Maio et al., *Can. Immunol.* 10 *Immunother.* 30:34-42, 1989; U.S. Patent Nos. 4,762,791 and 4,727,138), IL-12, IL-15 (Grabstein et al., *Science* 264:965-968, 1994), MF 59, MF 59 plus MTP, MF 59 plus IL-12, MPL plus TDM (trehalose dimycolate), QS-21, QS-21 plus IL-12, IL-2 (American Type Culture Collection Nos. 39405, 15 39452 and 39516; see also U.S. Patent No. 4,518,584), dimethyldioctadecyl ammonium (ddA), ddA plus dextran, alum, Quil A, ISCOMS, (Immunostimulatory Complexes), Liposomes, Lipid Carriers, Protein Carriers, and Micro-encapsulation techniques. Additional adjuvants that may 20 be useful in the present invention are water-in-oil emulsions, mineral salts (for example, alum), nucleic acids, block polymer surfactants, and microbial cell walls (peptido glycolipids). While not limiting the scope of the invention it is believed that adjuvants may magnify 25 immune responses by allowing the slow release of antigens from the site of injection and/or modulation of the milieu at the site of injection including the cellular and cytokine constituents.

Particularly preferred is IL-12 either alone or in
30 conjunction with another adjuvant. It has been found that
immunization of guinea pigs with purified major *M. tuberc-*
ulosis extracellular proteins in the presence of IL-12
alone, or in the presence of IL-12 plus another adjuvant,
for example, MF 59, enhances protective immunity over that
35 obtained without IL-12. By increasing the capacity of the

vaccine to induce protective immunity, IL-12 renders the vaccine more efficacious.

It was known that murine IL-12 stimulates both murine lymphoblasts and human lymphoblasts, and that human IL-12 stimulates human lymphoblasts, but it was not known if either mouse or human IL-12 stimulates guinea pig lymphoblasts. To determine if murine or human IL-12 stimulates guinea pig lymphoblasts, IL-12 activity was assayed using the protocol described in Current Protocols in Immunology, 1993, Cytokines and their Receptors entitled "Lymphoblasts Proliferation Assay for IL-12 Activity" Alternate Protocol), pages 6.16.3 through 6.16.5.

Example 30

Spleen cells were isolated from a male Hartley strain guinea pig, incubated at a concentration of 10^7 cells/75cm² culture flask containing 20 ml supplemented medium for 3 days with PHA at a concentration of 8 μ g/ml, diluted 1:1 with supplemental medium, and incubated for 1 day with IL-2 at a concentration of 50 IU/ml. The lymphoblasts were washed, counted, dispensed into 96 well flat-bottom, microtiter plates at a cell density of 2×10^4 lymphoblasts/well, and incubated for 24h with 0 to 5 μ g/ml IL-12 (R&D Systems, Minneapolis, MN). ³H-thymidine (0.25 μ Ci) was added to each well for an additional 18h, and the cells then were harvested and assayed for incorporated ³H-thymidine.

The results of two independent experiments using spleen cells from different outbred guinea pigs are shown in Fig. 21 and Fig. 22. Data are the mean DPM \pm S.D. for sextuplicate wells.

In each experiment, both murine and human IL-12 strongly stimulated proliferation of guinea pig lymphoblasts in a dose-dependent fashion.

08786533-012197

To determine if IL-12 would enhance the efficacy of a vaccine consisting of purified *M. tuberculosis* 30, 32A, and 16KD major extracellular proteins, guinea pigs were immunized with the vaccine in the presence or absence of IL-12 and challenged with virulent *M. tuberculosis* by aerosol. IL-12 was found to enhance the capacity of the vaccine to protect the animals against weight loss and growth of *M. tuberculosis* in the lungs of challenged animals.

10

Example 31

Guinea pigs (6 per group) were immunized intradermally three times with 100 μ g of purified *M. tuberculosis* 30, 32A and 16 KD major extracellular proteins in the presence of adjuvant (MF 59) and recombinant mouse IL-12 purchased from R&D Systems (Minneapolis, MN). Control animals (6 per group) were sham-immunized with adjuvant and IL-12 only. The animals were then challenged with an aerosol of virulent *M. tuberculosis* Erdman strain and weighed weekly thereafter until killed at 10 weeks. Sham-immunized animals exhibited greater weight loss than animals immunized with the proteins in the presence of adjuvant plus IL-12. The results are shown in Fig. 23.

Example 32

Guinea pigs (6 per group) were immunized three times intradermally with 100 μ g of purified *M. tuberculosis* 30, 32A, and 16 KD major extracellular proteins in the presence of adjuvant (MF 59) alone, IL-12 alone, or adjuvant +IL-12 or sham-immunized with adjuvant alone, or adjuvant +IL-12. IL-12 was purchased from R&D Systems. The animals were then challenged with virulent *M. tuberculosis* Erdman strain and weighed weekly thereafter until killed at 10 weeks. Fig. 24 shows the mean net weight gain or loss of each group from the weight on the day of the challenge. Animals immunized with the proteins exhibited

less weight loss than both groups of sham-immunized controls. Of the sham-immunized animals, animals immunized with adjuvant in the presence of IL-12 lost less weight than animals immunized with adjuvant only. Of the
5 protein-immunized animals, animals immunized with proteins in the presence of adjuvant plus IL-12 exhibited less weight loss over the course of the experiment than animals immunized with the proteins in the presence of either IL-12 only or adjuvant only. Thus, during the critical
10 period of disease from 4 to 10 weeks after challenge, animals immunized with proteins in the presence of both adjuvant and IL-12 exhibited the least amount of weight loss at weeks 5, 6, 7, and 10 and the second least amount of weight loss at weeks 4 and 8.

15

Example 33

Animals were immunized three times intradermally with 100 μ g of *M. tuberculosis* 30, 32A, and 16 KD major extra-cellular proteins in the presence of MF 59 or MF 59 + IL-12, or sham-immunized with MF 59 only, IL-12 only or MF 59
20 + IL-12. The animals were challenged with virulent *M. tuberculosis* by aerosol, observed for 10 weeks, and killed. The right lung was removed and cultured for *M. tuberculosis* on 7H11 agar plates. Data shown in Table AE are the mean CFU per right lung.

08786533-013197

CFU in Lungs of Animals Immunized with 3 purified Major Extracellular *M. tuberculosis* Proteins (30, 32A, 16 KD) in the Presence of Various Adjuvants

10 Animals immunized with proteins had fewer CFU than
animals sham-immunized without proteins but with the same
adjuvant preparation. Thus, animals immunized with
proteins plus MF 59 (C) had 0.7 log fewer CFU in the lungs
than animals immunized with MF 59 only (A); and animals
15 immunized with proteins with MF 59 + IL-12 (E) had 0.4 log
fewer CFU in the lungs than animals immunized with MF 59
+ IL-12 only (B), and 1.1 log fewer CFU in the lungs than
animals immunized with MF 59 only.

25 Example 34

UCLA\ID-VACCINE\120243.APP\MAK/R/121296 9:03am

The animals were then challenged with an aerosol of virulent *M. tuberculosis* Erdman strain and weighed weekly thereafter until killed at 10 weeks. Sham-immunized animals exhibited greater weight loss than animals immunized with the proteins in the presence of either adjuvant only or adjuvant plus IL-12. Of the animals immunized with proteins, animals immunized with proteins in the presence of adjuvant only lost more weight than animals immunized with proteins in the presence of adjuvant plus IL-12. Furthermore, sham-immunized animals had a higher mortality during the course of the experiment - 24% of the sham-immunized animals died vs. only 6% of animals immunized with proteins. Of the animals immunized with proteins, animals immunized with proteins in the presence of adjuvant only had a higher mortality (11%) than animals immunized with proteins in the presence of adjuvant plus IL-12 (0%). The results are shown in Fig. 25.

Those skilled in the art will also appreciate that DNA encoding the peptides can be synthesized and used to express the peptides, individually or collectively, or can be combined in a DNA vaccine injected directly into humans or other mammals. A construct consisting of only the immunogenic epitopes (or the DNA coding therefor) would focus the immune response on the protective portions of the molecule. By avoiding irrelevant or even immunosuppressive epitopes such a construct may induce a stronger and more protective immune response.

Smaller protein subunits of the majorly abundant extracellular products, molecular analogs thereof, genes encoding therefore, and respective combinations thereof are within the scope of the present invention as long as they provoke effective immunoprophylaxis or function as an immunodiagnostic reagent. Moreover, recombinant protein products such as fusion proteins or extracellular products modified through known molecular recombinant techniques

are entirely compatible with the teachings of the present invention. In addition, immunogenically generated analogs of the selected immunoactive determinants or peptides and nucleotides derived using directed evolution are also
5 within the scope of the invention. Moreover, the selected immunoactive determinants can be modified so as to bind more tightly to specific MHC molecules of humans or other species or be presented more efficiently by antigen presenting cells. Further, the selected immunoactive
10 determinants can be modified so as to resist degradation in the vaccinated host.

Similarly, the formulation and presentation of the immunogenic agent to the host immune system is not limited to solutions of proteins or their analogs in adjuvant.
15 For example, the immunogenic determinant derived from the appropriate extracellular proteins may be expressed by *M. tuberculosis*, different species of *Mycobacteria*, different species of bacteria, phage, mycoplasma or virus that is nonpathogenic and modified using recombinant
20 technology. In such cases the whole live organism may be formulated and used to stimulate the desired response. Conversely, large scale vaccination programs in hostile environments may require very stable formulations without complicating adjuvants or additives. Further, the vaccine
25 formulation could be directed to facilitate the stability or immunoreactivity of the active component when subjected to harsh conditions such as lyophilization or oral administration or encapsulation. Accordingly, the present invention encompasses vastly different formulations of the
30 immunogenic determinants comprising the subject vaccines depending upon the intended use of the product.

Those skilled in the art will appreciate that vaccine dosages should be determined for each pathogen and host utilizing routine experimentation. At present, it is
35 believed that the lowest practical dosage will be on the order of 0.1 μg though dosages of 2.0 μg , 20.0 μg , 100 μg

and even 1 mg may be optimum for the appropriate system. The proper dosage can be administered using any conventional immunization technique and sequence known in the art.

5 Those skilled in the art will further appreciate that the present invention may be embodied in other specific forms without departing from the spirit or central attributes thereof. In that the foregoing description of the present invention discloses only exemplary embodiments
10 thereof, it is to be understood that other variations are contemplated as being within the scope of the present invention. Accordingly, the present invention is not limited to the particular embodiments which have been described in detail herein. Rather, reference should be
15 made to the appended claims as indicative of the scope and content of the present invention.

U.S. PAT. & TRADEMARK OFFICE

- (viii) ATTORNEY/AGENT INFORMATION:
 (A) NAME: MacLean, Kurt A.
 (B) REGISTRATION NUMBER: 31,118
 (C) REFERENCE/DOCKET NUMBER: 118-119

- 5 (ix) TELECOMMUNICATION INFORMATION:
 (A) TELEPHONE: (714) 263-8250
 (B) TELEFAX: (714) 263-8260

(2) INFORMATION FOR SEQ ID NO:1:

- 10 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- 15 (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: N-terminal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
- Asn Ser Lys Ser Val
 1 5

(2) INFORMATION FOR SEQ ID NO:2:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- 30 (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: N-terminal

UCLAID-VACCINE\120243.APP\MAK/R/121196 11:08am

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

5 Thr Asp Arg Val Ser
 1 5

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5 amino acids
 10 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

15 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

 Ala Arg Ala Val Gly
 1 5

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
 25 (A) LENGTH: 5 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

30 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

UCLAID-VACCINE\20243.APP\MAK\R\121196

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

5 Thr Glu Lys Thr Pro
 1 5

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5 amino acids
 10 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

15 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Asp Pro Glu Pro Ala
 1 5

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
 25 (A) LENGTH: 5 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

30 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

UCLAVID-VACCINE\120243.APP\MAX\R\121196

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

5 Phe Ser Arg Pro Gly
 1 5

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5 amino acids
 10 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

15 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

 Phe Ser Arg Pro Gly
 1 5

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
 25 (A) LENGTH: 5 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

30 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

007833-0149
 467270-EE993480

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

5 Phe Ser Arg Pro Gly
 1 5

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5 amino acids
 10 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

15 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Ala Pro Tyr Glu Asn
 1 5

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5 amino acids
 25 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

30 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

UCLA-IR#E0909280

- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

5 Ala Pro Lys Thr Tyr
 1 5

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5 amino acids
 10 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

15 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Ala Glu Thr Tyr Leu
 1 5

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 25 (A) LENGTH: 5 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

30 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

UCLAID-VACCINE120243.APP\MAK/R/121196 11:08am

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

5 Ala Tyr Pro Ile Thr
 1 5

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5 amino acids
 10 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

15 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

 Ala Asp Pro Arg Leu
 1 5

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 5 amino acids
 25 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

30 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

UCLAID-VACCINE\20243.APP\MAK\11\12\196 11:08am

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*
(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

5 Phe Asp Thr Arg Leu
 1 5

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 40 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

15 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*
(B) STRAIN: Erdman

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Phe Ser Arg Pro Gly Leu Pro Val Glu Tyr Leu Gln Val Pro Ser
1 5 10 15

Pro Ser Met Gly Arg Asp Ile Lys Val Gln Phe Gln Ser Gly Gly
16 20 25 30

25 Asn Asn Ser Pro Ala Val Tyr Leu Leu Asp
 31 35 40

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH: 40 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

DE 93-0449

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:

- 5 (A) ORGANISM: *Mycobacterium tuberculosis*
(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

	Phe	Ser	Arg	Pro	Gly	Leu	Pro	Val	Glu	Tyr	Leu	Gln	Val	Pro	Ser
	1				5					10					15
10	Pro	Ser	Met	Gly	Arg	Asp	Ile	Lys	Val	Gln	Phe	Gln	Ser	Gly	Gly
	16				20					25					30
	Asn	Asn	Ser	Pro	Ala	Val	Tyr	Leu	Leu	Asp					
	31				35					40					

(2) INFORMATION FOR SEQ ID NO:17:

- 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

20 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:

- 25 (A) ORGANISM: *Mycobacterium tuberculosis*
(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

	Phe	Ser	Arg	Pro	Gly	Leu	Pro	Val	Glu	Tyr	Leu	Gln	Val	Pro	Ser
	1				5					10					15
30	Ala	Ser	Met	Gly	Arg	Asp	Ile								
	16				20										

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 48 amino acids
(B) TYPE: amino acid

UCLA-VID-VACCINE\120243.APP\MAK/R/121196 11:08am

UCLA-ID-VACCINE\120243.APP\MAK/r/121196 11:08am

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Ala Asp Pro Arg Leu Gln Phe Thr Ala Thr Thr Leu Ser Gly Ala
 1 5 10 15
 5 Pro Phe Asp Lys Ala Ser Leu Gln Gly Lys Pro Ala Val Leu Trp
 21 20 25 30

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: N-terminal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Ala Asp Pro Arg Leu Gln Phe Thr Ala Thr Thr Leu Ser Gly Ala
 1 5 10 15
 20 Pro Phe Asp Lys Ala Ser Leu Gln Gly Lys Pro Ala Val Leu Trp
 16 20 25 30

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 47 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: N-terminal

UCLAVID-VACCINE\120243.APP\MAK\11\121196 11:08am

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

5 Ala Tyr Pro Ile Thr Gly Cys Leu Gly Ser Glu Leu Thr Met Thr
 1 5 10 15
 Asp Thr Val Gly Gln Val Val Leu Gly Trp Lys Val Ser Asp Leu
 16 20 25 30
 10 Phe Lys Ser Thr Ala Val Ile Pro Gly Tyr Thr Val Xaa Glu Gln
 31 35 40 45
 Gln Ile
 46

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 15 (A) LENGTH: 47 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 20 (iii) HYPOTHETICAL: NO
 (iv) ANTI-SENSE: NO
 (v) FRAGMENT TYPE: N-terminal
 (vi) ORIGINAL SOURCE:
 25 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Ala Tyr Pro Ile Thr Asx Lys Leu Gly Ser Glu Leu Thr Met Thr
 1 5 10 15
 30 Asp Thr Val Gly Gln Val Val Leu Gly Trp Lys Val Ser Asp Leu
 16 20 25 30
 Tyr Lys Ser Thr Ala Val Ile Pro Gly Tyr Thr Val Xaa Glu Gln
 31 35 40 45
 Gln Ile
 46

(2) INFORMATION FOR SEQ ID NO:23:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 22 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

10 (v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

15 Ala Glu Thr Tyr Leu Pro Asp Leu Asp Trp Asp Tyr Gly Ala Leu
 1 5 10 15

Glu Pro His Ile Ser Gly Gln
 16 20

(2) INFORMATION FOR SEQ ID NO:24:

20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 13 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

30 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Ala Pro Lys Thr Tyr Xaa Glu Glu Leu Lys Gly Thr Asp
 1 5 10

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 60 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO
 (iv) ANTI-SENSE: NO
 (v) FRAGMENT TYPE: N-terminal
 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

15	Ala	Pro	Tyr	Glu	Asn	Leu	Met	Asx	Pro	Ser	Pro	Ser	Met	Gly	Arg
	1				5					10					15
	Asp	Ile	Pro	Val	Ala	Phe	Leu	Ala	Gly	Gly	Pro	His	Ala	Val	Tyr
	16				20					25					30
20	Leu	Leu	Asp	Ala	Phe	Asn	Ala	Gly	Pro	Asp	Val	Ser	Asn	Trp	Val
	31				35					40					45
	Thr	Ala	Gly	Asn	Ala	Met	Met	Thr	Leu	Ala	Xaa	Lys	Gly	Ile	Cys
	46				50					55					60

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 60 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO
 (iv) ANTI-SENSE: NO
 (v) FRAGMENT TYPE: N-terminal
 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

08786533-01196

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Ala Pro Tyr Glu Asn Leu Met Val Pro Ser Pro Ser Met Gly Arg
 1 5 10 15
 5 Asp Ile Pro Val Ala Phe Leu Ala Gly Gly Pro His Ala Val Tyr
 16 20 25 30
 Leu Leu Asp Ala Phe Asn Ala Gly Pro Asp Val Ser Asn Trp Val
 31 35 40 45
 Thr Ala Gly Asn Ala Met Met Thr Leu Ala Xaa Lys Gly Ile Ser
 46 50 55 60

10 (2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 40 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 15 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: N-terminal
- 20 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Phe Ser Arg Pro Gly Leu Pro Val Glu Tyr Leu Gln Val Pro Ser
 25 1 5 10 15
 Pro Ser Met Gly Arg Asp Ile Lys Val Gln Phe Gln Ser Gly Gly
 16 20 25 30
 Asn Asn Ser Pro Ala Val Tyr Leu Leu Asp
 31 35 40

30 (2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 40 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 35 (D) TOPOLOGY: linear

DESeq-01249

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

5 (vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

```

10 Phe Ser Arg Pro Gly Leu Pro Val Glu Tyr Leu Gln Val Pro Ser
    1           5           10           15

    Pro Ser Met Gly Arg Asp Ile Lys Val Gln Phe Gln Ser Gly Gly
    16           20           25           30

    Asn Asn Ser Pro Xaa Leu Tyr Leu Leu Asp
    31           35           40

```

15 (2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

20 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

25 (vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

```

30 Phe Ser Arg Pro Gly Leu Pro Val Glu Tyr Leu Gln Val Pro Ser
    1           5           10           15

    Ala Xaa Met Gly Arg Asp Ile
    16           20

```

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(iii) HYPOTHETICAL: NO

10 (v) FRAGMENT TYPE: N-terminal

(A) ORGANISM: *Mycobacterium tuberculosis*
(B) STRAIN: Erdman

15 Asp Pro Glu Pro Ala Pro Pro Val Pro Asp Asp Ala Ala Ser Pro
1 5 10 15

Pro Asp Asp Ala Ala Ala Pro Pro Ala Pro Ala Asp Pro Pro Xaa
16 20 25 30

20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: N-terminal

30 (A) ORGANISM: *Mycobacterium tuberculosis*
(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Thr Glu Lys Thr Pro Asp Asp Val Phe Lys Leu Ala Lys Asp Glu
 1 5 10 15
 Lys Val Leu Tyr Leu
 5 16 20

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 6 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
 10
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO
 (iv) ANTI-SENSE: NO
 15 (v) FRAGMENT TYPE: N-terminal
 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
 20 Ala Arg Ala Val Gly Ile
 1 5

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 8 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
 25
 (ii) MOLECULE TYPE: protein
 (iii) HYPOTHETICAL: NO
 30 (iv) ANTI-SENSE: NO
 (v) FRAGMENT TYPE: N-terminal
 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Thr Asp Arg Val Ser Val Gly Asn
1 5

(2) INFORMATION FOR SEQ ID NO:34:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(vi) ORIGINAL SOURCE:

- 15 (A) ORGANISM: *Mycobacterium tuberculosis*
- (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Asn Ser Lys Ser Val Asn Ser Phe Gly Ala His Asp Thr Leu Lys
1 5 10 15

20 Val Xaa Glu Arg Lys Arg Gln
16 20

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 978 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

30 ATGACAGACG TGAGCCGAAA GATTCGAGCT TGGGGACGCC GATTGATGAT 50
CGGCACGGCA GCGGCTGTAG TCCTTCCGGG CCTGGTGGGG CTTGCCGGCG 100
GAGCGGCAAC CGCGGGCGCG TTCTCCCGGC CGGGGCTGCC GGTTCGAGTAC 150
CTGCAGGTGC CGTCGCCGTC GATGGGCCGC GACATCAAGG TTCAGTTCCA 200

GAGCGGTGGG AACAACTCAC CTGCGGTTTA TCTGCTCGAC GGCCTGCGCG 250
 CCCAAGACGA CTACAACGGC TGGGATATCA ACACCCCGGC GTTCGAGTGG 300
 TACTACCAGT CGGGACTGTC GATAGTCATG CCGGTCGGCG GGCAGTCCAG 350
 CTTCTACAGC GACTGGTACA GCCCGGCCTG CGGTAAGGCT GGCTGCCAGA 400
 5 CTTACAAGTG GGAAACCTTC CTGACCAGCG AGCTGCCGCA ATGGTTGTCC 450
 GCCAACAGGG CCGTGAAGCC CACCGGCAGC GCTGCAATCG GCTTGTCGAT 500
 GGCCGGCTCG TCGGCAATGA TCTTGGCCGC CTACCACCCC CAGCAGTTCA 550
 TCTACGCCGG CTCGCTGTCG GCCCTGCTGG ACCCCTCTCA GGGGATGGGG 600
 CCTAGCCTGA TCGGCCCTCGC GATGGGTGAC GCCGGCGGTT ACAAGGCCGC 650
 10 AGACATGTGG GGTCCCTCGA GTGACCCGGC ATGGGAGCGC AACGACCCTA 700
 CGCAGCAGAT CCCCAAGCTG GTCGCAAACA ACACCCGGCT ATGGGTTTAT 750
 TCGGGGAACG GCACCCCGAA CGAGTTGGGC GGTGCCAACA TACCCGCCGA 800
 GTTCTTGGAG AACTTCGTTC GTAGCAGCAA CCTGAAGTTC CAGGATGCGT 850
 ACAACGCCGC GGGCGGGCAC AACGCCGTGT TCAACTTCCC GCCCAACGGC 900
 15 ACGCACAGCT GGGAGTACTG GGGCGCTCAG CTCAACGCCA TGAAGGGTGA 950
 CCTGCAGAGT TCGTTAGGCG CCGGCTGA 978

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1017 base pairs
 20 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

25 ATGCAGCTTG TTGACAGGGT TCGTGGCGCC GTCACGGGTA TGTCGCGTCG 50
 ACTCGTGGTC GGGGCCGTCG GCGCGGCCCT AGTGTCGGGT CTGGTCGGCG 100
 CCGTCGGTGG CACGGCGACC GCGGGGGCAT TTTCCCGGCC GGGCTTGCCG 150
 GTGGAGTACC TGCAGGTGCC GTCGCCGTCG ATGGGCCGTG ACATCAAGGT 200
 CCAATTCCAA AGTGGTGGTG CCAACTCGCC CGCCCTGTAC CTGCTCGACG 250

GCCTGCGCGC GCAGGACGAC TTCAGCGGCT GGGACATCAA CACCCCGGCG 300
 TTCGAGTGGT ACGACCAGTC GGGCCTGTCTG GTGGTCATGC CGGTGGGTGG 350
 CCAGTCAAGC TTCTACTCCG ACTGGTACCA GCGCGCCTGC GGCAAGGCCG 400
 GTTGCCAGAC TTACAAGTGG GAGACCTTCC TGACCAGCGA GCTGCCGGGG 450
 5 TGGCTGCAGG CCAACAGGCA CGTCAAGCCC ACCGGAAGCG CCGTCGTCCG 500
 TCTTTTCGATG GCTGCTTCTT CGGCGCTGAC GCTGGCGATC TATCACCCCC 550
 AGCAGTTCGT CTACGCGGGA GCGATGTCCG GCCTGTTGGA CCCCTCCCAG 600
 GCGATGGGTC CCACCCTGAT CGGCCTGGCG ATGGGTGACG CTGGCGGCTA 650
 CAAGGCCTCC GACATGTGGG GCCCGAAGGA GGACCCGGCG TGGCAGCGCA 700
 10 ACGACCCGCT GTTGAACGTC GGGAAGCTGA TCGCCAACAA CACCCGCGTC 750
 TGGGTGTACT GCGGCAACGG CAAGCCGTCG GATCTGGGTG GCAACAACCT 800
 GCCGGCCAAG TTCCTCGAGG GCTTCGTGCG GACCAGCAAC ATCAAGTTCC 850
 AAGACGCCTA CAACGCCGGT GGCGGCCACA ACGGCGTGTT CGACTTCCCG 900
 GACAGCGGTA CGCACAGCTG GGAGTACTGG GGCGCGCAGC TCAACGCTAT 950
 15 GAAGCCCGAC CTGCAACGGG CACTGGGTGC CACGCCCAAC ACCGGGCCCCG 1000
 CGCCCCAGGG CGCCTAG 1017

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- 25 (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: N-terminal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

Phe Ser Arg Pro Gly Leu Pro Val Glu Tyr Leu Gln Val Pro Ser
1 5 10 15

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

15 (A) ORGANISM: *Mycobacterium tuberculosis*
(B) STRAIN: Erdman

Leu Pro Val Glu Tyr Leu Gln Val Pro Ser Pro Ser Met Gly Arg
1 5 10 15

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE: internal

(A) ORGANISM: *Mycobacterium tuberculosis*
(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Leu Gln Val Pro Ser Pro Ser Met Gly Arg Asp Ile Lys Val Gln
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:40:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 15 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Pro Ser Met Gly Arg Asp Ile Lys Val Gln Phe Gln Ser Gly Gly
 1 5 10 15

20 (2) INFORMATION FOR SEQ ID NO:41:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 30 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Asp Ile Lys Val Gln Phe Gln Ser Gly Gly Asn Asn Ser Pro Ala
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:42:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- 10 (ii) MOLECULE TYPE: peptide
 (iii) HYPOTHETICAL: NO
 (iv) ANTI-SENSE: NO
 (v) FRAGMENT TYPE: internal
- 15 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Phe Gln Ser Gly Gly Asn Asn Ser Pro Ala Val Tyr Leu Leu Asp
1 5 10 15

20 (2) INFORMATION FOR SEQ ID NO:43:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- 25 (ii) MOLECULE TYPE: peptide
 (iii) HYPOTHETICAL: NO
 (iv) ANTI-SENSE: NO
 (v) FRAGMENT TYPE: internal
- 30 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Asn Asn Ser Pro Ala Val Tyr Leu Leu Asp Gly Leu Arg Ala Gln
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:44:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 15 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

Val Tyr Leu Leu Asp Gly Leu Arg Ala Gln Asp Asp Tyr Asn Gly
1 5 10 15

20 (2) INFORMATION FOR SEQ ID NO:45:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 30 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

UCLAVID-VACCINE\120243.APP\MAK\R\121196 11:08am

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Gly Leu Arg Ala Gln Asp Asp Tyr Asn Gly Trp Asp Ile Asn Thr
1 5 10 15

(2) INFORMATION FOR SEQ ID NO:46:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 15 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

Asp Asp Tyr Asn Gly Trp Asp Ile Asn Thr Pro Ala Phe Glu Trp
1 5 10 15

20 (2) INFORMATION FOR SEQ ID NO:47:

- 25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

- 30 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

Trp Asp Ile Asn Thr Pro Ala Phe Glu Trp Tyr Tyr Gln Ser Gly
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:48:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- 10 (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 15 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:
- Pro Ala Phe Glu Trp Tyr Tyr Gln Ser Gly Leu Ser Ile Val Met
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:49:

- 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- 25 (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 30 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:
- Tyr Tyr Gln Ser Gly Leu Ser Ile Val Met Pro Val Gly Gly Gln
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:50:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

15 Leu Ser Ile Val Met Pro Val Gly Gly Gln Ser Ser Phe Tyr Ser
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:51:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

30 Pro Val Gly Gly Gln Ser Ser Phe Tyr Ser Asp Trp Tyr Ser Pro
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:52:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:
- | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 15 | Ser | Ser | Phe | Tyr | Ser | Asp | Trp | Tyr | Ser | Pro | Ala | Cys | Gly | Lys | Ala |
| | 1 | | | | 5 | | | | | 10 | | | | | 15 |

(2) INFORMATION FOR SEQ ID NO:53:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:
- | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 30 | Asp | Trp | Tyr | Ser | Pro | Ala | Cys | Gly | Lys | Ala | Gly | Cys | Gln | Thr | Tyr |
| | 1 | | | | 5 | | | | | 10 | | | | | 15 |

(2) INFORMATION FOR SEQ ID NO:54:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

10 (v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

15 Ala Cys Gly Lys Ala Gly Cys Gln Thr Tyr Lys Trp Glu Thr Phe
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:55:

20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

25 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

Gly Cys Gln Thr Tyr Lys Trp Glu Thr Phe Leu Thr Ser Glu Leu
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:56:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- 10 (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:
- 15 Lys Trp Glu Thr Phe Leu Thr Ser Glu Leu Pro Gln Trp Leu Ser
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:57:

- 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- 25 (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:
- Leu Thr Ser Glu Leu Pro Gln Trp Leu Ser Ala Asn Arg Ala Val
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:58:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

10 (v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

15 Pro Gln Trp Leu Ser Ala Asn Arg Ala Val Lys Pro Thr Gly Ser
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:59:

20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

25 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

Ala Asn Arg Ala Val Lys Pro Thr Gly Ser Ala Ala Ile Gly Leu
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:60:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

10 (v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

15 Lys Pro Thr Gly Ser Ala Ala Ile Gly Leu Ser Met Ala Gly Ser
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:61:

20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

25 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

Ala Ala Ile Gly Leu Ser Met Ala Gly Ser Ser Ala Met Ile Leu
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:62:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 5 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

 (ii) MOLECULE TYPE: peptide
 (iii) HYPOTHETICAL: NO
 (iv) ANTI-SENSE: NO
 10 (v) FRAGMENT TYPE: internal
 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:
 15 Ser Met Ala Gly Ser Ser Ala Met Ile Leu Ala Ala Tyr His Pro
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:63:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 20 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

 (ii) MOLECULE TYPE: peptide
 (iii) HYPOTHETICAL: NO
 25 (iv) ANTI-SENSE: NO
 (v) FRAGMENT TYPE: internal
 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

 Ser Ala Met Ile Leu Ala Ala Tyr His Pro Gln Gln Phe Ile Tyr
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:64:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

10 (v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

15 Ala Ala Tyr His Pro Gln Gln Phe Ile Tyr Ala Gly Ser Leu Ser
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:65:

20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

25 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

Gln Gln Phe Ile Tyr Ala Gly Ser Leu Ser Ala Leu Leu Asp Pro
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

10 (v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

15 Ala Gly Ser Leu Ser Ala Leu Leu Asp Pro Ser Gln Gly Met Gly
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

25 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

Ala Leu Leu Asp Pro Ser Gln Gly Met Gly Pro Ser Leu Ile Gly
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:68:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:
- | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 15 | Ser | Gln | Gly | Met | Gly | Pro | Ser | Leu | Ile | Gly | Leu | Ala | Met | Gly | Asp |
| | 1 | | | | 5 | | | | | 10 | | | | | 15 |

(2) INFORMATION FOR SEQ ID NO:69:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:
- | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 30 | Pro | Ser | Leu | Ile | Gly | Leu | Ala | Met | Gly | Asp | Ala | Gly | Gly | Tyr | Lys |
| | 1 | | | | 5 | | | | | 10 | | | | | 15 |

(2) INFORMATION FOR SEQ ID NO:70:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

15	Leu	Ala	Met	Gly	Asp	Ala	Gly	Gly	Tyr	Lys	Ala	Ala	Asp	Met	Trp
	1				5					10					15

(2) INFORMATION FOR SEQ ID NO:71:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

Ala	Gly	Gly	Tyr	Lys	Ala	Ala	Asp	Met	Trp	Gly	Pro	Ser	Ser	Asp
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:72:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

10 (v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

15 Ala Ala Asp Met Trp Gly Pro Ser Ser Asp Pro Ala Trp Glu Arg
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:73:

20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

25 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

Gly Pro Ser Ser Asp Pro Ala Trp Glu Arg Asn Asp Pro Thr Gln
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:74:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

15	Pro	Ala	Trp	Glu	Arg	Asn	Asp	Pro	Thr	Gln	Gln	Ile	Pro	Lys	Leu
	1				5					10					15

(2) INFORMATION FOR SEQ ID NO:75:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

Asn	Asp	Pro	Thr	Gln	Gln	Ile	Pro	Lys	Leu	Val	Ala	Asn	Asn	Thr
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:76:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

10 (v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

15 Gln Ile Pro Lys Leu Val Ala Asn Asn Thr Arg Leu Trp Val Tyr
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:77:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

25 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

Val Ala Asn Asn Thr Arg Leu Trp Val Tyr Cys Gly Asn Gly Thr
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:78:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

15	Arg	Leu	Trp	Val	Tyr	Cys	Gly	Asn	Gly	Thr	Pro	Asn	Glu	Leu	Gly
	1				5					10					15

(2) INFORMATION FOR SEQ ID NO:79:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

Cys	Gly	Asn	Gly	Thr	Pro	Asn	Glu	Leu	Gly	Gly	Ala	Asn	Ile	Pro
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:80:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

15	Pro	Asn	Glu	Leu	Gly	Gly	Ala	Asn	Ile	Pro	Ala	Glu	Phe	Leu	Glu
	1				5					10					15

(2) INFORMATION FOR SEQ ID NO:81:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

Gly	Ala	Asn	Ile	Pro	Ala	Glu	Phe	Leu	Glu	Asn	Phe	Val	Arg	Ser
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:82:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

10 (v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

15 Ala Glu Phe Leu Glu Asn Phe Val Arg Ser Ser Asn Leu Lys Phe
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:83:

20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

25 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

Asn Phe Val Arg Ser Ser Asn Leu Lys Phe Gln Asp Ala Tyr Asn
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:84:

5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

10 (v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

15 Ser Asn Leu Lys Phe Gln Asp Ala Tyr Asn Ala Ala Gly Gly His
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:85:

20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

25 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

Gln Asp Ala Tyr Asn Ala Ala Gly Gly His Asn Ala Val Phe Asn
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:86:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

15	Ala	Ala	Gly	Gly	His	Asn	Ala	Val	Phe	Asn	Phe	Pro	Pro	Asn	Gly
	1				5					10					15

(2) INFORMATION FOR SEQ ID NO:87:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

Asn	Ala	Val	Phe	Asn	Phe	Pro	Pro	Asn	Gly	Thr	His	Ser	Trp	Glu
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:88:

- 5 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- 10 (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:
- 15 Phe Pro Pro Asn Gly Thr His Ser Trp Glu Tyr Trp Gly Ala Gln
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:89:

- 20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- 25 (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- 30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:
- Thr His Ser Trp Glu Tyr Trp Gly Ala Gln Leu Asn Ala Met Lys
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:90:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

15	Tyr	Trp	Gly	Ala	Gln	Leu	Asn	Ala	Met	Lys	Gly	Asp	Leu	Gln	Ser
	1				5					10				15	

(2) INFORMATION FOR SEQ ID NO:91:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: C-terminal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

Leu	Asn	Ala	Met	Lys	Gly	Asp	Leu	Gln	Ser	Ser	Leu	Gly	Ala	Gly
1				5				10					15	

(2) INFORMATION FOR SEQ ID NO:92:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 480 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

ATGAAGCTCA CCACAATGAT CAAGACGGCA GTAGCGGTCG TGGCCATGGC 50
10 GGCCATCGCG ACCTTTGCGG CACCGGTCGC GTTGGCTGCC TATCCCATCA 100
CCGGA AAACT TGGCAGTGAG CTAACGATGA CCGACACCGT TGGCCAAGTC 150
GTGCTCGGCT GGAAGGTCAG TGATCTCAAA TCCAGCACGG CAGTCATCCC 200
CGGCTATCCG GTGGCCGGCC AGGTCTGGGA GGCCACTGCC ACGGTCAATG 250
CGATTCGCGG CAGCGTCACG CCCGCGGTCT CGCAGTTCAA TGCCCGCACC 300
15 GCCGACGGCA TCAACTACCG GGTGCTGTGG CAAGCCGCGG GCCCCGACAC 350
CATTAGCGGA GCCACTATCC CCCAAGGCGA ACAATCGACC GGCAAAATCT 400
ACTTCGATGT CACCGGCCCA TCGCCAACCA TCGTCGCGAT GAACAACGGC 450
ATGGAGGATC TGCTGATTTG GGAGCCGTAG 480

(2) INFORMATION FOR SEQ ID NO:93:

20 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1437 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: not relevant

25 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

GTGACGGAAA AGACGCCCCG CGACGTCTTC AAAGTTGCCA AGGACGAGAA 50
GGTCGAATAT GTCGACGTCC GGTTCGTGTA CCTGCCTGGC ATCATGCAGC 100
ACTTCACGAT TCCGGCTTCG GCCTTTGACA AGAGCGTGTT TGACGACGGC 150
30 TTGGCCTTTG ACGGCTCGTC GATTCGCGGG TTCCAGTCGA TCCACGAATC 200
CGACATGTTG CTTCTTCCCG ATCCCGAGAC GGCGCGCATC GACCCGTTCC 250

GCGCGGCCAA GACGCTGAAT ATCAACTTCT TTGTGCACGA CCCGTTCAACC 300
 CTGGAGCCGT ACTCCCGCGA CCCGCGCACC ATCGCCCGCA AGGCCGAGAA 350
 CTACCTGATC AGCACTGGCA TCGCCGACAC CGCATACTTC GGCGCCGAGG 400
 CCGAGTTCTA CATTTTCGAT TCGGTGAGCT TCGACTCGCG CGCCAACGGC 450
 5 TCCTTCTACG AGGTGGACGC CATCTCGGGG TGGTGAACA CCGGCGCGGC 500
 GACCGAGGCC GACGGCAGTC CCAACCGGGG CTACAAGGTC CGCCACAAGG 550
 GCGGGTATTT CCCAGTGGCC CCCAACGACC AATACGTCGA CCTGCGCGAC 600
 AAGATGCTGA CCAACCTGAT CAACTCCGGC TTCATCCTGG AGAAGGGCCA 650
 CCACGAGGTG GGCAGCGGCG GACAGGCCGA GATCAACTAC CAGTTCAATT 700
 10 CGCTGCTGCA CGCCGCCGAC GACATGCAGT TGTACAAGTA CATCATCAAG 750
 AACACCGCCT GGCAGAACGG CAAAACGGTC ACGTTCATGC CCAAGCCGCT 800
 GTTCGGCGAC AACGGGTCCG GCATGCACTG TCATCAGTCG CTGTGGAAGG 850
 ACGGGGCCCC GCTGATGTAC GACGAGACGG GTTATGCCGG TCTGTCGGAC 900
 ACGGCCCCGTC ATTACATCGG CGGCCTGTTA CACCACGCGC CGTCGCTGCT 950
 15 GGCCTTCACC AACCCGACGG TGAACCTCCTA CAAGCGGCTG GTTCCCGGTT 1000
 ACGAGGCCCC GATCAACCTG GTCTATAGCC AGCGCAACCG GTCGGCATGC 1050
 GTGCGCATCC CGATCACCGG CAGCAACCCG AAGGCCAAGC GGCTGGAGTT 1100
 CCGAAGCCCC GACTCGTCGG GCAACCCGTA TCTGGCGTTC TCGGCCATGC 1150
 TGATGGCAGG CCTGGACGGT ATCAAGAACA AGATCGAGCC GCAGGCGCCC 1200
 20 GTCGACAAGG ATCTCTACGA GCTGCCGCCG GAAGAGGCCG CGAGTATCCC 1250
 GCAGACTCCG ACCCAGCTGT CAGATGTGAT CGACCGTCTC GAGGCCGACC 1300
 ACGAATACCT CACCGAAGGA GGGGTGTTCA CAAACGACCT GATCGAGACG 1350
 TGGATCAGTT TCAAGCGCGA AAACGAGATC GAGCCGGTCA ACATCCGGCC 1400
 GCATCCCTAC GAATTCGCGC TGTACTACGA CGTTTAA 1437

0870653-04249
 067770-000000

(2) INFORMATION FOR SEQ ID NO:94:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 687 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

GTGCGCATCA AGATCTTCAT GCTGGTCACG GCTGTCGTTT TGCTCTGTTG 50
 10 TTCGGGTGTG GCCACGGCCG CGCCCAAGAC CTACTGCGAG GAGTTGAAAG 100
 GCACCGATAC CGGCCAGGCG TGCCAGATTC AAATGTCCGA CCCGGCCTAC 150
 AACATCAACA TCAGCCTGCC CAGTTACTAC CCCGACCAGA AGTCGCTGGA 200
 AAATTACATC GCCCAGACGC GCGACAAGTT CCTCAGCGCG GCCACATCGT 250
 CCACTCCACG CGAAGCCCCC TACGAATTGA ATATCACCTC GGCCACATAC 300
 15 CAGTCCGCGA TACCGCCGCG TGGTACGCAG GCCGTGGTGC TCAAGGTCTA 350
 CCAGAACGCC GGC GGACGC ACCCAACGAC CACGTACAAG GCCTTCGATT 400
 GGGACCAGGC CTATCGCAAG CCAATCACCT ATGACACGCT GTGGCAGGCT 450
 GACACCGATC CGCTGCCAGT CGTCTTCCCC ATTGTGCAAG GTGAACTGAG 500
 CAAGCAGACC GGACAACAGG TATCGATAGC GCCGAATGCC GGCTTGGACC 550
 20 CGGTGAATTA TCAGAACTTC GCAGTCACGA ACGACGGGGT GATTTTCTTC 600
 TTCAACCCGG GGGAGTTGCT GCCCGAAGCA GCCGGCCCAA CCCAGGTATT 650
 GGTCCCACGT TCCGCGATCG ACTCGATGCT GGCCTAG 687

(2) INFORMATION FOR SEQ ID NO:95:

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 900 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

ATGAAGGGTC GGTCCGGCGCT GCTGCGGGCG CTCTGGATTG CCGCACTGTC 50
 ATTCGGGTTG GCGGTGTGTC CGGTAGCCGC GGAACCCACC GCCAAGGCCG 100
 CCCCATACGA GAACCTGATG GTGCCGTCGC CCTCGATGGG CCGGGACATC 150
 5 CCGGTGGCCT TCCTAGCCGG TGGGCCGCAC GCGGTGTATC TGCTGGACGC 200
 CTTCAACGCC GGCCCGGATG TCAGTAACTG GGTCACCGCG GGTAACGCGA 250
 TGAACACGTT GCGGGGCAAG GGGATTTCGG TGGTGGCACC GGCCGGTGGT 300
 GCGTACAGCA TGTACACCAA CTGGGAGCAG GATGGCAGCA AGCAGTGGGA 350
 CACCTTCTTG TCCGCTGAGC TGCCCGACTG GCTGGCCGCT AACCGGGGCT 400
 10 TGGCCCCCGG TGGCCATGCG GCCGTTGGCG CCGCTCAGGG CGGTTACGGG 450
 GCGATGGCGC TGGCGGCCTT CCACCCCGAC CGCTTCGGCT TCGCTGGCTC 500
 GATGTCGGGC TTTTGTACC CGTCGAACAC CACCACCAAC GGTGCGATCG 550
 CGGCGGGCAT GCAGCAATTC GGCGGTGTGG ACACCAACGG AATGTGGGGA 600
 GCACCACAGC TGGGTCGGTG GAAGTGGCAC GACCCGTGGG TGCATGCCAG 650
 15 CCTGCTGGCG CAAAACAACA CCCGGGTGTG GGTGTGGAGC CCGACCAACC 700
 CGGGAGCCAG CGATCCCGCC GCCATGATCG GCCAAGCCGC CGAGGCGATG 750
 GGTAACAGCC GCATGTTCTA CAACCAGTAT CGCAGCGTCG GCGGGCACAA 800
 CGGACACTTC GACTTCCCAG CCAGCGGTGA CAACGGCTGG GGCTCGTGGG 850
 CGCCCCAGCT GGGCGCTATG TCGGGCGATA TCGTCGGTGC GATCCGCTAA 900

(2) INFORMATION FOR SEQ ID NO:96:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

F S R P G L P V E Y L Q V P S

(2) INFORMATION FOR SEQ ID NO:97:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: Internal

- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

L P V E Y L Q V P S P S M G R

(2) INFORMATION FOR SEQ ID NO:98:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: Internal

- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman

0378933-0419

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

L Q V P S P S M G R D I K V Q

(2) INFORMATION FOR SEQ ID NO:99:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

P S M G R D I K V Q F Q S G G

(2) INFORMATION FOR SEQ ID NO:100:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

D I K V Q F Q S G G A N S P

UCLA-VD-VACCINE\20243.APP\MAK\R\12\196 11:08am

(2) INFORMATION FOR SEQ ID NO:101:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*
- (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

F Q S G G A N S P A L Y L L D

(2) INFORMATION FOR SEQ ID NO:102:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*
- (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

A N S P A L Y L L D G L R A Q

(2) INFORMATION FOR SEQ ID NO:103:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids

0878633.0429

- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

L Y L L D G L R A Q D D F S G

(2) INFORMATION FOR SEQ ID NO:104:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

G L R A Q D D F S G W D I N T

(2) INFORMATION FOR SEQ ID NO:105:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

08785633-012196

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

D D F S G W D I N T P A F E W

(2) INFORMATION FOR SEQ ID NO:106:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

W D I N T P A F E W Y D Q S G

(2) INFORMATION FOR SEQ ID NO:107:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:
- P A F E W Y D Q S G L S V V M

(2) INFORMATION FOR SEQ ID NO:108:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:
- Y D Q S G L S V V M P V G G Q

(2) INFORMATION FOR SEQ ID NO:109:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal

007863-0449

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

L S V V M P V G G Q S S F Y S

(2) INFORMATION FOR SEQ ID NO:110:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

P V G G Q S S F Y S D W Y Q P

(2) INFORMATION FOR SEQ ID NO:111:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

S S F Y S D W Y Q P A C G K A

(2) INFORMATION FOR SEQ ID NO:112:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

D W Y Q P A C G K A G C Q T Y

(2) INFORMATION FOR SEQ ID NO:113:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

A C G K A G C Q T Y K W E T F

UCLA-IR | 2024-01-11 11:08am

(2) INFORMATION FOR SEQ ID NO:114:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*
- (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

G C Q T Y K W E T F L T S E L K Y K W E T F

(2) INFORMATION FOR SEQ ID NO:115:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*
- (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

K W E T F L T S E L P G W L Q

(2) INFORMATION FOR SEQ ID NO:116:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid

08786533-012196

- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:
L T S E L P G W L Q A N R H V

(2) INFORMATION FOR SEQ ID NO:117:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:
P G W L Q A N R H V K P T G S

(2) INFORMATION FOR SEQ ID NO:118:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

007893-0499

- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:
- A N R H V K P T G S A V V G LK

(2) INFORMATION FOR SEQ ID NO:119:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:
- A P T G S A V V G L S M A A S

(2) INFORMATION FOR SEQ ID NO:120:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO

037853-0149
"037853-0149"

- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

A V V G L S M A A S S A L T L

(2) INFORMATION FOR SEQ ID NO:121:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

S M A A S S A L T L A I Y H P

(2) INFORMATION FOR SEQ ID NO:122:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*

(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

S A L T L A I Y H P Q Q F V Y

(2) INFORMATION FOR SEQ ID NO:123:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

A I Y H P Q Q F V Y A G A M S

(2) INFORMATION FOR SEQ ID NO:124:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

Q Q F V Y A G A M S G L L D P

(2) INFORMATION FOR SEQ ID NO:125:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*
- (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

A G A M S G L L D P S Q A M G

(2) INFORMATION FOR SEQ ID NO:126:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*
- (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

G L L D P S Q A M G P T L I G

(2) INFORMATION FOR SEQ ID NO:127:

UCLAID-VACCINE\120243.APP\MAK/R/121196

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:
- S Q A M G P T L I G L A M G D P

(2) INFORMATION FOR SEQ ID NO:128:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:
- S T L I G L A M G D A G G Y K

(2) INFORMATION FOR SEQ ID NO:129:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:

264710-6633280

- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:
- L A M G D A G G Y K A S D M W

(2) INFORMATION FOR SEQ ID NO:130:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:
- A G G Y K A S D M W G P K E D

(2) INFORMATION FOR SEQ ID NO:131:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

UCLA ID VACCINE\20243.APP\IMAK\11\121196 11:08am

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(B) STRAIN: Erdman

A S D M W G P K E D P A W Q R

(D) TOPOLOGY: linear

(B) STRAIN: Erdman

G P K E D P A W Q R N D P L L

(D) TOPOLOGY: linear

(iv) ANTI-SENSE: NO

- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

 P A W Q R N D P L L N V G K L

(2) INFORMATION FOR SEQ ID NO:134:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

 N D P L L N V G K L I A N N T

(2) INFORMATION FOR SEQ ID NO:135:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*

UCLAID-VACCINE\120243.APP\MAK\121196 11:08am

(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

N V G K L I A N N T R V W V Y

(2) INFORMATION FOR SEQ ID NO:136:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

I A N N T R V W V Y C G N G K

(2) INFORMATION FOR SEQ ID NO:137:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(B) STRAIN: Erdman

UCLA-VID-VACCINE\120243.APP\MAK/R/121196 11:08am

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

R V W V Y C G N G K P S D L G

(2) INFORMATION FOR SEQ ID NO:138:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

C G N G K P S D L G G N N L P

(2) INFORMATION FOR SEQ ID NO:139:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

P S D L G G N N L P A K F L E

UCLAID-VACCINE\20243.APP\MAK\R\121196

(2) INFORMATION FOR SEQ ID NO:140:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:
G N N L P A K F L E G F V R TA

(2) INFORMATION FOR SEQ ID NO:141:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:
G K F L E G F V R T S N I K F

(2) INFORMATION FOR SEQ ID NO:142:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids

UCLA-VD-VACCINE\120243.APP\MAK\11\121196

- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:
G F V R T S N I K F Q D A Y N

(2) INFORMATION FOR SEQ ID NO:143:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:
S N I K F Q D A Y N A G G G H

(2) INFORMATION FOR SEQ ID NO:144:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

0378643-014197

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

Q D A Y N A G G G H N G V F D

(2) INFORMATION FOR SEQ ID NO:145:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

A G G G H N G V F D F P D S G

(2) INFORMATION FOR SEQ ID NO:146:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO

007663-0129

- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:
- N G V F D F P D S G T H S W E

(2) INFORMATION FOR SEQ ID NO:147:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:
- F P D S G T H S W E Y W G A Q

(2) INFORMATION FOR SEQ ID NO:148:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal

UCLA-VID-VACCINE120243.APP\MAK/R/121196 11:08am

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

T H S W E Y W G A Q L N A M K

(2) INFORMATION FOR SEQ ID NO:149:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

Y W G A Q L N A M K P D L Q R

(2) INFORMATION FOR SEQ ID NO:150:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

L N A M K P D L Q R A L G A T

(2) INFORMATION FOR SEQ ID NO:151:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

P D L Q R A L G A T P N T G P

(2) INFORMATION FOR SEQ ID NO:152:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: C-Terminal

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycobacterium tuberculosis*

(B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

A L G A T P N T G P A P Q G A

007933-0119

(2) INFORMATION FOR SEQ ID NO:153:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-Terminal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*
- (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

F S R P G L P V E Y L Q V P S P S M

(2) INFORMATION FOR SEQ ID NO:154:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: Internal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Mycobacterium tuberculosis*
- (B) STRAIN: Erdman

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

D I K V Q F Q S G G A N S P A L

(2) INFORMATION FOR SEQ ID NO:155:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 amino acids

- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

P V G G Q S S F Y S D W Y Q P A C

(2) INFORMATION FOR SEQ ID NO:156:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:

S M A A S S A L T L A I Y H P Q Q

(2) INFORMATION FOR SEQ ID NO:157:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

0378633-012197

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:

P Q Q F V Y A G A M S G L L D P S Q

(2) INFORMATION FOR SEQ ID NO:158:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: *Mycobacterium tuberculosis*
 - (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

C G N G K P S D L G G N N L P A K

(2) INFORMATION FOR SEQ ID NO:159:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 16 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO

UCLA-VAACINE\20243.APP\MAK\11\121196

- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:
 F Q D A Y N A G G G H N G V F D

(2) INFORMATION FOR SEQ ID NO:160:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 14 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (v) FRAGMENT TYPE: Internal
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mycobacterium tuberculosis*
 (B) STRAIN: Erdman
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:
 P D L Q R A L G A T P N T G

What is claimed is:

1. A vaccinating agent for use in promoting an effective immune response, in a mammalian host, against an infectious pathogen from the genus *Mycobacterium*, said vaccinating agent comprising:

- 5 at least a portion of at least one majorly abundant extracellular product selected from the group consisting of *M. tuberculosis* 110 KD protein, 80 KD protein, 71 KD protein, 58 KD protein, 45 KD protein, 32A KD protein, 32B KD protein, 30 KD protein, 24 KD protein, 10 23.5 KD protein, 23 KD protein, 16 KD protein, 14 KD protein, 12 KD protein and respective analogs, homologs, and subunits thereof; and
- an adjuvant selected from the group consisting of IL-12 and MF 59.

2. The vaccinating agent of claim 1 wherein said at least one majorly abundant extracellular product is *M. tuberculosis* 32A KD protein.

3. The vaccinating agent of claim 1 wherein said at least one majorly abundant extracellular product is a mixture of *M. tuberculosis* 32A KD protein, 30 KD protein, and 16 KD protein.

4. The vaccinating agent of claim 1 wherein said adjuvant is IL-12.

5. The vaccinating agent of claim 1 wherein said adjuvant is a mixture of IL-12 and MF 59.

6. A method for immunizing a mammalian host against an infectious pathogen of the genus *Mycobacterium*, said method comprising the steps of:

- providing a vaccinating agent comprising at least a
5 portion of at least one majorly abundant extracellular

087566-0159
467270-00000000

10

7. The method of Claim 6 wherein said at least one majorly abundant extracellular product is *M. tuberculosis* 32A KD protein.

8. The method of claim 6 wherein said at least one majorly abundant extracellular product is a mixture of *M. tuberculosis* 32A KD protein, 30 KD protein, and 16 KD protein.

9. The method of claim 6 wherein said adjuvant is IL-12.

10. The method of claim 6 wherein said adjuvant is a mixture of IL-12 and MF 59.

11. A vaccinating agent for use in promoting an effective immune response, in a mammalian host, against an infectious pathogen from the genus *Mycobacterium*, said vaccinating agent comprising:

at least one immunodominant epitope of at least one majorly abundant extracellular product selected from the group consisting of *M. tuberculosis* 110 KD protein, 80 KD protein, 71 KD protein, 58 KD protein, 45 KD protein, 32A KD protein, 32B KD protein, 30 KD protein, 24 KD protein, 23.5 KD protein, 23 KD protein, 16 KD protein,

14 KD protein, 12 KD protein, and respective analogs, homologs, and subunits thereof.

12. The vaccinating agent of claim 11 wherein said at least one majorly abundant extracellular product is *M. tuberculosis* 32A KD protein.

13. The vaccinating agent of claim 12 wherein said at least one immunodominant epitope is selected from the group consisting of *M. tuberculosis* 32A KD protein subunits having the amino acid sequences

	<u>Peptide Sequence</u>	<u>Seq. ID No.</u>
5	G L R A Q D D F S G W D I N T	104
	W D I N T P A F E W Y D Q S G	106
	P A F E W Y D Q S G L S V V M	107
	P V G G Q S S F Y S D W Y Q P	110
10	G C Q T Y K W E T F L T S E L	114
	K W E T F L T S E L P G W L Q	115
	A N R H V K P T G S A V V G L	118
	A V V G L S M A A S S A L T L	120
	S A L T L A I Y H P Q Q F V Y	122
15	A I Y H P Q Q F V Y A G A M S	123
	Q Q F V Y A G A M S G L L D P	124
	G L L D P S Q A M G P T L I G	126
	S Q A M G P T L I G L A M G D	127
	N D P L L N V G K L I A N N T	134
20	N V G K L I A N N T R V W V Y	135
	I A N N T R V W V Y C G N G K	136
	C G N G K P S D L G G N N L P	138

and respective analogs, homologs, and subunits thereof including single or multiple amino acid substitutions, deletions, insertions, and inversions.

14. An immunodiagnostic agent for use in promoting a detectable immune response in a mammalian host identifying an infectious pathogen from the genus *Mycobacterium*, said immunodiagnostic agent comprising:

5 at least one immunodominant epitope of at least one majorly abundant extracellular product selected from the group consisting of *M. tuberculosis* 110 KD protein, 80 KD protein, 71 KD protein, 58 KD protein, 45 KD protein, 32A KD protein, 32B KD protein, 30 KD protein, 24 KD
10 protein, 23.5 KD protein, 23 KD protein, 16 KD protein, 14 KD protein, 12 KD protein and respective analogs, homologs, and subunits thereof.

15. The immunodiagnostic agent of claim 14 wherein said at least one majorly abundant extracellular product is *M. tuberculosis* 32A KD protein.

16. The immunodiagnostic agent of claim 15 wherein said at least one immunodominant epitope is selected from the group consisting of *M. tuberculosis* 32A KD protein subunits having the amino acid sequences

	<u>Peptide Sequence</u>	<u>Seq. ID No.</u>
5	G L R A Q D D F S G W D I N T	104
	W D I N T P A F E W Y D Q S G	106
	P A F E W Y D Q S G L S V V M	107
	P V G G Q S S F Y S D W Y Q P	110
10	G C Q T Y K W E T F L T S E L	114
	K W E T F L T S E L P G W L Q	115
	A N R H V K P T G S A V V G L	118
	A V V G L S M A A S S A L T L	120
	S A L T L A I Y H P Q Q F V Y	122
15	A I Y H P Q Q F V Y A G A M S	123
	Q Q F V Y A G A M S G L L D P	124
	G L L D P S Q A M G P T L I G	126

	<u>Peptide Sequence</u>	<u>Seq. ID No.</u>
	S Q A M G P T L I G L A M G D	127
	N D P L L N V G K L I A N N T	134
20	N V G K L I A N N T R V W V Y	135
	I A N N T R V W V Y C G N G K	136
	C G N G K P S D L G G N N L P	138

and respective analogs, homologs, and subunits thereof including single or multiple amino acid substitutions, deletions, insertions, and inversions.

17. A method of immunizing a mammalian host against an infectious pathogen of the genus *Mycobacterium*, said method comprising the steps of:

providing at least one immunodominant epitope of at least one majorly abundant extracellular product selected from the group consisting of *M. tuberculosis* 110 KD protein, 80 KD protein, 71 KD protein, 58 KD protein, 45 KD protein, 32A KD protein, 32B KD protein, 30 KD protein, 24 KD protein, 23.5 KD protein, 23 KD protein, 16 KD protein, 14 KD protein, 12 KD protein and respective analogs, homologs, and subunits thereof; and

introducing said at least one immunodominant epitope to said mammalian host to induce an effective immune response to subsequent infection by said infectious pathogen.

18. The method of claim 17 wherein said at least one majorly abundant extracellular product is *M. tuberculosis* 32A KD protein.

19. The method of claim 18 wherein said at least one immunodominant epitope is selected from the group consisting of *M. tuberculosis* 32A KD protein subunits having the amino acid sequences

	<u>Peptide Sequence</u>	<u>Seq. ID No.</u>
5	G L R A Q D D F S G W D I N T	104
	W D I N T P A F E W Y D Q S G	106
	P A F E W Y D Q S G L S V V M	107
	P V G G Q S S F Y S D W Y Q P	110
10	G C Q T Y K W E T F L T S E L	114
	K W E T F L T S E L P G W L Q	115
	A N R H V K P T G S A V V G L	118
	A V V G L S M A A S S A L T L	120
	S A L T L A I Y H P Q Q F V Y	122
15	A I Y H P Q Q F V Y A G A M S	123
	Q Q F V Y A G A M S G L L D P	124
	G L L D P S Q A M G P T L I G	126
	S Q A M G P T L I G L A M G D	127
	N D P L L N V G K L I A N N T	134
20	N V G K L I A N N T R V W V Y	135
	I A N N T R V W V Y C G N G K	136
	C G N G K P S D L G G N N L P	138

and respective analogs, homologs, and subunits thereof
including single or multiple amino acid substitutions,
25 deletions, insertions, and inversions.

20. A method for detecting the presence of an immune
response in a mammal against a pathogen of the genus
Mycobacterium, said method comprising the steps of:

providing at least one immunodominant epitope of
5 at least one majorly abundant extracellular product
selected from the group consisting of *M. tuberculosis* 110
KD protein, 80 KD protein, 71 KD protein, 58 KD protein,
45 KD protein, 32A KD protein, 32B KD protein, 30 KD
protein, 24 KD protein, 23.5 KD protein, 23 KD protein, 16
10 KD protein, 14 KD protein, 12 KD protein and respective
analogs, homologs, and subunits thereof;

administering said at least one immunodominant epitope to said mammal; and
measuring the resultant immune response.

21. The method of claim 20 wherein said at least one majorly abundant extracellular product is *M. tuberculosis* 32A KD protein.

22. The method of claim 21 wherein said at least one immunodominant epitope is selected from the group consisting of *M. tuberculosis* 32A KD protein subunits having the amino acid sequences

	<u>Peptide Sequence</u>	<u>Seq. ID No.</u>
5	G L R A Q D D F S G W D I N T	104
	W D I N T P A F E W Y D Q S G	106
	P A F E W Y D Q S G L S V V M	107
	P V G G Q S S F Y S D W Y Q P	110
10	G C Q T Y K W E T F L T S E L	114
	K W E T F L T S E L P G W L Q	115
	A N R H V K P T G S A V V G L	118
	A V V G L S M A A S S A L T L	120
	S A L T L A I Y H P Q Q F V Y	122
15	A I Y H P Q Q F V Y A G A M S	123
	Q Q F V Y A G A M S G L L D P	124
	G L L D P S Q A M G P T L I G	126
	S Q A M G P T L I G L A M G D	127
	N D P L L N V G K L I A N N T	134
20	N V G K L I A N N T R V W V Y	135
	I A N N T R V W V Y C G N G K	136
	C G N G K P S D L G G N N L P	138

and respective analogs, homologs, and subunits thereof including single or multiple amino acid substitutions,
25 deletions, insertions, and inversions.

23. A process for producing a majorly abundant extracellular product selected from the group consisting of *M. tuberculosis* 110 KD protein, 80 KD protein, 71 KD protein, 58 KD protein, 45 KD protein, 32A KD protein, 32B
 5 KD protein, 30 KD protein, 24 KD protein, 23.5 KD protein, 23 KD protein, 16 KD protein, 14 KD protein, 12 KD protein and respective analogs, homologs, and subunits thereof, said process comprising the steps of:

transforming a host cell with a vector to form
 10 a transformed cell, said vector comprising a nucleic acid molecule encoding one of said majorly abundant extracellular products; and

culturing said transformed cell to thereby produce said majorly abundant extracellular product.

24. The process of claim 23 wherein said nucleic acid molecule encodes for the 32A KD *M. tuberculosis* protein.

25. The process of claim 24 which includes the additional step of recovering said majorly abundant extracellular product that is produced by culturing of said transformed cell.

26. The process of claim 24 wherein said vector comprises pSMT3.

27. The process of claim 24 wherein said host cell is *M. smegmatis* or *M. vaccae*.

28. The process of claim 24 wherein said transformed cell is cultured at a temperature of 28°C.

FIG. 1a.




FIG. 1b.




FIG. 1c. FIG. 1d.





FIG. 2.

PURIFIED EXTRACELLULAR PROTEINS STUDIED	
APPARENT MW BY SDS-PAGE (KD)	N TERMINAL 5 AMINO ACIDS
110	NSKSV
80	TDRVS
*71	ARAVG
58	TEKTP
45	DPEPA
*32A	FSRPG
32B	FSRPG
*30	FSRPG
24	APYEN
23.5	APKTY
*23	AETYL
*16	AYPIT
14	ADPRL
12	FDTRL

FIG. 3.

EXTENDED N-TERMINAL SEQUENCE OF 30/32 KD COMPLEX OF M. TUBERCULOSIS EXTRACELLULAR PROTEINS	
	1 10 20
30	F S R P G L P V E Y L Q V P S P S M G R
32A	- - - - - - - - - - - - - - - - - -
32B	- - - - - - - - - - - - - - A - - - -
	21 30 40
30	D I K V Q F Q S G G N N S P A V Y L L D
32A	- - - - - - - - - A - - - - L - - - -
32B	- - - - -

08786533





FIG. 4.

FIG. 5.



08780533

08780533




FIG. 6. WEEKS AFTER AEROSOL CHALLENGE WITH *M. TUBERCULOSIS*

08786533




FIG. 7.

786533




FIG. 8b.




FIG. 8a.

08786533




FIG. 9.

08786533




FIG. 10.

08786533

08786533-012197




FIG. 11.

08786533-01197

08786533




FIG. 12a.




FIG. 12b.





FIG 13

FIG. 14



46T20-EE998280




FIG. 15.

08786533




FIG. 16.




FIG. 17.

08786533




FIG. 18.






FIG. 19




FIG. 20

IL-12 (Murine and Human)

2×10^4 Lymphoblasts/well




FIG 21

IL-12 (Murine and Human)




FIG. 22




FIG. 23

000000000000000000

000000000000000000






FIG. 24



Declaration and Petition

As a below-named inventor, I hereby declare that:

This declaration is of the following type:

(check one) ☒ original ☐ design ☐ supplemental ☐ national stage of PCT
☐ divisional ☐ continuation ☐ continuation-in-part (C-I-P)

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

ABUNDANT EXTRACELLULAR PRODUCTS AND METHODS FOR THEIR PRODUCTION AND USE

(check one) ☒ is attached hereto. ☐ was filed on _____ as Application Serial No. _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119, of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

	NONE		Priority Claimed
(Number)	(Country)	Day/Month/Year Filed	<input type="checkbox"/> Yes <input type="checkbox"/> No
.....	<input type="checkbox"/> Yes <input type="checkbox"/> No
(Number)	(Country)	Day/Month/Year Filed	<input type="checkbox"/> Yes <input type="checkbox"/> No
.....	<input type="checkbox"/> Yes <input type="checkbox"/> No
(Number)	(Country)	Day/Month/Year Filed	<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

	NONE	
(Application Serial No.)	(Filing date)	(Status) (patented, pending, abandoned)
.....
(Application Serial No.)	(Filing date)	(Status) (patented, pending, abandoned)
.....
(Application Serial No.)	(Filing date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Wherefore I pray that Letters Patent be granted to me for the invention described and claimed in the foregoing specification and claims, and I hereby subscribe my name to the foregoing specification and claims, declaration, and this petition.

Full name of sole or first inventor MARCUS A. HORWITZInventor's signature Marcus A. Horwitz Date 1-9-97Residence 1275 Stradella Road, Los Angeles, California 90077, USACitizenship USAPost Office Address 1275 Stradella Road, Los Angeles, California 90077, USAFull name of second inventor, if any GÜNTHER HARTHInventor's signature Günter Harth Date 1-9-97Residence 1525 Sawtelle Boulevard, #16, Los Angeles, California 90025, USACitizenship GermanPost Office Address 1525 Sawtelle Boulevard, #16, Los Angeles, California 90025, USAFull name of third inventor, if any BAI-YU LEEInventor's signature Bai-Yu Lee Date 1-9-97Residence 2901 South Speulveda, Apt. No. 230, Los Angeles, California 90064, USACitizenship Republic of China (Taiwan)Post Office Address 2901 South Speulveda, Apt No. 230, Los Angeles, California 90064, USA